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 Abstract 
Tyrosine Kinase Receptors (RTKs) regulate fundamental cellular processes 
including cell proliferation, survival and invasion and thus, dysregulation of their 
activation is implicated in human malignancies. The canonical mechanism of 
activation is initiated by receptor activation through ligand-induced dimerization, 
and autophosphorylation of key tyrosine residues along the C-terminal cytoplasmic 
domain. It has been demonstrated in the past that FGFR2, an RTK, can dimerise in 
the absence of ligand resulting in signal activation or inhibition depending on the 
equilibrium of C-terminal-binding proteins i.e. GRB2 and PLCγ1. This study 
provided the first indication of a novel direct interaction between FGFR2 and a non-
selective cation channel, TRPA1, through the C-terminal domain of FGFR2 and the 
Ankyrin repeat domain of TRPA1. The interaction was studied by protein interaction 
techniques in an overexpression system. The FGFR2-TRPA1 complex was also 
detected in a human lung adenocarcinoma cell line suggesting a possible 
implication in cancer.  
The regulatory effect of TRPA1 on FGFR2 was also investigated. In basal 
conditions, the interaction with TRPA1 exhibits an inhibitory effect on FGFR2 
autophosphorylation which results in downstream PLCγ1 pathway inhibition. Co-
immunoprecipitation experiments revealed a decrease in PLCγ1 binding to FGFR2 
in the presence of TRPA1 explaining the reduction in the PLCγ1 pathway 
activation. Upon stimulating conditions, TRPA1-mediated receptor inhibition is 
raised, as shown by increase in p-FGFR2 however, binding of PLCγ1 to the C-
terminal of FGFR2 is still impeded. Finally, a model of TRPA1-mediated regulation 
of the FGFR2 signalling was proposed in which TRPA1 prevents aberrant basal 
stimulation of the receptor while maintaining PLCγ1 pathway inhibition even in the 
presence of ligand. These findings provided the first evidence of direct interaction 
between an RTK and a TRP channel as well as proposed a novel regulatory 
mechanism of FGFR2 signalling that can facilitate in the development of 
therapeutic strategies for FGFR2-related diseases. 
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 Chapter 1 
Introduction 
1.1. Receptor Tyrosine Kinases (RTKs) 
1.1.1. Kinases 
A wide variety of cellular processes including cell cycle progression, proliferation, 
differentiation, cell survival, metabolism, transcription and cytoskeleton 
rearrangement are regulated by specific enzymes called protein kinases and 
protein phosphatases. These enzymes control the activity of other kinases as well 
as effector signalling proteins involved in cellular responses (Bhullar et al., 2018; 
Manning et al., 2002). Protein kinases phosphorylate their substrates by 
transferring the γ- phosphate group from an ATP molecule to the hydroxyl group of 
specific tyrosine, serine or threonine residues located on the substrate (Figure 1.1). 
As a result of this modification substrates are usually activated, a reaction that can 
be reversed by protein phosphatases which remove phosphate groups from 
phosphorylated residues (Bhullar et al., 2018; Huse and Kuriyan, 2002). Protein 
kinase genes account for nearly 2% of the human genome with a total of 518 genes 
identified so far (Manning et al., 2002). Being key regulators of cellular signalling, 
mutations on these enzymes that cause aberrant kinase activity are linked to 
oncogenesis. Subsequently, numerous small-molecule kinase inhibitors have been 
developed for the treatment of malignancies including breast and lung cancer 
during the last decades (Bhullar et al., 2018). 
Protein tyrosine kinases can be divided into two larger groups: non-receptor (32 
genes) and Receptor Tyrosine Kinases (RTKs) (58 genes) (Endicott et al., 2012; 
Robinson et al., 2000).  
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Figure 1. 1: Protein phosphorylation reaction using ATP by kinase enzymes. 
The γ-phosphate group from the ATP molecule is transferred to the tyrosine, serine, 
threonine or histidine residues of the protein releasing ADP. 
1.1.2. RTK families 
Extracellular signals including growth factors, cytokines and hormones are 
transmitted into the cytoplasm through specific membrane glycoproteins that 
possess a tyrosine kinase activity. Those transmembrane receptors are named 
Receptor Tyrosine Kinases or RTKs and are crucial components of cellular 
signalling in all multicellular eukaryotic organisms. Mutations in these receptors are 
observed in numerous diseases including cancer, bone disorders and diabetes. 
There are 58 RTK genes reported in the human genome divided into 20 subfamilies 
based on ligand specificity, sequence homology and structural features. Those 
subfamilies include EGFR (Epidermal Growth Factor Receptor), IR (Insulin 
Receptor), PDGFR (Platelet-derived Growth Factor Receptor), VEGFR (Vascular 
Endothelial Growth Factor Receptor) , FGFR (Fibroblast Growth Factor Receptor), 
PTK7 (Tyrosine-protein kinase-like 7), TRK (Tropomyosin Receptor Kinase), ROR 
(RAR-related Orphan Receptor), MuSK (Muscle-Specific Kinase), MET (Tyrosine 
protein kinase Met), AXL, TIE (Angiopoietin Receptor), EPH (erythropoietin-
producing human hepatocellular receptors), RET (rearranged during transfection), 
DDR (Discoidin domain receptor), ROS, LMR, ALK (Anaplastic lymphoma kinase) 
- 3 - 
and STYK1 (Serine/Threonine/Tyrosine Kinase 1) (Figure 1.2). All RTKs share 
common structural and functional characteristics including the extracellular ligand-
binding domain, a single transmembrane domain, a juxtamembrane region and an 
intracellular kinase domain followed by a C-terminal domain (Schlessinger, 2000). 
 
 
Figure 1. 2: Schematic of the extracellular and intracellular domains of 20 
Tyrosine Kinase Receptor Families. (Taken from (Lemmon and Schlessinger, 
2010) 
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1.1.3. RTK structural features 
1.1.3.1. The Extracellular domain of RTKs 
The N-terminal region of every RTK exists in the extracellular space where it mainly 
serves as a ligand-binding domain. RTK extracellular domains are rich in intra chain 
disulphide bonds as well as N-linked glycosylation sites and consist of multiple 
structural motifs that provide ligand specificity. Most common motif is the 
Immunoglobulin (Ig) motif which is present in various repeats in 10 RTK 
subfamilies. For instance, the FGFRs contain two to three Ig-like domains while 
VEGFR and PTK7 contain up to seven of those motifs. Leucine- and cysteine-rich 
motifs as well as fibronectin type III are also common among RTK extracellular 
domains (e.g. EGFR and IR) (Lemmon and Schlessinger, 2010).  
Apart from ligand recognition, extracellular domains are also important for receptor 
dimerization following ligand binding because they participate in receptor-receptor 
interactions that stabilise the dimeric state. One extreme of this function is the 
ligand-induced dimerisation of EGFR that is completely receptor mediated and 
occurs via interactions between the “dimerisation arm” located in the Cysteine-rich 
motif (domain II) of one receptor with the domain II of the partner receptor (Burgess 
et al., 2003). Furthermore, extracellular domains can interact with cell surface 
adhesion molecules. For example, it has been shown that E-cadherin can directly 
interact with EGFR resulting in receptor inhibition (Qian et al., 2004). Moreover, 
unlike most RTKs that bind to soluble ligands, Eph receptors recognise membrane-
bound ligands called ephrins that are located on the membrane of neighbouring 
cells. This interaction occurs through the ephrin-binding domains in the extracellular 
region and serves as point of contact with other cells (Lisabeth et al., 2013). 
1.1.3.2. The Transmembrane domain of RTKs 
The transmembrane domain connects the extracellular domain with the intracellular 
kinase domain. The transmembrane domain consists of hydrophobic and basic 
- 5 - 
residues and contributes to RTK signalling in two manners: thermodynamicly, 
because it contributes to dimer stability by forming sequence-specific interactions, 
and structurally, because it controls the orientation of the kinase domain 
maintaining the active-conformation of the dimer (Li and Hristova, 2010). The 
importance of the transmembrane domain in signal regulation is highlighted by the 
fact that mutations in that domain can cause ligand-independent receptor activation, 
as reported in PDGFR, FGFR and EGFR (Bargmann and Weinberg, 1988; Li et al., 
1997; Velghe et al., 2014; Webster and Donoghue, 1996).  
1.1.3.3. The kinase domain of RTKs 
The kinase domain of RTKs is located at the cytoplasmic region, between the 
juxtamembrane and the C-terminal region. Like all serine/threonine and tyrosine 
kinases, the RTK kinase domain adopts a similar architecture with two lobes, one 
N-terminal and one C-terminal. The conformation of the lobes and interactions 
between their components dictate the level of catalytic activity of the kinase. The N-
lobe consist of 5 β-strands (β1-β5) that form a twisted β-sheet and an αC helix. The 
primary role of the N-lobe is to facilitate the binding and proper orientation of the 
ATP. The C-lobe consist of two β-strands (β7 and β8) and five α-helices (αD to αI) 
that facilitate the substrate binding and catalytic activity. The Activation-loop 
tyrosine residues whose phosphorylation state regulates the kinase activity are also 
located in the C-lobe (Wybenga-Groot et al., 2001). 
1.1.4. RTK activation 
The conserved activation mechanism follows a generalised model that starts with 
the binding of a growth factor on the extracellular domain causing receptor 
dimerisation. Subsequent conformational changes release the receptor-specific cis-
autoinhibition activating the kinase domain which trans-phosphorylates tyrosine 
residues along the cytoplasmic domain of the receptor. Phosphotyrosines are 
crucial for enhancing the tyrosine kinase activity (Activation-loop) as well as serving 
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as docking areas for phosphotyrosine-binding-motif-containing downstream 
proteins initiating a cascade of protein interactions and reactions that end in cellular 
responses (Lemmon and Schlessinger, 2010). 
1.1.4.1. Ligand-mediated receptor dimerization 
The ligand-mediated mechanism of RTK activation is supported by structures of 
ligand-bound RTK ectodomains that have been published so far. Even though all 
RTKs require ligand binding to be activated, the exact mechanism and network of 
interactions vary among receptor subfamilies.  
One case involves a dimeric ligand that simply brings two receptor monomers 
together into a dimer. For example, one molecule of the dimeric SCF (Stem Cell 
Factor) interacts with the immunoglobulin-like domains 1, 2 and 3 (D1-3) of one KIT 
molecule ectodomain and so does the second SCF molecule creating a homodimer 
with 2:2 stoichiometry. This interaction changes the orientation of the membrane 
proximal D4 and D5 domains enabling D4:D4 and D5:D5 homotypic interactions 
that further stabilise the dimer. D4 homotypic affinities are low and the polarised 
electrostatic surface causes repulsion of proximal receptors preserving the inactive 
monomeric state. In the presence of SCF, the local receptor concentration is 
increased and therefore, the D4 affinity becomes adequate to create homotypic 
interactions and stabilise the complex (Yuzawa et al., 2007). Subsequently, 
mutations in the D4-D5 domains that increase the dimerisation constant by 250-fold 
cause ligand-independent receptor dimerisation. Similarly, homotypic interactions 
occur along the KIT ectodomain (D4-D5) and continue throughout the receptor 
(transmembrane and intracellular domain) in a “zipper-like” manner creating a 
network of weak contacts that stabilise the dimer (Reshetnyak et al., 2015). Similar 
model of receptor dimerisation has been shown for the VEGFR-1/VEGF-A complex. 
Each VEGFR-1 molecule interacts with both VEGF-A protomers through the D2-D3 
binding site. The remaining D4-D7 domains in the extracellular region create 
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homotypic contacts that further stabilise the dimeric state (Markovic-Mueller et al., 
2017). In the cases described above, both receptor-ligand and receptor-receptor 
interactions are combined in order to form a stable dimer and induce receptor 
activation.  
In the case of the neurotrophin receptor TrkA, receptor-ligand interactions are the 
only ones that mediate the dimerisation. There are no receptor-receptor interactions 
between the LRRs (leucine-rich repeat) nor the Ig-like domains along the 
ectodomain. The dimer interface solely consists of interactions mediated by the Ig-
C2 domain of each receptor with both molecules of the NGF (nerve growth factor) 
dimeric ligand creating a 2:2 complex (Wehrman et al., 2007).  
On the contrary, EGFR dimerization interface comprises solely of receptor-receptor 
interactions, as shown by two crystal structures of EGFR ectodomains bound to 
TNF-α and EGF ligands (Burgess et al., 2003; Garrett et al., 2002; Ogiso et al., 
2002). Since the dimerization is receptor-mediated, autoinhibitory mechanisms are 
crucial to prevent dimer formation in the absence of ligands. In the monomeric 
state, intramolecular interactions between domain II and IV (D2, D4) keep EGFR in 
the tethered conformation which prevents D2 from interacting with respective 
domains in neighbouring receptors. The autoinhibition is released in the presence 
of ligand. Each ligand molecule binds to one of the receptor monomers by 
contacting D1 and D3 of the EGFR ectodomain. This interaction causes D1 re-
orientation that releases D2 autoinhibitory contacts and allows intermolecular 
interactions with neighbouring D2 creating the dimerization interface.  
In the case of FGFR, accessory molecules i.e. heparin or heparin sulphate 
proteoglycans, are involved in the process of receptor dimerisation. Similar to 
EGFs, FGF ligands are monomeric; however, each FGF binds to D2 and D3 of both 
FGFR molecules. In a 2:2:2 stoichiometry of an FGFR1c:FGF2:heparin complex 
there is a network of receptor-ligand, receptor-receptor, receptor-heparin and 
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ligand-heparin interactions that stabilise the dimeric FGFR (Plotnikov et al., 2000; 
Schlessinger, 2000).  
However, there is evidence that receptors exist in dimeric forms even in the 
absence of extracellular stimulation. The Insulin Receptor (IR) and IGF-1R are 
examples of RTK receptors whose monomers are linked with disulphide bonds and 
form αβ2 dimers. Moreover, the formation of inactive FGFR2 pre-dimers has also 
been reported. Binding of ligands to those dimers cause conformational changes 
that activate the kinase domain of the receptors and fire signalling cascade 
(Lawrence et al., 2007; Lin et al., 2012; Ward et al., 2007). In general, the inactive 
state of RTKs, either monomeric or dimeric, requires ligand binding to remove auto-
inhibitory molecular interactions and fully activate the receptors. 
1.1.4.2. Kinase domain activation 
Either monomer or dimeric, RTKs remain inactive (or low activity) until their specific 
ligand binds to the extracellular domain. Inactivity of free receptors (not ligand-
bound) is achieved by cis-autoinhibition mechanisms that are receptor specific. For 
example, tyrosine Y1162 in the Activation-loop of the Insulin Receptor (IR) 
completes with tyrosines of the substrate for the active site. This set of interactions 
between Y1162 and the active site result in ATP access restriction and thus, 
inhibition of autophosphorylation (Hubbard, 1997). Similar autoinhibition 
mechanisms involving projection of Activation-loop tyrosines in the active site has 
been observed in receptors including TrkA and Ror2 (Artim et al., 2012).  
However, more than one mechanisms of cis-autoinhibition can be implemented by 
one receptor. Except for the Activation-loop autoinhibition, IR implements a 
juxtamembrane-mediated inhibitory effect. Tyrosine Y984 in the juxtamembrane 
region disrupts the positioning of ATP through interactions with the αC helix which 
prevents phosphorylation of substrates. Mutation of Y984 to Phenylalanine or 
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Alanine increased the basal catalytic activity which verifies the inhibitory role for 
Y984 (Li et al., 2003).  
Similar autoinhibitory mechanisms are utilized by juxtamembrane regions of other 
RTKs including EphB2 receptor, Muscle-specific Kinase Receptor (Musk), KIT 
receptor and the Fms-like tyrosine kinase 3 (FLT3) receptor (Chan et al., 2003; 
Griffith et al., 2004; Till et al., 2002). For example, the tyrosines Y604 and Y610 of 
the EphB2 receptor juxtamembrane domain interact with the αC helix at the N-
terminal kinase lobe involved in nucleotide binding which impedes the correct 
orientation of the ATP. When Tyrosine 788 in the Activation-loop is phosphorylated, 
the catalytic domain is ordered in a favourable orientation and increases the kinase 
activity. Upon Y604 and Y610 phosphorylation, contacts with the catalytic domain 
are lost and the autoinhibitory effect is raised (Wybenga-Groot et al., 2001).   
The involvement of the C-terminal domain in receptor regulation at basal states has 
also been reported. The structure of the Tie2 receptor, for example, revealed that 
tyrosines in the C-terminal domain form contacts with the kinase domain which 
result in adoption of inhibitory conformation and obscure substrate binding. 
Phosphorylation of those tyrosines release the autoinhibitory effects in a manner 
similar to that of juxtamembrane Tyrosines. Deletion of the Tie2 C-terminal region 
led to increased autophosphorylation activity and downstream signalling in vitro 
(Shewchuk et al., 2000).  Similarly, PDGFR-β and Ron (Met family) C-terminal 
domains are shown to inhibit kinase activity in vitro, however, structural details are 
still to be determined (Chiara et al., 2004; Yokoyama et al., 2005).  
1.1.4. RTK-mediated signalling pathways 
The first step for an RTK activation is ligand binding to the extracellular domain 
which results in receptor dimerization and thus, conformational changes that allow 
autophosphorylations of Tyrosine residues in the Activation-loop. The first substrate 
of an RTK is the receptor itself and the autophosphorylation of tyrosines along the 
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cytoplasmic domain occurs in a precise order. The autophosphorylation serves two 
purposes: to increase the catalytic activity of the kinase as well as to create 
phosphotyrosine binding sites for downstream docking and effector proteins. For 
example, FRS2 (FGFR-related substrate 2) and IRS (insulin receptor substrate), 
that are docking proteins of FGFRs and IR receptors respectively, are bound to and 
get phosphorylated by the receptors. Phosphotyrosines on the docking proteins are, 
in turn, recognised by downstream proteins resulting in the formation of signalling 
complexes. There are three major signalling pathways initiated by RTKs, the MAPK 
(mitogen-activated protein kinase), PLCγ1 (phospholipase c γ1) and the PI3K 
(phosphoinositide-3 kinase) pathway which are described in detail in the context of 
FGFR2 signalling in the section 1.2.4 (Lemmon and Schlessinger, 2010). 
1.1.5. RTKs implication in cancer 
Based on the latest WHO global statistics, ischaemic heart disease and stroke still 
remain the leading causes of death accounting for 15 out of 56.4 million of total 
deaths in 2015 worldwide (WHO, “The top 10 causes of death,”). The next bigger 
killer is cancer and all cancers combined account for 8.8 million deaths meaning 
that almost one out of six deaths are cancer-related. Moreover, cancer is one of the 
most frequent diseases. In 2012, approximately 14 million new cancer cases were 
recorded worldwide (Torre et al., 2015). Notably, lung cancer is the deadliest 
cancer of all (1.7 million deaths in 2015), ranking fourth just by itself in the top 10 
causes of death following heart disease, strokes and chronic obstructive pulmonary 
disease (WHO, “The top 10 causes of death,”; Torre et al., 2015). Lung cancer 
incidents are most frequent among men rather than women. However, lung cancer 
is the number one cause of cancer-related mortality in men and women after breast 
cancer (Torre et al., 2015). Lung cancer remains the greatest cancer-related 
challenge and it is expected to be responsible for 3 million deaths in 2035 
(Didkowska et al., 2016). 
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Lung cancer originates from epithelial cells of the respiratory epithelium and can be 
divided into two categories based on histological characteristics: small-cell lung 
cancer (SCLC) accounting for approximately 15% of all lung cancer cases and non-
small cell lung cancer (NSCLC) that accounts for the rest of the cases (85%). 
NSCLC is also divided into further subtypes including the most common lung 
cancer type called lung adenocarcinoma (LUAD) (38.5%), squamous cell 
carcinoma (20%) and large cell carcinoma (2.9%) (Dela Cruz et al., 2011). Due to 
the advanced-stage of diagnosis, the 5-year survival of lung cancer is 18.8% 
(SEER, “Cancer of the Lung and Bronchus - Cancer Stat Facts,”.). At the stage of 
diagnosis, 16% of the cases are localised, 22% are regional and 57% are distant, 
having a 5-year survival of 55.6%, 28.9% and 4.5%, respectively. Due to the fact 
that most cases are diagnosed in advanced stages, lung cancer is usually coupled 
with metastatic disease that mainly includes brain metastasis. Both SCLC and 
NSCLC are associated with brain metastasis and nearly 50% of all cases are 
expected to present secondary brain tumours (Tamura et al., 2015). 
Cancer is usually described as the uncontrolled proliferation and accumulation of 
cells that impairs normal tissue function. However, cancer is not only a mass of 
proliferating cells but also a sophisticated tissue that in addition to cancer cells, 
composes of stromal cells, immune cells and vasculature forming the tumour 
microenvironment. Within a tumour, multiple and complex intracellular interactions 
occur orchestrating fundamental hallmarks of cancer like cellular proliferation and 
growth, survival, immortality, angiogenesis and invasion. Those cancer 
characteristics derive from deregulated signals that otherwise would regulate 
cellular growth and tissue homeostasis. Most signals are recognised by membrane 
receptors that are usually overexpressed in cancer cells, increasing responses to 
minimal stimulation, or mutated and thus ubiquitously activated, initiating signal-
independent responses. Downstream signalling components as well as the signals 
themselves can also be altered in favour of cancer cell growth (Hanahan and 
- 12 - 
Weinberg, 2011). So far, the tyrosine kinase receptors (RTKs) have been highly 
implicated in cancer initiation and progression. However, additional types of 
membrane receptors have been associated with cancer like ion channels whose 
role is also emerging, possibly characterising cancer as a channelopathy (Litan and 
Langhans, 2015). 
Signalling pathways are extremely fine-tuned processes important for cellular 
homeostasis. Thus, deregulation of those pathways is highly implicated in several 
diseases and malignancies. As critical nodes in signalling, RTKs are involved in 
cancer progression mainly by autocrine stimulation, gene amplification and protein 
overexpression, activating mutations as well as chromosomal translocations that 
form fused proteins with altered functions (Lemmon and Schlessinger, 2010).  
For example, ErbB2 (HER2) that belongs to the EGFR family of RTKs, is 
overexpressed in 15-30% of breast cancers and is also associated with poor overall 
survival. The ErbB2 gene is amplified 25-50 times creating 40-100 times more 
protein meaning that there are around 2 million ErbB2 receptors on the surface of 
breast cancer cells initiating pathways that favour tumour progression (Kallioniemi 
et al., 1992; Ornitz and Itoh, 2015). The monoclonal antibody Trastuzumab 
(Herceptin) is approved from the FDA for treatment of HER2-positive breast cancer. 
Trastuzumab recognises the IV extracellular domain of ErbB2 attenuating 
signalling, inhibiting angiogenesis and causing antibody-dependent cellular 
cytotoxicity and demonstrated 33% improvement in overall patient survival. 
However, some HER2-positive breast cancers acquire resistance to Trastuzumab 
due to a truncated version of ErbB2 (p95HER2) that misses the extracellular 
domain but still maintains a functional tyrosine kinase domain. Instead, Lapatinib, 
an ErbB2 and EGFR tyrosine kinase inhibitor, is more effective in inhibiting 
p95HER2 phosphorylation and downstream signalling activation in breast cancer 
cells and is also used in combination therapy against HER2-positive advanced and 
metastatic breast cancer (Scaltriti et al., 2007). Moreover, ErbB2 is found 
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overexpressed in other malignancies including gastric, ovarian and endometrial 
cancers (Kallioniemi et al., 1992). Among others, VEGFR has also been 
overexpressed in multiple types of cancers promoting angiogenesis and metastasis 
as well as FGFR1 which has also been found overexpressed in 17% of NSCLC, 6% 
of SCLC and 15% of hormone-receptor-positive breast cancers (Babina and Turner, 
2017; Regad, 2015).  
Most cases of RTK fusion proteins are usually found in leukemias. In translocations, 
RTKs are fused with a dimerising partner that assists in receptor dimerization 
resulting in constitutively active kinase activity and aberrant signalling. The most 
common paradigm is the translocation t(2:5)(p23;q35) between ALK (anaplastic 
lymphoma kinase) and NPM (Nucleophosmin) creating the fusion protein NPM-ALK 
that is found in 50-60% of all anaplastic large cell lymphoma (ALCLs). Additional 
examples include the fusion protein ZNF198-FGFR1 found in 48% of 8p11 
myeloproliferative syndrome (EMS) and the PDGFRB-ETV6 fusion protein found in 
n chronic myelomonocytic leukemia (CMML) (Peiris et al., 2019).  
Furthermore, activating mutations are very frequent within RTK-related cancers. C-
kit, a stem cell factor receptor involved in cell maintenance and differentiation, is 
highly mutated in many cancers including melanoma, mastocytosis and 80% in 
GIST (gastrointestinal stromal tumours). The majority of the mutations are located 
in the juxtamembrane region of the receptor which is responsible for receptor 
autoinhibition, causing constitutive kinase activation. Mutations in exon 11 
(juxtamembrane region) occur in 65% of GIST, while mutations in exon 17 (kinase) 
often result in hematopoietic malignancies (Abbaspour Babaei et al., 2016). 
Moreover, mutations that activate the kinase domain and change signalling 
specificity of PDGFRA also occur in 5% of GIST (Heldin et al., 2018).  
The dominant RTK alteration in lung cancer is EGFR mutations occurring in 10-
15% of Caucasian and 40% in Asian populations (Lo Russo et al., 2017). These 
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mutations include deletions in exon 19 and L858R mutation in exon 21 that 
constitutively activate the receptor and are sensitive to first generation tyrosine 
kinase inhibitors such as erlotinib and gefetinib used as a treatment for NSCLC 
(Russo et al., 2017; Tanaka et al., 2017). Mutations in the extracellular domain 
have also been reported. For instance, M277E is a recently discovered mutation, 
also sensitive to RTK inhibitors (RTKIs) (Yu et al., 2017). However, more than 50% 
of the cases acquire resistance to RTKIs. Resistance is also acquired after 
treatment with afatinib, a second generation irreversible inhibitor within the first year 
of treatment. Mechanisms of acquired resistance include the secondary mutation 
T790M which is reported in 50-60% of all cases that are resistant to first and 
second generation inhibitors. The T790M mutation is located in exon 20 and 
impairs the ability of inhibitors to bind and inhibit the kinase activity (Pao et al., 
2005). D761Y, L747S and L854A are all secondary mutations linked to acquired 
resistance. Apparently, these mutations are pre-existing in a smaller subpopulation 
of cancer cells and become the dominant forms of EGFR following RTKI treatment 
through selection. Likely, third generation RTKIs are under development or clinical 
trials and seem to be promising in treating NSCLC patients. Osimertinib and 
Rociletinib are two examples of third generation RTKIs that selectively target 
mutated EGFRs and not wild type receptors (200 and 22 times higher selectivity for 
mutated receptors, respectively). The mechanism of action differs from other RTKIs 
because they recognise and covalently bind to C797 located in the ATP-binding site 
(Russo et al., 2017).  
The translocation between ALK and echinoderm microtubule-associated protein-like 
4 (EML-4) genes has been reported in approximately 5% of NSCLC cases as the 
main oncogenic driver of the disease (Muller et al., 2017; Soda et al., 2007). This 
translocation creates the EML4-ALK fusion protein that dimerises due to the EML-4 
coiled-coil domain resulting in constitutively activated kinase of ALK. Resistance to 
first generation EML4-ALK inhibitors (crizotinib and cevitinib) has been reported to 
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22% of the patients and usually originates form secondary ALK mutations that 
impair drug-binding or even overexpression of EGFR. A more effective second 
generation inhibitor specifically designed to target EML4-ALK mutations like 
L1196M is Alectinib, which was approved from the FDA in 2016 (Muller et al., 
2017). 
1.2. The Fibroblast Growth Factor Receptor 2 (FGFR2) 
1.2.1. An overview of the FGFR2 structure 
The human Fibroblast Growth Factor Receptor 2 (FGFR2) belongs to the FGFR 
family of RTKs that consists of FGFR1, FGFR2, FGFR3 and FGFR4 encoded by 
FGFR1, FGFR2, FGFR3 and FGFR4 genes. FGF receptors recognize specific 
ligands belonging to the Fibroblast Growth Factor (FGF) family of growth factors 
consisting of 18 members (FGF1 to FGF18) (Ahmad et al., 2012).  
All FGFRs share similar structural characteristics. They belong to the 
immunoglobulin-like superfamily of proteins due to the presence of three 
extracellular Ig-like domains (D1, D2, D3) (Figure 1.3). D2 and D3 are important for 
ligand binding and specificity. In more detail, D2 and the D2-D3 linker are 
responsible for non-specific FGF ligand recognition, while D3 is necessary for 
ligand specificity (Plotnikov et al., 2000). FGF ligand specificity is established 
through alternative splicing of the D3 region. As illustrated in Figure 1.4, isoform IIIb 
includes exon 8 but misses exon 9 whilst, isoform IIIc includes exon 9 but misses 
exon 8. Residues in that area determine ligand specificity therefore, FGFR2IIIb 
recognizes FGF-1, -3, -7, -10, -22 while FGFRIIIc recognizes FGF-1, -2, -4, -6, -9, -
17 and -18. FGF-1 is a general FGFR ligand that binds to all FGF receptors 
(Eswarakumar et al., 2005). The first Ig-like domain (D1) and the acidic box (a 
series of acidic residues) are considered to be involved in the auto-inhibition of the 
receptor. Based on FGFR3c/FGF1 structures and SPR data, intramolecular 
interactions between a) the D1-D2 linker and the D2 heparin-binding region and b) 
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the D1 and the D2-D3 fragment, keep the receptor in a “closed”, auto-inhibitory 
configuration (Olsen et al., 2004).  
The transmembrane (TM) domain is followed by a long, compared to other RTKs, 
juxtamembrane region consisting of conserved residues that bind to phospho-
tyrosine binding (PTB) domains. FGFR-related substrate 2 (FRS2) is a PTB 
containing adaptor protein that is constitutively bound to the juxtamembrane region 
of FGFRs, participating in signal transduction (Ong et al., 2000). Each FGF receptor 
carries a split tyrosine kinase domain and a C-terminal region that are important for 
receptor activation and signal transduction (Figure 1.3).  
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Figure 1. 3: Fibroblast Growth Factor Receptor 2 structure and splicing. 
Simplified structure of FGFR2. Two FGFR2 monomers dimerise to create a dimer 
upon FGF/HSPG binding in the D2-D3 extracellular domains. D1 is involved in 
receptor auto-inhibition and an acid box is located between the first and the second 
Ig-like domain. Each FGFR2 subunit carries one split intracellular tyrosine kinase 
domain which is crucial for downstream signalling activation. HSPG = heparin 
sulphate proteoglycan, TK = tyrosine kinase, FGF = fibroblast growth factor, D1, 
D2, D3 = immunoglobulin-like domain 1, 2, 3. 
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Figure 1. 4: FGFR2 D3 alternative splicing. FGFR isoform IIIb and IIIc are 
products of alternative splicing of the D3 domain. Isoform IIIb includes exon 8 while 
in isoform IIIc, exon 8 is replaced by exon 9. 
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1.2.2. Activation mechanism of FGFR2 
Similar to all FGF receptors, FGFR2 is activated upon dimerization of two FGFR2 
monomers. Dimerisation is triggered by the binding of FGF ligands to the receptor 
monomers in combination with Heparin Sulfate Proteoglycans (HSPC) which are 
also vital components of this interaction that increase the binding affinity and 
stability between ligand-receptor. X-ray crystallography analysis revealed that in the 
pentamer of FGFR2-FGF1-hepaprin in a 2:2:1 stoichiometry, the heparin molecule 
interacting with the dimeric FGF1 that binds to the dimeric FGFR2, binds to only 
one of the FGFR2 monomers (Pellegrini et al., 2000). Following receptor 
dimerization, the tyrosine kinase domains of the two monomers come in close 
proximity enabling trans-phosphorylation on specific tyrosine residues that differ on 
each receptor. Under non-stimulating conditions, FGFRs have a fine-regulated 
intrinsic basal kinase activity that is inadequate to trigger FGFR activation without 
the extracellular signal. Upon ligand binding and subsequent dimerization, the 
intrinsic kinase phosphorylates primary tyrosine residues of the activation loop that 
activate the kinase domain on its maximum potential. Next, the fully activated 
kinase phosphorylates secondary tyrosine residues in the kinase insert, 
juxtamembrane region and C-termainal domain, which act as binding sites for 
downstream signalling proteins that are also phosphorylated and activated by the 
receptor (Chen et al., 2013).  
In FGFR1 for instance, Y653 that belongs to the activation loop is phosphorylated 
first increasing the kinase activity 50-100 fold. Next, the phosphorylation of the rest 
of the tyrosine residues occurs in a sequential order: Y583 (kinase insert), Y463 
(juxtamembrane region), Y585 (kinase insert) and Y766 (C-terminal) are 
phosphorylated and form docking sites for downstream proteins. Lastly, Y654 
located in the activation loop is phosphorylated increasing the kinase activity by 
500-1000 fold. (Furdui et al., 2006). Counterpart tyrosine residues on the FGFR2 
are shown in Figure 1.5. Y656 and Y657 comprise the activation loop of FGFR2 
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while, Y466, Y586/Y588 and Y769 are located at the juxtamembrane region, kinase 
insert and C-terminal region of FGFR2, respectively (Huang et al., 2016; Luo et al., 
2009). Phosphotyrosines serve as binding sites for SH2-containing proteins. One of 
them is PLCγ1 that binds to pY769 of FGFR2 through the cSH2 domain and gets 
phosphorylated at Y771 and Y783 activating the phospholipase enzymatic activity, 
as described in the PLCγ1 section (section 1.2.1.4.). In 2016, Huang et al. 
demonstrated that the recruitment and the phosphorylation of the substrate (PLCγ1) 
by FGFR2 cannot be executed by the same kinase in –cis. Notably, the synergistic 
participation of both monomers is required for succesful substrate phosphorylation. 
The substrate is recruited by one monomer and then phosphorylated by the other in 
–trans highlighting the importance of receptor dimerization in both kinase activation 
and substrate phosphorylation during signal transduction (Huang et al., 2016).  
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Figure 1. 5: Phosphotyrosine residues on FGFR2. Activated FGFR2 results in 
auto-phosphorylation of multiple tyrosine residues along the cytoplasmic domain of 
the receptor. The activation loop consists of phospho-tyrosine 656 and 657 located 
within the second tyrosine kinase domain. Phospho-tyrosine 466 is located at the 
juxtamebrane region, phospho-tyrosine 586 and 588 at the kinase insert, phospho-
tyrosine 733 at TK2 and finally, phospho-tyrosine 769 at the C-terminal region 
serving as a docking area for PLCγ1. Proline 810 and 813 belong to the C-terminal 
proline-rich motif which both Grb2 and PLCγ1 complete for, in non-stimulating 
conditions. 
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1.2.3. The kinase autoinhibition mechanism of FGFR2 
Solved structures of the wild type, active and inactive FGFR2 kinase domains as 
well as those that are constitutively active because of point mutations, have 
revealed an autoinhibitory mechanism that prevents receptor activation prior to 
phosphorylation of tyrosines in the Activation-loop (Chen et al., 2007).  
Upon phosphorylation of the tyrosine Y657 located in the Activation-loop, 
conformational changes occur because of newly-formed interactions including 
hydrogen-bonds between pY657, R649 and K569 in the Activation-loop (Chen et 
al., 2007). At the same time, the inward rotation of the N-lobe brings it closer to the 
C-lobe resulting in appropriate alignment of the catalytic residues located in the 
Activation-loop, catalytic-loop and αC-helix. The new rearrangement facilitates the 
binding of ATP and substrate to their respective binding pockets and enhances the 
efficiency of the catalysis (Figure 1.6).  
According to Chen and colleagues, the molecular autoinhibition prior to Activation-
loop phosphorylation is achieved by three residues, E565 (kinase hinge), N549 
(loop αC-β4) and K641 (β8), as revealed by structures of mutated and constitutively 
active FGFR2 kinases (Chen et al., 2007). In a wild type FGFR2 kinase, hydrogen-
bonds mediated between these residues stabilise the autoinhibitory conformation 
by abrogating the inward twist of the N-lobe towards the C-lobe. Phosphorylation of 
the Activation-loop causes dissociation of those hydrogen-bonds allowing the N-
lobe twist and Activation-loop rearrangement, ready for catalysis. Similarly, 
activating mutations of the FGFR2 kinase domain disrupt the network of hydrogen 
bonds causing constitutively active kinases.  
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Figure 1. 6: Structure of the wild-type FGFR2 kinase domain in a ribbon 
diagram. a) Unphosphorylated FGFR2 kinase domain. The kinase insert is shown 
in black, the kinase hinge region in orange, the nucleotide binding site in blue, the 
catalytic-loop in yellow and the Activation-loop in purple. b) phosphorylated FGFR2 
kinase domain. The non-hydrolysable ATP analog and the substrate are shown in a 
stick diagram. Adapted from Chen et al., 2007. 
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1.2.4.  FGFR2-induced signalling pathways 
1.2.4.1. The PLCgamma1 pathway 
PLCγ1 is a phospholipase that belongs to the Phospholipase C –γ subfamily of 
phospholipases. When activated, PLC enzymes catalyse the hydrolysis of the 
phospholipid phosphatidylinositol 4,5-biphosphate (PIP2) to Inositol 1,4,5-tri-
phosphate (IP3) and diacylglycerol (DAG). IP3 and DAG are second messenger 
molecules that can trigger downstream signal transduction. The PLCγ1 structure 
contains a pleckstrin homology domain (PH) followed by an EF hand series, 
followed by the catalytic domain called triosephosphate isomerase (TIM) barrel and 
a C2 domain (Figure 1.7). The TIM barrel is divided into X- and Y- boxes which are 
linked by an extended linker containing an N-terminal and a C-terminal SH2 domain 
(nSH2 and cSH2) as well as a SH3 domain, all within a split PH domain (Figure 1.7) 
(Poulin et al., 2005). 
The cSH2 domain of PLCγ1 is a critical regulator of the lipase auto-inhibition and 
activation. In non-stimulating conditions, intramolecular interactions between the 
cSH2 and the TIM barrel inhibit the phospholipase enzymatic activity. Upon FGFR2 
activation by FGF binding to the extracellular domain, tyrosine Y769 on the C-
terminal of the receptor gets phosphorylated attracting PLCγ1 that binds to the 
phospho-tyrosine through the nSH2 domain. As illustrated in Figure 1.8, the 
outcome of this interaction is the phosphorylation of Y783 located on PLCγ1 X-Y 
linker, a major residue involved in the phospholipase activation. The auto-inhibition 
is eliminated when cSH2 engages with the pY783 resulting in conformational 
changes that release the active site enabling interaction with the substrate (Hajicek 
et al., 2013). 
 
 
 
- 25 - 
 
 
 
 
Figure 1. 7: PLCγ1 domains. PLCγ1 is composed of an N-terminal PH domain 
and a series of EF-hand domains followed by the catalytic domain called 
triosephosphate isomerase (TIM) barrel, which is followed by a C2 C-terminal 
domain. The catalytic domain is split into X and Y boxes which are linked by a X-Y 
linker containing two SH2 and one SH3 domain surrounded by a PH domain (P and 
H are the split PH domain in the amino acid sequence). Intramolecular interactions 
between c-SH2 and the X-Y boxes inhibits the enzymatic activity of PLCγ1. PH = 
plekstrin homology domain, EF = EF-hand, 
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Figure 1. 8: The PLCγ1 pathway. Upon FGFR2 activation by FGF binding, 
tyrosine 769 is phosphorylated and can be recognized by the n-SH2 domain of 
PLCγ1. This binding is followed by tyrosine 783 phosphorylation located within the 
X-Y linker triggering the release of auto-inhibition. PLCγ1 can now hydrolyze PIP2 
into IP3 and DAG, second messenger molecules that promote cell motility. nSH2 
and cSH2 = N- and C- terminal SH2 domains, PIP2 = phospholipid 
phosphatidylinositol 4,5-biphosphate, IP3 = Inositol 1,4,5-triphosphate, DAG = 
diacylglycerol, NFAT= Nuclear factor of activated T-cells, PKC = Protein kinase C, 
MARCKS = Myristoylated alanine-rich C-kinase substrate 
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The recruitment of PLCγ1 to the receptor facilitates not only the activation of the 
enzyme but also places PLCγ1 in close proximity to the membrane where the 
substrate is located. IP3, one of the two products of the PIP2 hydrolysis, binds to 
the IP3 receptors in the endoplasmic reticulum triggering Ca2+ release into the 
cytoplasm which activates calcium-dependent proteins like calcineurin which in turn 
activates NFAT, a transcription factor that translocates to the nucleus activating the 
expression of cell motility genes. On the other hand, DAG activates the protein 
kinase C (PKC) which phosphorylates and activates substrates like the 
myristoylated Ala-rich C kinase substrate (MARCKS), a regulator of cell motility 
(Figure 1.8) (Goetz and Mohammadi, 2013). An alternative way of PLCγ1 activation 
under non-stimulating conditions includes interaction with the FGFR2 receptor 
through the SH3 domain of PLCγ1 binding to the proline-rich motif of the receptor at 
the C-terminal domain (Timsah et al., 2014). This phenomenon is explained in the 
next section. 
. 
1.2.4.2. The Ras/MAPK and PI3k/Akt pathway 
Two additional pathways can be initiated by FGFR2 activation called mitogen-
activated protein kinase (MAPK) and PI3k-Akt pathway. The first and most critical 
component of these pathways is FGFR-related substrate 2 (FRS2). FRS2 is an 
adaptor protein, meaning that it lacks catalytic activity, and is also a substrate of 
FGFR2 (the first substrate (FRS1) of FGF receptors is actually PLCγ1). Not all 
RTKs can bind FRS2 since its PTB domain recognizes residues only on FGFRs, 
neurotrophin receptors and RET. Both isoforms of FRS2, FRS2α and FRS2β, carry 
a myristilation sequence at the N-terminal which anchors them to the plasma 
membrane, a PTB domain that binds to either phosphorylated or non-
phosphorylated tyrosine residues on specific RTKs and a series of tyrosines that 
can be phosphorylated by activated receptors and act as docking sites for 
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downstream signaling proteins such as GRB2 and Shp2 (Figure 1.9). Both FRS2α 
and -β have 2 binding sites for SH2-containing tyrosine phosphatase (Shp2). 
FRS2α also has 4 binding sites for Grb2, another adaptor protein, while FRS2β has 
three (Gotoh, 2008). 
Notably, FRS2 constitutively binds to specific tyrosine residues on the 
juxtamembrane region of FGFRs that are not phosphorylated, meaning that it is 
bound to FGFRs even in the absence of extracellular stimulation. However, the 
binding to RET and neurotrophine receptors is activation-dependent and the 
binding is mediated through the PTB domain of FRS2 that recognizes 
phosphotyrosines in the juxtamembrane region of those receptors. When FGFRs 
are activated, FRS2 is phosphorylated by the receptor at the tyrosine residues 
creating docking areas for Grb2 and Shp2. Grb2 contains one SH2 domain that 
uses to bind to the phosphorylated FRS2 and two SH3 domains that interact with 
downstream proteins such as SOS, Gab1 and Cbl (Figure 1.10) (Gotoh, 2008). 
SOS stands for son-of-sevenless and is a guanine nucleotide exchange factor 
(GEF) for Ras, a GTPase. The binding of SOS to Grb2 through the N-terminal SH3 
domain of Grb2 results in SOS activation due to the release of C-terminal inhibition 
and also brings SOS in close proximity to the membrane-bound Ras, where it can 
exchange GDP with GTP resulting in Ras-GTP, the activated form of Ras (Zarich et 
al., 2006). Ras, in turn, activates the first kinase of the pathway called Raf, which is 
a serine/threonine kinase, initiating a cascade of kinase phosphorylation and 
activation. MEK1/2 phosphorylation and activation by Raf is followed by MEK1/2-
mediated ERK1/2 activation. ERK1/2 can translocate to the nucleus where it 
phosphorylates transcription factors like c-Fos that regulate gene expression 
promoting cell proliferation (Figure 1.10) (Dhillon et al., 2007). 
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Figure 1. 9: Figure 1.4: FRS2 and Grb2 adaptor proteins. FRS2 contains a 
myristilation sequence that uses to anchor to the cell membrane, a PTB domain 
that recognises residues in the juxtamembrane region of FGFR2 and a series of 
phospho-tyrosines responsible for Grb2 and Shp2 recruitment through SH2 
domains. Grb2 contains a single SH2 domain surrounded by two SH3 domains. 
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Figure 1. 10: The MAPK pathway. A stimulated receptor phosphorylates tyrosine 
residues on FRS2 which interact with Grb2. Grb2, in turn, interacts with Gab1, that 
initiates the PI3k/Akt pathway, Cbl1, that triggers receptor degradation and SOS, 
which activates the Ras/Raf/MAPK pathway. 
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Gab1 stands for Grb2-associated binding protein 1 and is another adaptor protein 
that binds to the C-terminal SH3 domain of Grb2 triggering the PI3k-Akt pathway as 
illustrated in Figure 1.11. Upon receptor activation the formation of the complex 
FRS2/Grb2/Gab1 causes phosphorylation of Gab1 recruiting the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3k) that produces PIP3. PIP3 is 
recognized by plekstrin (PH) domains contained in proteins like Akt (or PKB for 
Protein Kinase B) and phosphoinositide-dependent kinase-1 (PDK-1). As a first 
step, the binding of Akt to PIP3 releases the auto-inhibition caused by 
intermolecular interactions between the PH domain and the kinase domain. The 
complete activation of Akt occurs following phosphorylation of the threonine 308 by 
the also membrane-recruited PDK-1 and the phosphorylation of serine 473 by 
mTOR complex 2 (mTORC2). Negative regulation of the PI3k-Akt pathway is 
mediated by the Phosphatase and tensin homolog (PTEN) which reverses the 
production of PIP3 by PI3k as well as by two phosphatases named Protein 
phosphatase 2 (PP2A) and PH domain and Leucine rich repeat Protein 
Phosphatases (PHLPP) that dephosphorylate thr308 and Ser473 on Akt, 
respectively, resulting in Akt inhibition (Hers et al., 2011). 
Activated Akt phosphorylates a variety of downstream effector proteins regulating 
cell survival and apoptosis pathways, metabolism and cell proliferation (Figure 
1.11). Akt positively regulates glucose transportation through negative 
phosphorylation of PTP11B, a downstream effector that inhibits insulin signalling. 
Metabolism is also regulated by phosphorylation of GSK3-β which inhibits the 
kinase activity resulting in the activation of the glycogen synthase enzyme and 
subsequently increase in the glycogen synthesis by the cell. GSK3 also stimulates 
cyclin D1 and E as well as c-jun and c-myc degradation and therefore, 
phosphorylation and inhibition by Akt promotes cell proliferation. Moreover, Akt 
regulates cell survival by phosphorylating pro-apoptotic Bcl-2 homology domain 
(BH3)-only proteins that inactivate pro-survival proteins like the Bcl-2 members. The 
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phosphorylation of BH3-only proteins inhibits their ability to inactivate pro-survival 
proteins promoting cell survival. Another Akt effector is ASK1 (apoptosis signal 
related kinase), whose phosphorylation prevents apoptosis. Furthermore, Akt 
promotes cell survival by regulating effectors in a transcriptional level. Akt 
negatively phosphorylates transcription factors of the FOXO (forkhead box) family 
preventing BH3-only proteins and Fas-ligand expression and subsequent apoptosis 
signalling pathways. Except for negative regulation, Akt positively phosphorylates 
transcription factors like CREB and NF-κB that activate the expression of Bcl-2 
proteins and c-IAP1 & 2, respectively, triggering cell survival. Lastly, Akt positively 
regulates the mTORC1 pathway that stimulates cellular growth as well as 
negatively phosphorylates TSC2 (Tuberous Sclerosis Complex 2) and PRAS40 
(Proline-rich AKT1 substrate 1), inhibitors of mTORC1 (Hers et al., 2011). 
However, the adaptor protein FRS2 triggers both positive and negative signals. The 
binding of Cbl (Casitas B-lineage Lymphoma) to the complex of FGFR/FRS2/Grb2 
causes ubiquitination and subsequently degradation of the receptor as a form of 
signal elimination (Kaabeche et al., 2004). 
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Figure 1. 11: FGFR2-mediated Akt/PI3k pathway. A stimulated FGFR2 receptor 
recruits the Grb2-Gab1 complex through FRS2. Gab1 activates PI3k that converts 
PIP2 to PIP3 which is in turn recognised by Akt and PDK1 through its plekstrin 
domain. In this way, Akt is recruited to the cell membrane where it gets 
phosphorylated by PKD1 in threonine 308 and by mTORC2 in serine 473. The 
phosphorylation causes Akt kinase upregulation which phosphorylates a series of 
targets like GSK3, the anti-apoptotic proteins BAD and BIK, the transcription factors 
of the FOXO family, CREB and NF-Κb and mTORC1 promoting cell proliferation, 
glycogen synthesis, cell survival and cell growth. 
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1.2.5. Importance of Proline-rich motifs in signal transduction  
The most common type of protein motif found in eukaryotic cells is the 
proline-rich motif which frequently includes a sequence of mainly proline 
residues with additional flanking residues that form a special secondary 
structure called left-handed Polyproline II helix (PPII) (Rubin et al., 2000). 
The PPII helix features a pseudo-symmetry of three residues per turn, 
explaining the observed proline-rich motif patterns in proteins which are 1) 
PxxPxxP and 2) xPPxPPx, where x represents any other residue. Only six 
different types of proline-rich motif-binding domains have been described so 
far; SH3, WW, EVH1, GYF, UEV domain and the single-domain profiling 
proteins (Ball et al., 2005).  
Proline-rich motifs are great binding targets for protein interactions due to 
several characteristics. The low entropic binding of proline-rich motifs to 
binding sites facilitates a relatively strong and stable binding. Polyproline 
peptides have an incredibly limited mobility (and thus entropy), coming from 
the fact that prolines have restricted degrees of rotational freedom, which is 
reduced even more upon interaction with proline-rich binding domains 
stabilizing the interaction. Therefore, the binding is stronger compared to an 
interaction involving a regular, more flexible polypeptide. An additional 
advantage originates from the fact that the backbone of the polyproline 
peptides lacks intramolecular hydrogen bond formation due to the 
unavailability of the amide of the prolines, making the carbonyl groups 
available for intermolecular hydrogen bonding. Similarly, carbonyl groups of 
prolines are electron-rich due to the interaction of the methyl group with the 
amide nitrogen, causing prolines to be good hydrogen bond acceptors rather 
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than donors, as other amino acids are. An interesting feature of PPII helices 
is that the side chains and the carbonyl groups of the backbone are pointed 
outward to the solvent at regular intervals (C2 pseudo-symmetry) explaining 
the property of binding sites to interact in two directions; the forward and 
reverse orientation (Ball et al., 2005; Williamson, 1994; Zarrinpar et al., 
2003).  
Notably, there is a wide range of proteins carrying proline-rich motifs. Firstly, 
hydroxylated polyproline motifs have a more structural rather than a 
binding/interaction role. They exist in proteins like collagen, the most 
abundant protein in animals, whose triple-stranded helix consists of three 
PPII helices in which proline residues stabilize the collagen structure. 
Additional examples of proline-rich motifs with structural role are the blood 
complement protein C1q as well as the plant cell wall proteins called 
extensins. Apart from the structural role, proline-rich motifs are generally 
involved in protein interactions necessary for different processes. One 
example is the salivary proline-rich proteins whose sequence is mainly 
constituted of proline-rich motifs. These proteins account for the 70% of all 
the proteins in the saliva and use the proline-rich motifs to bind to dietary 
polyphenols in order to eliminate the toxic effects. Mutual proline-rich 
interactions are also crucial for transcription processes. RNA Pol II 
possesses a series of repeated proline-rich motifs at the C-terminal domain 
which is speculated that it is involved in the assembly of multiple 
transcriptional activators forming transcription complexes. Furthermore, 
proline-rich motifs are also implicated in synaptic vesicle release process. 
Syntaxin-1, for instance, carries proline-rich motifs that uses to interact with 
membrane-bound proteins like VAMP-1 and synaptophysin, also proline-rich 
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proteins, activating vesicle release at synapses. A final type of proline-rich 
proteins that has also attracted a lot of interest due to the involvement in 
signal transduction is the proteins that bind to SH3 domains. SH3-containing 
proteins can have a catalytic activity like PLCγ1, Src, Abl or can be adaptor 
proteins like Grb2 (Williamson, 1994).  
SH3 domains are sequences of around 60 residues long that bind to the 
PxxP motif in two orientations and thus, they are divided into two classes. 
SH3 Class I binds in the forward orientation (N- to C-) and recognizes the 
motif (R/K)xxPxxP, where R = Arginine and K = Lysine and SH3 Class II 
binds in reverse orientation (C- to N-) and recognizes the motif PxxPx(R/K). 
SH3 domains form two anti-parallel β-sheets and two loops, named RT and 
c-Src loop. The interaction occurs when aromatic residues of the SH3 
domain (Tyrosine and Tryptophan) that form hydrophobic groves, form 
hydrogen bonds with the backbone carbonyl groups of the PPII. The 
exposed side chains of the prolines 1 and 4 (periodic turn every 3 residues) 
enter the hydrophobic pockets of the SH3 surface just like ridges and 
groves. Specificity is accomplished by residues in the surrounding loops 
flanking the core binding area that interact with opposite flanking residues on 
the PPII helix of the proline-rich motif (Ball et al., 2005; Zarrinpar et al., 
2003).  
SH3 domains can have a recruitment as well as a regulatory role. For 
instance upon stimulation, FGFR2 is activated and phosphorylates FRS2 
creating phosphotyrosine binding sites for the SH2 domain of Grb2. Grb2 is 
already bound to SOS through the nSH3 domain that recognizes the proline-
rich motif (VPPPVPPRRR peptide) on SOS, the activator of Ras. As Ras is 
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myristoylated and membrane-bound, Grb2 brings SOS in membrane vicinity 
resulting in co-localisation with Ras and subsequent activation of the 
GTPase (Terasawa et al., 1994). In this case, interaction between SH3 
domains and proline-rich motifs connects the activation of receptor tyrosine 
kinases with the Ras-Raf-MAPK pathway. In other cases, SH3 domains 
regulate protein activity such as the SH3 domain in src kinase that once 
bound to targets, releases the inhibitory effect that was established by 
intramolecular interactions with the src SH2 domain (113).  
Apart from adaptor and effector proteins, proline-rich motifs exist in the C-
terminal domain of tyrosine kinase receptors. The proline-rich motif of 
FGFR2 has been proved to be involved in signal transduction regulation via 
protein-protein interactions. The first binding partner was identified in 2010 
by Ahmed et al who described the direct interaction between the proline-rich 
motif of FGFR2 with the c-SH3 domain of the adaptor protein Grb2. In basal 
conditions, dimeric Grb2 binds to FGFR2 causing dimerization and basal 
auto-phosphorylation activity, yet no downstream signalling pathway is 
activated. The binding covers tyrosine residues inhibiting phosphorylation 
and complete activation of the receptor (Figure 1.12a). Upregulation of the 
kinase activity occurs when the receptor is stimulated by an FGF ligand 
resulting in Grb2 phosphorylation in tyrosine Y209. Grb2 is no longer 
capable of binding to FGFR2, enabling the receptor to get fully activated and 
trigger downstream signalling pathways (Figure 1.12b) (Ahmed et al., 2010). 
The second binding partner was identified in 2014 by Timsah et al, who 
demonstrated that PLCγ1 can interact with the proline-rich motif of FGFR2 
via its SH3 domain. In basal conditions. PLCγ1 auto-inhibition prevails and 
the pathway is inactive. PLCγ1 auto-inhibition is released upon binding to 
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the proline-rich motif of the receptor resulting in pathway activation and 
increased cellular invasion. Notably, the interaction with FGFR2 depends on 
protein concentration since Grb2 is also competing for the binding site 
(Figure 1.12c) (Timsah et al., 2014). Nevertheless, PLCγ1 can also be 
“canonically” activated by interacting with phospho-tyrosines on stimulated 
FGFR2 via its SH2 domain, as described in the PLCγ1 section.  
Both of these cases highlight the importance of receptor-proline rich motifs in 
signal transduction regulation under non-stimulating conditions, either by 
inhibiting receptor activation or by regulating pathways depending on protein 
equilibrium. However, not all the binding partners have been identified. SH3-
containing proteins are more prominent because they are known to 
recognise proline-rich motifs. So far, both Grb2 and PLCγ1 interact with 
FGFR2 through their SH3 domains. Interestingly, there is evidence of direct 
interaction between proline-rich motifs and Ankyrin repeat domains, another 
common protein motif explained in detail in the TRPA1 section. According to 
Rader et al, the mouse Ankyrin-repeat family A protein (ANKRA) interacts 
with the proline-rich motif-containing cytoplasmic domain of rat megalin (a 
low-density lipoprotein receptor found in epithelial kidney cells) through its 
ankyrin repeats (Rader et al., 2000). Based on this evidence, there could be 
possible ankyrin repeat containing binding partners for the proline-rich motif 
of FGFR2. One of them is the ion channel TRPA1 which is described in 
section 1.3 and studied in this project.  
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Figure 1. 12: FGFR2 proline-rich motif protein interactions and role in signal 
transduction. a. Dimeric Grb2 regulates the basal FGFR2 phosphorylation levels 
by interacting with the C-terminal proline-rich motif of the receptor through its cSH3 
domain. b. Under stimulating conditions, FGFR2 kinase activity is upregulated and 
phosphorylates Grb2 in tyrosine 209 resulting in Grb2 dissociation and activation of 
downstream pathways. c. PLCγ1 competes with Grb2 for the proline-rich motif of 
FGFR2. Under non-stimulating conditions and low Grb2 concentrations, PLCγ1 
binds to the receptor and gets activated resulting in PLCγ1 pathway activation and 
increased cell invasion.  
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1.2.6. FGFR2 implication in cancer  
Aberrant FGFR signalling is responsible for various skeletal disorders as 
well as numerous carcinomas. Aberrant signalling can originate from gene 
amplification, protein overexpression, activating mutations or chromosomal 
translocations that all result in enhanced receptor activity and downstream 
signalling (Hallinan et al., 2016).  
Out of all FGFRs, gene amplifications are more frequent in FGFR1 gene and 
have been reported in 16% of squamous NSCLC, 15% of ER-positive and 
4.1% of triple-negative breast cancers (Lee et al., 2014; Schildhaus et al., 
2013, p. 1). However, FGFR2 gene and protein are also amplified/elevated 
in 4.7% and 12.8% of triple-negative breast cancers, respectively, and 
FGFR2 SNPs have been associated with increased breast cancer risk 
(Campbell et al., 2016; Lee et al., 2014). Moreover, FGFR2 is found 
overexpressed in approximately 4-9% of gastric cancers and is associated 
with aggressive tumours and poor prognosis (Ahn et al., 2016; Deng et al., 
2012). Inhibition of FGFR2 with PD173074 in FGFR2–amplified gastric cell 
lines resulted in decreased cell proliferation and increased apoptosis. 
Concomitant with the enhanced FGFR2 signalling, increased 
phosphorylated EGFR, Her2 and Erbb3 levels were observed which 
conferred resistance to anti-EGFR treatment and were FGFR2-dependent 
(Kunii et al., 2008). Interestingly, overexpression of FGFR2 in those cancers 
is accompanied by the overexpression of the FGFR2-IIIb C3 isoform that 
has a shorter C-terminal region and lacks specific tyrosine and leucine 
residues important for receptor internalisation. The C3 isoform confers more 
stability and increased activity to the receptor promoting tumorigenic levels 
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of signalling (Cha et al., 2009). FGFR2 protein levels are also increased in 
11.1% of hepatocellular carcinoma and associated with poorer overall 
survival (Lee et al., 2015) Increased FGFR2 protein levels also occur in 
12.9% of NSLC and 52% of pancreatic cancer cases in which are correlated 
with advanced stages (Matsuda et al., 2014; Theelen et al., 2016). On the 
other hand, FGFR2 down-regulation has also been reported. Both main 
FGFR2 isoforms (IIIb and IIIc) are decreased in thyroid cancer suggesting 
the use of FGFR2 expression levels as a marker for early diagnosis (Redler 
et al., 2013).  
In contrast, FGFR2 activating mutations are more common in cancers. 
FGFR2 mutations similar to germline mutations responsible for skeletal 
syndromes are present in 10-16% of endometrial carcinoma including the 
most common S252W mutation that affects the D2-D3 extracellular ligand-
binding domain that enhances ligand affinity and alters specificity (Pollock et 
al., 2007; Yu et al., 2000). Inhibition of FGFR2 by PD173074 or shRNA 
reduced endometrial cell lines proliferation and induced apoptosis (Byron et 
al., 2008). FGFR2 mutations also occur in 2.7-5% of squamous NSCLC and 
2.2% of total NSCLC cases (Hibi et al., 2016; Liao et al., 2013). Most of 
these mutations are located in the extracellular domain increasing ligand-
binding or receptor dimerisation and activation. However, tyrosine kinase 
domain mutations also occur and are capable of promoting cellular 
transformation in xenografts which can be reversed by FGFR2 inhibitors 
(Liao et al., 2013; Tchaicha et al., 2014).  
FGFR2 fusion proteins are rare in cancers. However, FGFR2 fusions have 
been found in NSCLC (FGFR2-KIAA1967), breast cancer (FGFR2-AFF3), 
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prostate (SLC45A3-FGFR2) and thyroid cancer (FGFR2-OFD1), where the 
FGFR2-binding partner promotes receptor dimerization and kinase activation 
(Wu et al., 2013). The most common FGFR2 fusion is found in 
cholangiocarcinoma with the FGFR2-PPHLN1 fusion present in 16% of the 
cases (Sia et al., 2015).  
Moreover, FGFR2 isoform switch (IIIb to IIIc) is implicated in epithelial to 
mesenchymal transition (EMT) and cancer progression. FGFR2IIIb is 
characterised as an epithelial isoform due to involvement in epithelial cell 
differentiation while FGFR2IIIc is a mesenchymal isoform which is often 
overexpressed in epithelial tumours. Ranieri et al 2016 showed that human 
keratinocytes overexpressing IIIc instead of IIIb demonstrated morphological 
and cytoskeletal changes that favour invasive phenotypes like anchorage-
independent cell growth and expression of mesenchymal markers (Ranieri et 
al., 2015b). The phenotype actually occurs following FGF2 treatment 
indicating that stimulation is still required for activation of the receptor and 
EMT initiation. However, the two isoforms have different specificity and 
affinity for ligands thus, microenvironment signals are interpreted in different 
ways. The FGFR2IIIb-mediated keratinocyte invasiveness is also supported 
by the fact that E5 human papilloma virus 16 protein (16E5) was able to alter 
the FGFR2 splicing machinery in keratinocytes so that the IIIc isoform is 
produced, a switch necessary for EMT initiation in the early stages of 
carcinogenesis (Ranieri et al., 2015a). Similarly, the isoform switch to IIIc 
was observed in 90% of renal carcinomas and associated with a 
mesenchymal cell phenotype (Zhao et al., 2013). Presence of the IIIc 
isoform is also found in 27% of colorectal cancer cases and is associated 
with distant metastasis and poor prognosis. Colorectal cancer cell lines 
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overexpressing IIIc isoform demonstrated increased growth and invasion as 
well as increased formation of larger tumours in mice. These results were 
reversed by an FGFR2IIIc-specific antibody suggesting the FGFR2 isoform 
targeted therapy (Matsuda et al., 2012). Numerous studies have suggested 
the role of FGR2IIIc in tumour progression and EMT in various cancers like 
breast, cervical and prostate cancer (Cha et al., 2008; Kawase et al., 2010; 
Shoji et al., 2014). Despite this evidence, the role of IIIc remains elusive 
since it is also involved in mesenchymal to epithelial transition (MET) as 
reported in bladder cancer cell lines (Chaffer et al., 2006). 
 
1.3. The Transient Receptor Potential Ankyrin Repeat 1 (TRPA1) 
1.3.1. The TRP channels 
TRP (Transient Receptor Potential) channels are non-selective cation 
channels, meaning that they are permeable to monovalent (Na+, K+) and 
divalent (Ca2+, Mg2+) cations, with higher selectivity to Ca2+. Not all the 
structures of the known TRP channels have been elucidated yet, but they all 
seem to share the same membrane topology of six transmembrane domains 
(S1-S6) with a central pore formed by the pore helixes between S5 and S6. 
A functional channel is composed of four subunits forming homotetramers 
(Venkatachalam and Montell, 2007). However, heterotetramers have also 
been found within members of the same family like the TRPC family (Cioffi 
et al., 2012; Strübing et al., 2001; Woo et al., 2014) as well as members of 
different families (Kobori et al., 2009; Stewart et al., 2010). 
TRP channels are distinctive from the similar topology voltage-gated K+ 
channels due to the absence of charged residues in the S4 domain; thus 
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TRP channels are non-voltage-gated ion channels that are mainly expressed 
in sensory neurons. Conservation between species reveals the critical role of 
TRP channels in sensing environmental cues, from thermosensation all the 
way to noxious pain sensation (Venkatachalam and Montell, 2007). The 
implication of TRP channels into several sensations like heat and cold 
sensing, vision, hearing, olfaction, taste, touch and pain have been reported 
in the past however, the exact mechanism of action remains most of the 
times unknown (Bautista et al., 2007; Caterina et al., 1997; Cuajungco et al., 
2007; Grandl et al., 2010; Jin et al., 2017; Julius, 2013; Montell, 2005; Pyrski 
et al., 2017). Despite the identical membrane topology, diversity in the 
activity between TRP channels is noticed due to differences in the amino 
acid sequence of the N- and C-terminal domains, which both happen to be 
intracellular and carry variable motifs like Ankyrin repeats, coiled coil 
regions, TRP box, EF-hand, Ca2+/calmodulin binding sites, enzymatic 
activities and more (Voets et al., 2005).  
1.3.1.1. The trp mutant 
In 1969, Cosens D.J. and Manning A. discovered a new Drosophila 
Melanogaster mutant with impaired visual system based on behavioural 
tests. They described the mutant as nearly blind since the electroterinogram 
(ERG) response to a continuous bright light decreases after a period of 10 to 
15 seconds, followed by a recovery period during which the fly cannot 
respond to any light stimuli. They located this Mendelian factor in the third 
chromosome and identified it as a recessive mutation (Cosens and Manning, 
1969). Later on, in 1975, Minke, B. and colleagues named this D. 
Melanogaster mutant as transient receptor potential mutant (trp) due to the 
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fact that unlike wild-type flies, there was a transient large initial response to 
intense light that decays to the baseline, steady state potential that 
represents the response to dim light (Minke et al., 1975). During that time, 
the role of the trp locus was unknown, until 1989 when the trp gene was 
cloned. The trp RNA is 4.1kb long and produces a 1275 amino acid 
transmembrane protein with 8 putative TM domains that was not similar to 
any known protein in that time (Minke et al., 1975). However, it was believed 
that the TRP protein was involved in light signal transduction subsequent to 
the production of IP3 by PLC (PLC is activated by G-proteins activated by 
rhodopsin, a light-sensitive receptor in flies) (Montell and Rubin, 1989). 
The first evidence suggesting that the TRP protein is a calcium (Ca2+) 
channel came from experiments using the fly Calliphora in which Lathanum 
(La3+), a non-selective Ca2+ transporter blocker, was applied to the retina of 
the wild type fly. Similar to the Drosophilatrp mutant, the response to intense 
light stimulation was decreased after a short period of high receptor potential 
(Hochstrate, 1989). Soon enough, Suss Toby et al., verified the previous 
results and described that La3+ application caused a trp-like response in wild 
type flies but not in the trp mutant homologue in those flies, indicating that 
the TRP protein is a putative Ca2+ transporter that can be blocked by La3+ 
(Suss-Toby et al., 1991). 
In 1992, Hardie and Minke demonstrated that the TRP protein is indeed a 
non-voltage-gated Ca2+ channel that is absent in the trp mutant and tried to 
explain the trp phenotype based on that hypothesis. They proposed that 
there are at least two classes of light-sensitive Ca2+ channels involved in the 
phototransduction system of the fly and that TRP is the high Ca2+ 
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permeability one which is missing in the trp mutant. However, the stable-
plateau state is sustained by the second class of ion channels. They also 
explained that the TRP Ca2+ channel is indirectly activated by IP3 to initiate 
Ca2+ influx into the cell that is important for excitation during intense light 
stimulation (Hardie and Minke, 1992). At the same time, another group of 
researchers identified a trp homologue in the Drosophila genome with a 74% 
transmembrane amino acid sequence similarity that they named transient 
receptor potential-like (trpl) gene. The TRPL protein has 2 calmodulin-
binding sites, has 6 transmembrane domains and carries Ankyrin-like 
repeats. The group proposed that the TRPL protein is also a Ca2+ channel, 
expressed in rhabdomeres like the TRP protein, verifying the Hardie and 
Minke’s hypothesis of two separate classes of Ca2+ channels mediating the 
wild type response in intense light illumination (Phillips et al., 1992). 
1.3.1.2. The discovery of mammalian TRP channels 
After the discovery of TRP channels in arthropods, studies were focused on 
identifying the existence of those channels in vertebrate organisms. Since 
the first TRP channel in Drosophila, more than 100 homologues have been 
identified in several animals. In total, 28 channels have been found in 
mammals and only 27 channels, grouped in 6 families, have been found in 
humans; TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP 
(polycystin), TRPML (mucolipin) and TRPA (ankyrin) (Nilius and Owsianik, 
2011). 
The first human trp homologue was discovered in 1995. It was named 
Human trp-1 (Htrp-1) and it was almost 40% identical to the invertebrate trp 
(Zhu et al., 1995). The same year, another group identified a family of 
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human TRP channel genes named TRPC1-3 for transient receptor potential 
channel-related protein 1-3. Only the TRPC1 and 3 were actually expressed 
into proteins; TRPC2 is a pseudogene. These channels were widely 
expressed in human tissues (mainly brain, testis, ovaries and heart) and 
characterised as non-voltage gated ion channels due to the absence of 
charged residues in the S4 transmembrane domain. These discoveries 
revealed that trp proteins are conserved within species and mediate an 
important role in calcium replenishment. Another important observation is 
the conservation of Ankyrin repeats in the N-terminal domain of trp channels, 
suggesting a regulatory role in channels activation or signal transduction 
through the cytoskeleton (Wes et al., 1995). The next year, 7 TRP channels 
were identified in the mouse genome (Mtrp-1-6 and TRP7) (Okada et al., 
1999; Zhu et al., 1996). The mammalian TRP channels, had high similarity 
to the original Drosophila trp and later were grouped in the same category of 
TRP-canonical (TRPC) ion channels consisting of 7 members in humans 
(Montell et al., 2002). 
The next human trp channel was discovered in 1997 by David Julius group 
in an attempt to identify capsasin receptors (capsasin is the active ingredient 
in “hot” chilli peppers). A functional assay was performed based on the fact 
that capsasin stimulation results to Ca2+ influx in sensory neurons. The 
assay was designed to detect Ca2+ influx followed by capsasin treatment of 
non-neuronal cells transfected with cDNA clones from dorsal root ganglia 
neurons (DRG) library, thinking that the expression of the receptor-coding 
cDNA would mediate non-neuronal cell stimulation. The new receptor was 
named vanilliod receptor 1 (VR1) and was also heat-activated. VR1 was 
expressed in small diameter sensory neurons. Homology studies revealed 
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that VR1 was similar to other human TRPs and the original trp channels in 
Drosophila underlying the diverse role of trp channels (Caterina et al., 1997). 
Two years later, the vanilloid receptor-like protein 1 (VRL1) was cloned by 
the same group based on sequence similarity with VR1. The new protein 
was not activated by capsasin but noxious heat (52oC), was 66% identical to 
VR1 and seemed to belong to the trp family of ion channels (Caterina et al., 
1999). Within the next years, more ion channels similar to VR1 were 
identified and grouped in the same family of transient receptor potential 
vanilloid (TRPV) channels (Hoenderop et al., 2001; Montell et al., 2002; 
Smith et al., 2002). The TRPV family consists of 6 TRP ion channels in 
humans (Nilius and Owsianik, 2011). 
Melastatin was the founding member of the TRPM family of ion channels, 
first characterised in 1998 (Hunter et al., 1998; Montell et al., 2002). Only 8 
members of the TRPM family are expressed in the human genome . The 
founding member of the TRPP family is PKD2 (polycystic kidney disease-2) 
or Polycystin-2, a protein involved in Polycystic kidney disease. The human 
TRPP family consists of three members: TRPP2 (PKD2), TRPP3 (PKD2L1) 
and TRPP5 (PKD2L2) (Koulen et al., 2002; Nilius and Owsianik, 2011; 
Veldhuisen et al., 1999). The gene named MCOLN1 that is involved in 
Mycolipidosis IV, a degenerative disorder, encodes for the protein mucolipin, 
the founding member of the TRPML family of ion channels that consists of 
three channels in total (Nilius and Owsianik, 2011; Sun et al., 2000). The 
most recently discovered family of TRP channels is the TRPA family with the 
TRP-Ankyrin 1 (TRPA1) being the one and only member of this family in 
humans (Jaquemar et al., 1999). 
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1.3.1.3.  The discovery and characterisation of TRPA1 
TRPA1 was discovered in 1999 by D. Jaquemar et al. in an attempt to 
identify proteins with altered expression following oncogenic transformation 
(Jaquemar et al., 1999). It was found that TRPA1 was one of the 
transformation-sensitive proteins that were repressed in SV40-trasnformed 
human lung fibroblasts. This novel Ankyrin repeat-containing protein was 
named p120, was 1119 amino acid long and 127.5kDa. The gene is located 
at chromosome 8 in the region 8q13. p120 was expressed in very low levels 
in human tissues and mainly in lung fibroblasts and liposarcoma cells. Based 
on its amino acid sequence, p120 could be divided into two parts: an N-
terminal domain containing 14-18 ankyrin repeats resembling the 
cytoskeletal protein Ankyrin and, a C-terminal domain containing 6 
hydrophobic segments that could be transmembrane domains. Full length 
p120 could not be overexpressed in mammalian cells despite numerous 
attempts. High levels of the protein appeared to be toxic and abolished 
healthy cell growth. The function of the novel protein remained unknown, 
however it was noted that its topology was very similar to the TRP-like 
proteins, characterising it as putative ion exchanger which is involved in 
signal transduction (Jaquemar et al., 1999). 
Generally, TRP channels are involved in thermosensation and can be 
activated at different temperature thresholds like the heat-activated TRPV1 
at 43oC, TRPV3 at 33oC, TRPV2 at 55oC and the cool temperature- and 
menthol- activated TRPM8 (25oC) (Bautista et al., 2007; Bender et al., 2005; 
Grandl et al., 2010; Moqrich et al., 2005). In 2003, Story et al. identified 
TRPA1 as a cold-activated TRP channel after screening for proteins that 
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resemble TRP channels and could be involved in thermosensation (Story et 
al., 2003). The first evidence originated from the fact that TRPA1 was 
expressed in a small population of mouse DRG neurons including the non-
myelinated C and αδ fibres as well as Calcitonin gene-related peptide 
(CGRP) and substance P (SP)- positive neurons, which are also involved in 
sensing temperature and noxious cues. TRPA1 was further found to be co-
expressed with the heat-activated TRPV1-prositive neurons at 30%, while 
97% of the TRPA1-positive neurons expressed TRPV1 at the same time. By 
performing a series of calcium imaging and patch clamp experiments on 
TRPA1-transfected CHO and HEK cells as well as utilising Xenopus 
oocytes, Story et al. introduced that TRPA1 is a cold temperature-activated 
non-selective cation channel with a temperature threshold of approximately 
17oC. However, TRPA1 was not co-expressed with the cold-activated 
TRPM8, suggesting at least three distinct subpopulations of neurons: 
TRPV1+/TRPA1+/TRPM8- which can be activated at cold temperatures 
(~15oC) (as well as hot temperatures), TRPV1-/TRPA1-/TRPM8+ which can 
be activated at cool temperatures (~24oC) and menthol and lastly, 
TRPV1+/TRPA1-/TRPM8- activated at hot temperatures (Story et al., 2003). 
Following the discovery of TRPA1 thermosensitivity, a series of plant-based 
natural compounds were also identified as TRPA1 agonists including allyl-
isothiocyanate (mustard oil), cinnamaldehyde (cinnamon), gingerol (ginger), 
eugenol (cloves), methyl salicylate (wintergrass), D9-tetrahydrocannabinol 
(THC) and cannabinol (cannabis), describing TRPA1 as a noxious 
compound chemosensor of DRG and trigeminal ganglia neurons (Bandell et 
al., 2004; Jordt et al., 2004). Moreover, a panel of isothiocyanates (chemical 
group –N=C=S) known to cause skin irritation and inflammation were also 
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identified as TRPA1 specific agonists. Apart from the allyl-isothiocyanate 
found in mustard oil, this panel included benzyl-isothiocyanate (yellow 
mustard), phenylethyl-isothiocyanate (Brussel sprouts), isopropyl-
isothiocyanate (nasturtium seeds) and methyl-isothiocyantate (capers) (Jordt 
et al., 2004). Furthermore, it was demonstrated that TRPA1 can also be 
activated indirectly by bradykinin (a pain- and inflammation-inducing 
reagent) through B2R (bradykinin receptor) and the downstream activation 
of PLC effectors, supporting the nociceptive role of TRPA1. However, the 
exact mechanism of activation is not known yet (Bandell et al., 2004). 
Interestingly, Jordt et al. (2004) were the first to demonstrate that human 
TRPA1 is not a cold-sensitive channel, initiating the still ongoing controversy 
regarding the ability of the human TRPA1 to detect and be activated by cold 
temperatures. 
1.3.2. TRPA1 structure 
The structure of the human TRPA1 was determined in 2015 by David Julius’ 
group to approximately 4Å by electron cryo-EM-microscopy (Paulsen et al., 
2015). A functional TRPA1 channel consists of four subunits forming a 
homotetramer. Each subunit carries a cytoplasmic N-terminal domain 
consisting of 16 ankyrin repeats, six α-helices forming the transmembrane 
domain and a cytoplasmic C-terminal domain folded in a coiled-coil 
secondary structure (Figure 1.13 and 1.14). The most distinctive feature of 
TRPA1 is the extended N-terminal domain, which combined with the C- 
terminal domain, comprises 80% of the whole channel mass (Paulsen et al., 
2015). 
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Figure 1. 13: The structure of a TRPA1 tetramer as solved by Paulsen et al 
2015. Each subunit is represented in a colour-coded ribbon diagram. The 
extracellular view (top left), cytosolic view (bottom left) and side view (right) are 
shown and include the residues 446-1078. Unstructured regions including the AR1-
11 are excluded from this representation. The structures were made using the 
Chimera software and the data obtained from PDB 3J9P. 
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In more detail, the tetrameric C-terminal coiled-coil structure is located right 
underneath the channel’s pore and is crucial for inter-subunit interactions 
and channel assembly (Figure 1.13). It appears that stabilising factors like 
polyphosphates (inositol hexakisphosphate – InsP6) bind to this area 
supporting channel’s function and integrity. An additional stabilising element 
at this location is a group of five Ankyrin repeats (ANK12-ANK16) of the N-
terminal domain of each subunit surrounding the tetrameric coiled-coil 
providing extra support and all together forming the “stem” of the channel 
(Figure 1.13). The configuration of the remaining 11 ankyrin repeats is poorly 
determined however, it is speculated that this group of ankyrin repeats of 
each subunit forms a crescent shape and all four crescent-shaped wings 
adopt a “propeller” structure right at the bottom of the channel located in the 
cytoplasmic area (Paulsen et al., 2015). 
Right above the “stem” of the channel and adjacent to the transmembrane 
domain, there is a complex network of multiple interactions between different 
structural elements of the channel that allosterically regulate the pore gating. 
Following the 16th ankyrin repeat, a pre-S1 region joins the ankyrin repeat 
domain (ARD) with the first transmembrane α-helix (S1) (Figure 1.14). The 
pre-S1 region also contains a linker with two helix-turn-helix (HTH) motifs 
connected by two β-strands. On the other hand, a TRP-like domain which 
follows the sixth transmembrane α-helix (S6) and is parallel to the lipid 
bilayer, creates a series of interactions with the α-helices of the two HTH 
motifs and the β-strands of the pre-S1 linker. The TRP-like domain of 
TRPA1 is crucial for allosteric modulation since it interconnects with multiple 
structural elements including the pre-S1 region and linker as well as the S4-
S5 linker via hydrophobic interactions. Important cysteine and lysine 
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residues for electrophilic interactions with agonistic compounds are located 
in the pre-S1 region and linker (C621, C641, C665 and L710) causing 
conformational changes and mechanical forces all the way to the TRP-like 
domain which translate into the channel’s gating. However, the AITC-binding 
site bound to the agonist has not been solved yet and no particular 
interactions and structural changes have been described so far (Paulsen et 
al., 2015). 
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Figure 1. 14: Structure of TRPA1 dimer and monomer in ribbon diagrams 
(186). AR 12-16 interacting with the C-terminal coild-coil form the “stem” of the 
channel, as shown in the dimer representation. More detailed structural domains 
are shown in colour-coded ribon diagrams (monomer). The structures were made 
using the Chimera software and the data obtained from PDB 3J9P.S 
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Although TRPA1 pore resembles that of TRPV1 for having two major 
constrictions sites, the TRPA1 pore is formed by two pore helices between 
S5 and S6, compared to one helix of TRPV1 (Paulsen et al., 2015). A series 
of current recordings on human wild type TRPA1 and pore-residue mutants 
reveal the key amino acids that modulate pore selectivity. The first step for 
ion conductance is attracting cations to the mouth of the channel while 
repelling anions at the same time. Glutamate at position 920 (E920) is the 
master regulator of attracting cations to the pore due to its negative charge. 
The more distant E924 and E930 are also involved in attracting cations, yet 
to a lesser extent. The charge-neutralising mutation E920 to Alanine 
(E920A) decreased the inward current of Cs+ compared to the wild type, as 
well as abolished the channel’s blockage by Ba2+, indicating E920 role in 
cation collection. Further deeper into the pore, aspartate 915 (D915) 
comprises the first constriction site, as firstly described by D. Julius (Paulsen 
et al., 2015). Permeant ions partially lose waters of hydration and the 
negatively-charged side chains of D915 make up for those interactions 
forming a tight selectivity filter. It is estimated that the diameter of an open 
pore at this site is at least 8.2Å, based on a screening for multiple-sized 
organic cations currents, which is relatively small compared to other cation 
channels. D915E mutation caused a reduced ion conductance due to the 
bulkier side group of glutamate creating steric hindrance that impedes ion 
permeation. On the other hand, altering the charge of the residue by using 
the D915N mutation also weakened inward currents indicating that the 
negative charge also facilitates permeation. At the deepest site of the pore a 
second constriction site is formed by two hydrophobic residues, Ile957 and 
Val96. This is the narrowest point of the pore with a diameter of 
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approximately 6Å that hinders permeation of rehydrated ions. Moreover, a 
recent study also proposes the involvement of the first extracellular loop (S1-
S2 linker) as a key player in pore opening regulation (Marsakova et al., 
2017). 
Two most common TRPA1 inhibitors include HC-030031 and A-967079. 
Although D. Julius attempted to solve the inhibitor-bound state of the 
channel, only A-967079 appeared to be successful. A-967079 binding site is 
located between the S5, S6 and the first pore helix and the most implicated 
residue at this site is Phe909. It is speculated that the inhibition is mediated 
through hindering the lower pore gate which is mostly formed by S5 and S6. 
Mutations affecting A-967079 binding did not change HC-030031 inhibition 
suggesting a separate binding site which still remains unknown. In 2016, 
chimeric studies involving human and frog TRPA1 as well as point mutations 
showed that HC-030031 binds to the aspartate N855 located between S4 
and S5 via hydrogen bonds and the binding is stabilised by hydrophobic 
interactions between the hydrophobic part of HC-030031 and the 
hydrophobic pocket adjacent to N855 (Gupta et al., 2016). 
1.3.3. TRPA1 modulation 
One of the most well-studied activation mechanisms of TRPA1 is that of 
activation by covalent interactions with ligands. Most of these compounds 
share the common feature of eletrophilicity meaning that they carry a highly 
carbon moiety that interacts with thiol groups of specific Cysteine residues 
located on the linker region of TRPA1 (connecting Ankyrin repeats with the 
transmembrane domain) forming products called Michael adducts (Bang and 
Hwang, 2009). This method of activation differs from the usual receptor-
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ligand mechanism that requires high specificity and transient binding. 
Interestingly, the TRPA1 unconventional and probably primitive way of 
activation allows for a variety of structurally diverse electrophiles to 
covalently interact and activate fast responses to noxious stimuli (Hinman et 
al., 2006; Macpherson et al., 2007; Macpherson and Patapoutian, 2010). 
So far, numerous plant-derived natural compounds have been found to 
activate TRPA1 by covalent electrophilic attack including isothiocyanates 
(e.g. AITC), cinnamaldehyde (CA) and allicin found in garlic (Bautista et al., 
2007; Brône et al., 2008; Hinman et al., 2006; Macpherson et al., 2007, 
2005). However, there are many synthetic electrophilic compounds, mostly 
environmental pollutants and toxic inhalants that can also activate TRPA1 
through covalent modification such as tear gas (dibenz[b,f][1,4]oxazepine 
(CR), 1-chloroacetophenone (CN), 2-chlorobenzylidene malononitrile (CS)) 
and acrolein (found in cigarette smoke) (Bautista et al., 2006; Brône et al., 
2008). Although many N-terminal cysteine residues of TRPA1 have been 
proposed to participate in ligand binding, the exact cysteines involved and 
the actual mechanism of channel activation remains unknown (Paulsen et 
al., 2015). Hinman et al. in 2006 proposed that C619, C639, C663 and K708 
are sufficient to induce channel activation by exogenous electrophilic ligands 
based on amino acid substitution experiments, while Takahashi et al. (2008) 
suggested that C421 and C621 are important for TRPA1 activation by 
endogenous inflammatory reagents like 15-deoxy- Δ12,14-prostaglandin J2 
(15d-PGJ2), NO, H2O2, which are also electrophilic compounds (Hinman et 
al., 2006; Takahashi et al., 2008). A more recent study identifies C621 as a 
highly reactive residue that reacts 6,000 times faster than any other TRPA1 
cysteine. Although C621 mutants demonstrate a reduced channel activation, 
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C621 per se cannot activate TRPA1. Notably, TRPA1 activation requires 
C665. Replacement of C665 completely abolished channel activation. 
Moreover, a lysine adjacent to the reactive C621 (K620) also assists in 
TRPA1 activation by most likely decreasing C621’s pKα which increases its 
reactivity (Bahia et al., 2016). Interestingly, the rattlesnake TRPA1 is 
insensitive to electrophiles even though it has similar cysteine residues 
indicating that activation by electrophiles is not solely dependent on cysteine 
modification but also by other subcellular cofactors and subsequent 
structural changes in the TRPA1 molecule (Bahia et al., 2016; Cordero-
Morales et al., 2011). 
While specific cysteine mutations abrogate TRPA1 activation by 
electrophiles, TRPA1 still maintains its sensitivity to other structurally distinct 
compounds like cannabinoids and the cooling reagent icilin, suggesting 
multiple ways of activation (probably by the conventional receptor-ligand 
mechanism) (Bahia et al., 2016; Bang and Hwang, 2009). Other natural 
agonists of TRPA1 include thymol (thyme), carvacrol (oregano) and 
oleocanthal (olive oil) which are not capable of activating TRPA1 by cysteine 
modification (Alvarenga et al., 2016; Gachons et al., 2011; Lee et al., 2008). 
It has also been shown that anti-inflammatory drugs and anesthetics can 
also activate TRPA1 such as ibuprofen and lidocaine (Gachons et al., 2011; 
Piao et al., 2009). However, not all agonists are TRPA1-specific. For 
instance, carvacrol, thymol and ethyl vanillin (synthetic vanilla) are also 
agonists of TRPV3, both TRPA1 and TRPV1 can be activated by garlic 
compounds but so far, AITC and CA have been proposed as solely TRPA1-
specific agonists (Wu et al., 2017; H. Xu et al., 2006). 
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Two independent studies have also proposed TRPA1 direct activation by 
calcium ions which is consistent with the presence of an EF-hand domain 
located at the N-terminal Ankyrin repeat domain of the channel (Doerner et 
al., 2007; Zurborg et al., 2007). In fact, TRP channel regulation by calcium is 
not rare. TRPM2, TRPM5, TRPM8 and TRPC4 have all been found to be 
regulated by intracellular calcium concentrations (Chuang et al., 2004; Du et 
al., 2009, p. 2; Prawitt et al., 2003; Watanabe et al., 2003). Doerneret al. first 
demonstrated that the presence of extracellular calcium potentiates AITC, 
CA and carvacrol responses and introduced the mechanism of dose-
dependent direct activation by intracellular calcium that binds to the putative 
EF-hand (Asp468-Leu480) of TRPA1. It was proposed that specifically 
Leu474 was highly involved in the interaction with calcium ions and that no 
cytosolic factors like calmodulin, a calcium-dependent protein regulator, or 
PLC pathways, also described to activate TRPA1, were involved in the 
mechanism (Doerner et al., 2007). Similar data were obtained by another 
research group which also suggested a mechanism of indirect cold-
activation through the subsequent intracellular calcium increase following 
cooling. The finding was supported by the fact that calcium-insensitive 
TRPA1 mutants had similar responses to cold temperatures with the control 
cells. Together these data indicate that TRPA1 could be activated by any 
stimulus that increases calcium influx in the cytosol serving as a signal 
amplifier. Calclium-insensitive mutants did not potentiate the calcium influx in 
response to carbachol (cholinergic agonist) compared to wild type TRPA1, 
suggesting that calcium binding is a requirement for TRPA1 activation by 
PLC pathways (Zurborg et al., 2007). However, the presence of an EF-hand 
has not been verified yet. The idea of an interaction with the putative EF-
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hand was excluded in another study in which mutations of previously 
proposed calcium-interacting residues did not affect channel’s potentiation 
(Y. Y. Wang et al., 2008). The same study described that TRPA1 is also 
inactivated by calcium following potentiation, two mechanisms that appear to 
be independent. TRPA1 potentiation by calcium also explains the positive 
synergistic effect of TRPA1 and TRPV1 following simultaneous activation in 
sensory neurons (Hsu and Lee, 2015). Surprisingly, a 2017 study proposes 
for the first time the calmodulin-dependent mechanism of calcium 
potentiation and inactivation suggesting that the C-terminal rather than the 
N-terminal possesses a non-canonical calmodulin binding site of 17 amino 
acids (L995-N1011) (Hasan et al., 2017). 
Furthermore, TRPA1 serves as a signal amplifier since it can be activated 
indirectly through activation of other receptors. Numerous studies have 
shown that TRPA1 is activated by G protein-coupled receptors (GPCRs) 
which are involved in various cellular responses including inflammation and 
itch. GPCRs form complexes with heterotetramic G proteins (G-α, -β, -γ) 
which dissociate after receptor activation and subsequent exchange of GDP 
to GTP. Activated G proteins can generate second messengers like c-AMP 
and stimulate PLC pathway (Tuteja, 2009). TRPA1 was initially found to be 
activated by bradykinin through B2R which is a GPCR introducing PLC 
signalling as an essential mediator of TRPA1 activation (Bandell et al., 
2004). Bradykinin treatment caused increased calcium responses mediated 
by TRPA1 in either CHO or HEK cells co-expressing both receptors, 
compared to the single transfected cells, while the use of U-73122, a PLC 
inhibitor, decreased those responses (Bandell et al., 2004; Hinman et al., 
2006). The exact mechanism that potentiates TRPA1 is not known but the 
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increase of intracellular calcium could be a possible explanation since 
elevated intracellular calcium levels have been shown to potentiate TRPA1 
(Bandell et al., 2004; Y. Y. Wang et al., 2008). However, there is evidence 
that PLC can act by releasing the inhibition by PIP2, a potential TRPA1 
inhibitor (Dai et al., 2007). Another study proposed B2R-mediated TRPA1 
activation through the PKA and cAMP pathway, also GPCR-inducible, due to 
the fact that PKA activators mimic while inhibitors decrease Bradykinin-
potentiated AITC responses (S. Wang et al., 2008). Additional GPCRs that 
have been reported to activate TRPA1 include m1 muscarinic acetylcholine 
receptor (m1AchR), protease-activated receptor-2 (PAR2), the bile acid 
receptor (TGR5), the Thymic Stromal Lymphopoietin receptor (TSLPR) and 
the Mas-related G-coupled receptors MrgprA3 and MrgprC11 (Dai et al., 
2007; Hinman et al., 2006; Lieu et al., 2014; Wilson et al., 2013, 2011). 
MrgprA3 and MrgprC11 are involved in histamine-independent itch and can 
be activated by two pruritogens, chloroquine and BAM, respectively. 
Although MrgpC11-induced TRPA1 activation requires Gαq/11 and 
activation of the downstream PLC pathway following BAM treatment, Gβ/γ 
pathway seems to be essential for MrgprA3-induced TRPA1 activation 
(Wilson et al., 2011). 
In 2011, Takahashi et al. presented a novel role of TRPA1 as an oxygen 
sensor in DRG neurons (Takahashi et al., 2011). The ability of TRPA1 to 
sense oxygen molecules is facilitated by reactive cysteine residues (C633 
and C856) in the N-terminal domain that interact with O2. Their model of 
action states that in normoxic conditions TRPA1 is inhibited by O2-
dependent PHDs (proline-hydroxylases) that hydroxylate P394 in the N-
terminal domain of TRPA1. When the oxygen levels drop (hypoxia), the 
- 63 - 
PHD-mediated TRPA1 inhibition is relieved resulting in TRPA1 activation. 
During increased O2 levels (hyperoxia), reactive cysteines are firstly 
oxidised forming sulfenic acid that can be easily reversed by cellular 
glutathione. In the second state, more stable intramolecular or intermolecular 
disulfide bonds are formed between the reactive cysteines activating the 
channel. The mechanism of activation involving reactive cysteines has been 
extensively studied for electrophilic agonists, as described above. However, 
the difference between the two types of agonists (O2 and electrophiles) is 
more likely due to the different stability of the end products. Michael adducts 
formed by electrophilic attack are more stable than the unstable and easily 
reversible oxidised products formed by interaction with O2. Since pain can 
also be induced by hypoxic conditions, the physiological role of TRPA1 in 
pain sensation can also be supported by the mechanism of hypoxia-
mediated TRPA1 activation. Concomitant with this observation, in vivo 
studies verify the above model of activation and link pain with TRPA1 
activation by hypoxia (So et al., 2016). 
1.3.4. The importance of the TRPA1 N-terminal domain 
The N-terminal domain of TRPA1 consists of 720 amino acids and accounts 
for 57% of the total protein (Hynkova et al., 2016). Based on the solved 
structure of TRPA1, the N-terminal domain is comprised of an Ankyrin 
repeat domain (ARD) which includes 16 tandem ankyrin repeats, and a pre-
S1 region that is connected to the ARD via a linker. The unusual large size 
of the N-terminal domain (more than half of the whole protein) predicts its 
involvement in the channel’s regulation and function. Indeed, chemo- , 
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thermo- and mechano-sensation as well as pore gating and channel 
assembly are all functions attributed to this domain (Paulsen et al., 2015). 
The N-terminal has been proposed to be a polymodal sensor of 
environmental stimuli which translates cues into channel gating. The vast 
majority of the TRPA1 agonists activate TRPA1 by cysteine modification on 
cysteine residues located within the ARD or the linker and pre-S1 region. 
Those include exogenous as well as endogenous inflammatory electrophilic 
compounds or even O2, as described earlier (Hinman et al., 2006; 
Takahashi et al., 2011, 2008). The agonist-involved residues are in close 
proximity to the TRP-like domain of TRPA1, a known allosteric modulator of 
the channel, suggesting a possible activation mechanism (Paulsen et al., 
2015). Moreover, a putative EF-hand located at the AR12 has been 
suggested to modulate TRPA1 based on the intracellular calcium levels (Y. 
Y. Wang et al., 2008). Other N-terminal-binding agonists include Zn2+ whose 
binding site was proposed to consist of both N- and C- terminal cysteine and 
histidine residues (Cordero-Morales et al., 2011). 
The larger part of the N-terminus consists of 16 ankyrin repeats (ARs), 
amino acids 1-688. Despite the numerous attempts to identify specific 
functions, the role of the human TRPA1 ARD still remains largely unknown. 
A study utilising different chimeric TRPA1 channels created by the human 
and the rattlesnake orthologues proposed the importance of the ARD 
domain in chemical and heat sensitivity (Cordero-Morales et al., 2011). The 
rattlesnake AR3-8 and AR10-15 conferred heat sensitivity to the heat-
insensitive human TRPA1 while conserving AITC-sensitivity, suggesting the 
role of specific ARs in thermosensation rather than the need for a particular 
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number of repeats. Cordero Morales and colleagues also highlighted the role 
of AR11-16 in chemical sensitivity as well as identified AR11 as an important 
locus for TRPA1 calcium desensitisation. Moreover, they recommended the 
division of the ARD into two modules (AR3-8 involved in signal recognition 
and AR10-15 serving as an enhancer region), a finding that agrees with the 
solved structure of TRPA1 which describes a group of five Ankyrin repeats 
(AR12-16) parallel to the C-terminal coiled-coil and close to the membrane 
portion of the channel and a second group of 11 ARs which form a crescent 
shape underneath the channel (Cordero-Morales et al., 2011; Paulsen et al., 
2015). 
The conserved tetrapeptide T/SPLH found in five of the ARs (AR2, AR6 and 
AR11-13) is important for sustaining the AR conformational integrity and 
mutations on key residues alter TRPA1 sensitivity to chemical, calcium and 
voltage changes (Hynkova et al., 2016). Destabilising mutations on AR2 and 
AR6 for example, disrupted the voltage-dependent regulation of TRPA1 and 
mutations on AR6 affected calcium-regulation and channel gating (Hynkova 
et al., 2016). Although TRPA1 is not a voltage-gated channel, it presents 
voltage-dependency. Indeed, another study has shown that the pore helix 
residue Leucine 906 is involved in voltage-dependent gating of the pore and 
it serves as a gate keeper rather than a voltage-sensor (Wan et al., 2014). 
Moreover, AR11-13 are shown to be crucial for the channel’s function due to 
the fact that T/SPLH mutations disrupt responses to stimuli (Hynkova et al., 
2016). This hypothesis is supported by the 3-dimensional positioning of the 
AR12-16 and the TRP-like domain allowing for an extended network of 
interactions that eventually regulate the pore opening (Paulsen et al., 2015). 
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The same study also proposed that the threonine and serine residues on the 
ARD are potential candidates for phosphorylation by different cellular 
kinases (Hynkova et al., 2016). In support to that, Meents et al. in 2016 
introduced a new mechanism of TRPA1 sensitisation by GPCRs involving 
activation of Protein Kinase A (PKA) and subsequent phosphorylation and 
sensitisation of TRPA1 (Meents et al., 2017). Forskolin (FSK), a PKA 
activator, increased TRPA1 responses after carvacrol-pulse-treatment-
induced desensitisation. The responses were also inhibited by H89 
treatment (PKA inhibitor) using Calcium imaging and whole-cell patch clamp 
experiments. After a series of point mutations on Serine and Threonine 
residues it became apparent that S86, S317 and S428, all located in the 
ARD region, are phosphorylation sites for PKA (Meents et al., 2017). TRPA1 
direct phosphorylation by PKA was also supported by another study which 
introduced an additional player in this process, A-kinase anchoring Protein 
79/150 (AKAP), which is a scaffold protein assisting in phosphorylation of 
membrane receptors by PKA and PKC (Brackley et al., 2017). However, 
Brackley et al. proposed S87 as a PKA phosphorylation site as well as S119, 
T281 and T529 as PKC phosphorylation sites (Brackley et al., 2017). Taken 
together these data highlight the role of ARD in regulation of TRPA1 function 
and gating of the channel. Nevertheless, contradictory studies exclude the 
involvement of the ARD domain in thermal and chemical sensitivity and 
describe the ability of TRPA1 to respond to cold and other chemical agonists 
(electrophilic or not) even in the absence of the ARD (Moparthi et al., 2014). 
A higher resolution structure of the complete ARD domain may reveal novel 
interactions and functions that modulate TRPA1. 
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Alternative ARD functions may arise from the intrinsic role of Ankyrin repeats 
as protein-protein interaction motifs. Each Ankyrin repeat usually consists of 
approximately 33 amino acids adopting a canonical Helix-Turn-Helix (HTH) 
orientation which extends in a loop forming a hairpin-like-beta-sheet with 
adjacent loops (Mosavi et al., 2004). The number of Ankyrin repeats within a 
protein varies from 2-34 and are named after the cytoskeletal protein Ankyrin 
that has 24 repeats. All ARs are linearly stalked in a helix bundle that adopts 
a concave shape which is usually described as a hand with a palm (inner 
helices) and fingers (loops). Inter- and intra- repeat hydrophobic interactions 
and hydrogen bonds are important for the stability of the bundle and the 
surface-exposed residues are involved in protein recognition. So far, ARDs 
are known to mediate protein-protein interactions and are present in a 
variety of proteins like membrane receptors (TRP channels, Notch), cell 
cycle regulatory proteins (INK4), transcription factor inhibitors (IkBa) and 
cytoskeletal proteins (Ankyrin). Due to the wide variety of proteins that can 
interact with an ARD, there are no universal characteristics that can describe 
those interactions. However, some generalisations could be made including 
the fact that AR binding sites are usually extended to a wider area of the 
protein-target rather than a short motif like SH3 or SH2 motifs bind to, as 
well as the fact that the palm and the fingers on the concave surface are 
mostly involved in the interactions with the target. Although ARs share the 
same structure and most of the residues are conserved, the loop residues 
and some located at the inner helix have been found to be involved in ligand 
recognition and ligand specificity (Mosavi et al., 2004; Voronin and Kiseleva, 
2008). 
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The ARD is not a unique characteristic of TRPA1. The TRPC and TRPV 
family also possess an N-terminal ARD, even though the number of repeats 
are limited to 4-6. To date, no protein-based ligands have been found to 
interact with any of the TRP ARDs. In fact, only calmodulin has been 
proposed to bind to TRPV1 ARD (Lishko et al., 2007). Instead, several non-
protein ligands have been shown to bind and regulate TRP channels. For 
instance, both TRPV1 and TRPV4 ARD have an ATP binding site, TRPV4 
ARD also binds β-D-glucose and glycerol, while TRPV2 ARD binds acetic 
acid (Inada et al., 2012; Jin et al., 2006; Lishko et al., 2007). The most 
common role of the ARD is electrophilic ligand recognition through cysteine 
residues. Even though no protein-based ligands have been reported so far, it 
is possible for TRPA1 to interact with other membrane proteins (Paulsen et 
al., 2015). 
Further information can be obtained from the non-mammalian TRPN 
channels that have the longest N-terminal ARD consisting of 29 repeats. 
TRPN channels have been extensively involved in mechanosensation 
(hearing and touch) and characterised as force-gated channels (Wilson and 
Corey, 2010). This hypothesis is favoured by the recently solved structure of 
the D. Melanogaster TRPN1 analogue, NOMPC (no mechanoreceptor 
potential) (Jin et al., 2017). The authors presented that the ARD of each 
subunit is shaped in a helical spring interacting with neighbouring ARDs in 
two major positions. 
The inter-subunit interactions, important for the integrity of the structure, 
involve three to four ARs of each subunit and are mediated by polar and 
charged residues located on those ARs. They also described three different 
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classes of the channel with differences in ARD confirmation which suggests 
that the N-terminal domain is very flexible allowing for movements in the 
ARD. Structural analysis of the rest of the channel revealed that a network of 
interactions involving the ARD, the pre-S1 elbow, and the linker region could 
possibly evoke the movement of the S6 that enlarges the lower restriction 
site, opening the channel. Jin and coleagues proposed that mechanical 
forces that displace the ARD spring (linked to cytoskeletal microtubules) are 
translated into pore opening, favouring the role of NOMPC as a 
mechanosensitive channel. Nevertheless, TRPN family of channels do not 
exist in mammals and the discovery of mammalian mechanosensory 
channels involved in hearing is still an ongoing process (Jin et al., 2017). 
TRPA1 has been proposed to serve as a mammalian mechanosensor, a 
feature that can be supported by the long ARD (Corey et al., 2004; Nagata 
et al., 2005; Zhang et al., 2008) However, the role of TRPA1 in mechanical 
sensitivity still remains largely unsolved (Kwan et al., 2006). 
1.3.5. Calcium channels in cancer  
Intracellular calcium is one of the most crucial second messengers and a 
major component of signalling pathways that regulate fundamental cellular 
processes including cell proliferation, survival, differentiation and motility. 
Due to its increased complexity, calcium signalling is still not completely 
understood. However, calcium-mediated signalling cascades usually 
modulate the activity of calcium-dependent proteins like Ca2+/calmodulin-
dependent protein kinase II (CaMKII), calmodulin, calpain and the 
transcription factors like NF-KB and NFAT altering gene expression and thus 
cellular responses. The ability of calcium signalling to alter the expression of 
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cyclins, also make it an important cell cycle regulator. Moreover, the spatial 
and temporal localisation of calcium also determines responses including 
cellular movement highlighting the complex but at the same time fine-
orchestrated calcium signalling (Cui et al., 2017). Consequently, 
deregulation of calcium signals originating from calcium transporters are 
implicated in malignancies (Leanza et al., 2016).  
Intracellular calcium levels are controlled by calcium homeostasis 
components: calcium pumps, exchangers and channels which have been 
reported to be modified in cancers. Calcium can be released form the 
endoplasmic reticulum (ER) into the cytoplasm through the IP3 receptor 
(IP3R) or ryanodine receptor (RyR) while it can return back to the ER 
through ER-Ca2+ ATPases (SERCA) that use the energy from the hydrolysis 
of ATP to move Ca2+ molecules against the gradient. Other organelles like 
mitochondria and Golgi also possess similar mechanisms of Ca2+ 
transportation including channels, ATPases and calcium exchangers like the 
Na+/Ca2+ exchangers that move calcium ions against the gradient taking 
advantage of the Na+ gradient. Calcium levels are also controlled by plasma 
membrane calcium transporters which regulate calcium influx and efflux 
to/from extracellular space/cytosol. Apart from plasma membrane Na+/Ca2+ 
exchangers and Ca2+ ATPases, calcium influx is supported by a diverse 
array of channels. Those include the voltage-gated calcium channels (Cav), 
ligand-gated calcium channels like P2X, transient receptor potential 
channels (TRP) and the store-operated channels Orai (Cui et al., 2017; 
Monteith et al., 2017).  
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Voltage-gated calcium channels (subfamilies Cav1-3) are characteristic of 
excitable cells as they are regulated by membrane depolarisation (Buchanan 
and McCloskey, 2016). However, some of these channels like Cav1.2 and 
Cav3.2 have been found overexpressed in cancer cells too (Martínez-
Delgado and Felix, 2017). Zhang et al (2017) found increased expression of 
Cav3.2 in glioblastoma patients which was also correlated with poor 
prognosis. Downregulation of Cav3.2 by RNAi or pharmacological inhibition 
by mibefradil (an FDA-approved hypertension drug) abolished cancer cell 
growth and increased survival via a mechanism that supresses survival 
pathways (AKT/mTOR) while enhancing pro-apoptotic pathways (BAX 
proteins) as well as by altering gene expression. Similar anti-tumorigenic 
results were obtained by in vivo studies after treatment with mibefradil, 
suggesting that targeting calcium channels can also be considered as a 
cancer therapy (Y. Zhang et al., 2017). The role of Cav3 channels have also 
been investigated in breast cancer cell lines in which they are usually found 
overexpressed, yet the exact effect still remains to be elucidated. For 
instance, the tumour suppressor role of Cav3.1 has been observed in MCF-7 
breast cancer cells while the role of Cav3.2 seems to be cell type-dependent 
(Ohkubo and Yamazaki, 2012; Pera et al., 2016; S. Zhang et al., 2017). The 
effect of Cav3.2 overexpression has also been examined in prostate cancer 
in which complex formation with potassium channels has also been 
observed (Gackière et al., 2013; Ohkubo and Yamazaki, 2012).  
Furthermore, several TRP channels, mostly TRPC, TRPV and TRPM 
members, are overexpressed in cancers (Shapovalov et al., 2016). TRPC5 
is overexpressed in colorectal cancer and has been correlated with 
increased metastasis, decreased cancer cell differentiation, tumour grading 
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and poorer overall patient survival (Chen et al., 2017b, 2017a; Zhang et al., 
2016). Up-regulated TRPC5 results in elevated calcium influx which in turn 
results in decreased E-cadherin (epithelial marker) and increased 
mesenchymal markers enhancing cancer cell proliferation, migration and 
invasion. The mechanism of TRPC5-mediated epithelial-to-mesenchymal 
transition (EMT) involves upregulation of HIF-1α/Twist signalling pathway 
while cancer cell differentiation is regulated by Wnt5α/β-cat pathway that 
increases the stemness of the cells (Chen et al., 2017b, 2017a). Importantly, 
TRPC5 is also involved in drug resistance in colon as well as breast cancer 
(Wang et al., 2017a). TRPC5 has been proposed as a non-invasive marker 
for breast cancer chemoresistance as it is found in resistant-cancer-cell-
derived exosomes (Wang et al., 2017b). Overexpression of TRPC1, TRPC3, 
TRPC4 and TRPC6 in NSCLC patients has been correlated with tumour 
grading while inhibition of TRPC channels in A549 cells abolished cancer 
cell proliferation (Jiang et al., 2013; Wang et al., 2017a). Silencing of 
TRPC1, in particular, causes cell cycle arrest in G(0)/G(1) of NSCLC cells 
and subsequent inhibition of cell growth and decreased cyclin D1 and D3 
expression (Tajeddine and Gailly, 2012). Simultaneously, EGFR-mediated 
signalling is also decreased. Tajeddine et al proposed the positive 
interaction loop between EGFR signalling and TRPC1 in NSCLC which 
includes TRPC1 activation by EGFR-mediated calcium entry and in turn, 
EGFR activation by TRPC1 calcium influx promoting NSCLC progression 
(Tajeddine and Gailly, 2012). TRPC1 has also been implicated in 
proliferation of hepatocellular carcinoma cells, drug resistance in ovarian 
cancer as well as breast cancer progression in which it functionally 
cooperates with calcium-activated potassium channels (Kca3.1) and 
- 73 - 
correlates with poor survival (Faouzi et al., 2016; Liu et al., 2016; Selli et al., 
2015). Other TRPC channels include TRPC6, reported in prostate, lung and 
pancreatic cancer as well as TRPC4, involved in meduloblastoma invasion 
(Bernichtein et al., 2017; Nielsen et al., 2017; Wei et al., 2017; Yang et al., 
2016).  
Among the TRPV family members, TRPV6 implication in prostate cancer 
has been highly studied. TRPV6 is found overexpressed in prostate cancer 
cell lines and patient tissues and is correlated with advance stages and poor 
survival (Fixemer et al., 2003; Lehen’Kyi et al., 2007). Silencing of TRPV6 in 
prostate cancer cell lines reduced cellular proliferation and increased 
apoptosis via a TRPV6-mediated Ca2+-dependent mechanism (NFAT 
activation) suggesting the direct role of TRPV6 in prostate cancer 
progression. Moreover, TRPV6 is a constitutively active calcium channel 
highly selective for calcium ions that mediates continuous calcium entry in 
prostate cells promoting proliferation (Lehen’Kyi et al., 2007, p. 6). TRPV6 
upregulation has been attributed to its translocation to the plasma 
membrane through a mechanism that involves the Orai/TRPC1 signalling 
pathway (Raphaël et al., 2014). Overexpression in pancreatic cancer cell 
lines has also been observed and TRPV6-mediated cellular proliferation 
occurs via NFAT activation (Lehen’Kyi et al., 2007; Skrzypski et al., 2016). 
TRPV6 channels have also been implicated in SCLC and breast cancer 
carcinogenesis (Guilbert et al., 2011; Lau et al., 2014; Peters et al., 2012; 
Skrzypski et al., 2016). Furthermore, TRPV3 is overexpressed in 67% of all 
lung cancer cases and correlates with tumour staging and poor patient 
survival. In vitro studies using lung cancer cell lines revealed that TRPV3 
promotes proliferation through calcium influx that assists in G1 to S phase 
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transition via activating CaMKII, upregulation of cyclin A, D1 and E as well 
as downregulation of the cell cycle suppressor p27 (Li et al., 2016). On the 
other hand, TRPV4 is responsible for breast cancer cell metastasis mediated 
by activation of AKT and FAK pathways and downregulation of E-cadherin 
and beta-catenin (epithelial markers) (Lee et al., 2017).  
Among the TRPM family members, TRPM8 has been implicated in various 
cancers including pancreatic, prostate, bladder and colorectal cancer 
(Borrelli et al., 2014; Xiao et al., 2014; Yee, 2016). However, the exact role 
of action is still unknown (Yee, 2015). It was recently shown that the 
glycosylation state of TRPM8 determines cancer progression in pancreatic 
cancer and that the splice variant TRPM8α increases invasion and regulates 
apoptosis in (LNCaP) pancreatic cancer cells (Peng et al., 2015; Ulăreanu et 
al., 2017). On the other hand, the protective effect of TRPM8 has also been 
observed in prostate cancer. Androgen-dependent early stages of prostate 
cancer are accompanied by TRPM8 overexpression which is decreased 
after anti-androgen therapy or transition to androgen-independent states 
suggesting that loss of TRPM8 expression is associate with advanced 
cancer stages. In fact, TRPM8 transcription is regulated by AR (androgen 
receptor) due to ARE-I binding sites however, the protein levels are 
negatively regulated due to increased ubiquitination and degradation of the 
channel. Inhibition of ubiquitination increased channel activity resulting in 
increased apoptosis, p53 and caspase 9 activity supporting the anti-tumour 
effect of TRPM8 (Asuthkar et al., 2015). Moreover, TRPM8 anti-metastatic 
role in prostate cancer has also been reported. TRPM8 is highly expressed 
in prostate cancer-derived endothelial cells in which it represses cell motility 
by a mechanism involving direct interaction and inhibition of GDP-RAP1 
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(GTPase), a protein involved in integrin signalling pathways. In this way, 
both in vitro would healing and vascular tubulogenesis was impaired 
indicating the anti-metastatic role of TRPM8 in prostate cancer (Genova et 
al., 2017). The overexpression of TRPM7 has also been reported in bladder, 
glioblastoma, pancreatic and breast cancer where it is involved in increasing 
cancer cell proliferation and invasion via activating various pathways (Cao et 
al., 2016; Gao et al., 2017; Nakashima et al., 2017; Rybarczyk et al., 2017; 
Wong et al., 2017; Yee, 2017). Importantly, the kinase activity of TRPM7 is 
also involved in phosphorylating substrates like myosin IIA regulating 
cytoskeleton and thus, cell motility (Song et al., 2017).  
Store-operated calcium entry (SOCE) is a key process in calcium signalling. 
SOCE is initiated when activated GPCRs activate PLC pathways that result 
in increased IP3 levels which causes IP3R-mediated calcium influx from the 
ER to the cytosol. This reduced ER calcium concentration is sensed by 
Stromal interaction molecules (STIM) membrane proteins which oligomerise 
and translocate closer to the plasma membrane where they form complexes 
with Orai receptors and initiate the store-operated calcium entry. There are 2 
isoforms of STIM proteins (STIM1 and STIM2) and three of Orai (Orai1, 2 
and 3) (Vashisht et al., 2015). As calcium signalling components, Orai/STIM 
complexes are also implicated in cancers. Among the three isoforms Orai3 
has been mostly implicated in malignancies like lung adenocarcinoma and 
breast cancer where it is overexpressed and proposed as a marker of poor 
prognosis. Silencing or inhibition of Orai3 in those cancer cell lines causes 
decrease in cell proliferation, arrest in G1 phase and reduction in cyclin D, E, 
CDK 2 and 4 as well as increase in cell cycle inhibitors (Ay et al., 2013, p. 3; 
Benzerdjeb et al., 2016; Faouzi et al., 2013, 2011; Motiani et al., 2010). 
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Increased Orai3 levels in prostate cancer cells cause heteromeric 
Orai1/Orai3 channels which have been suggested to mediate store-
independent Ca2+ entry and promote cancer progression (Dubois et al., 
2014). Orai1 channels have also been implicated in cancers like 
glioblastoma and gastric cancer and complexes consisting of Orai1, TRPC1 
and SK3 channels (small conductance calcium-activated potassium channel 
3) have also been implicated in colon cancer metastasis (Guéguinou et al., 
2016; Gui et al., 2016; Motiani et al., 2013; Xia et al., 2016). 
1.3.6. The role of TRPA1 in cancer 
Although several TRP channels have been shown to be dysregulated in a 
number of human cancers and thus proposed as novel pharmacological 
targets and possible prognostic markers, very little information exists 
regarding the role of TRPA1 in cancer progression. An expression profile 
study in 2016 showed that TRPA1 protein levels were elevated in 
nasopharyngeal carcinoma tissues and negatively correlated with patients 
survival presenting TRPA1 as a novel indicator of poor prognosis in 
nasopharyngeal carcinoma (Wu et al., 2016). It is important to note that 
TRPA1 can be upregulated as well as downregulated in cancers and the 
outcome of this alteration is cancer-type specific. For instance, another data-
driven study found that TRPA1 gene expression was substantially increased 
in kidney cancer and this change was correlated with better overall survival. 
C-index analysis revealed that TRPA1 is a great prognostic marker for 
kidney cancer especially when combined with other TRP channels including 
TRPC4, TRPM3 and TRPP1. On the other hand, the same study found 
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decreased TRPA1 gene expression in prostate cancer, highlighting the 
complex role of TRPA1 in cancer progression (Y. R. Park et al., 2016). 
So far, very little is known about the direct role of TRPA1 in lung cancer in a 
more detailed and mechanistic way. In 2013, TRPA1 levels were found 
elevated in small-cell lung cancer cell lines which demonstrated increased 
calcium influx and ERK1/2-mediated cell proliferation following AITC 
treatments. Increased cell viability was observed after administration of non-
toxic doses of AITC while TRPA1 downregulation by siRNA inhibited cell 
growth (Schaefer et al., 2013). Another study showed that the combination 
of TRPA1 and TRPM8 overexpression in Lewis lung cancer cells rather than 
the overexpression of the single channels promotes cell adhesion and 
invasion as well as resistance to cytotoxic T lymphocytes and chemotherapy 
(Derouiche et al., 2017; Du et al., 2014, p. 8). Both studies implicate the 
involvement of TRPA1 in lung cancer yet the exact mechanism of action still 
remains unsolved. Notably, no TRPA1 mutations have been linked to cancer 
so far, indicating that elevated levels of the channel rather than a decrease 
or increase in activation can be capable of promoting malignancies. 
Recent studies also highlight the indirect role of TRPA1 in prostate cancer 
which involves regulation of the tumour microenvironment (TME). While 
TRPA1 is absent in prostate cancer cells, overexpression in prostate stromal 
cells can regulate their paracrine effect and promote cancer progression 
(Derouiche et al., 2017). In early 2017, Roudbaraki’s group investigated the 
TRPA1 agonist triclosan (TCS), an antibacterial agent commonly used in 
cosmetics and hygiene products, in prostate stromal cells and showed that 
TCS treatment increased calcium influx which was blocked by TRPA1 
- 78 - 
inhibitors as well as TRPA1 siRNA knock down and promoted VEGF 
secretion. TCS-induced VEGF production was inhibited by HC-030031, a 
TRPA1 inhibitor, indicating the role of TRPA1 in the paracrine regulation of 
prostate cancer cells by the TME (Derouiche et al., 2017). Very recently, the 
same group verified the role of TRPA1 in the prostate cancer TME by 
studying an anti-cancer plant-derived compound, resveratrol (RES), which 
surprisingly activates TRPA1 expressed in prostate cancer-associated 
fibroblasts (CAFs). The prostate CAF cell line PS30 and primary CAFs 
produced HGF and VEGF following treatment with RES, an outcome that 
was prevented by TRPA1 inhibition or knock down. Moreover, prostate 
cancer cells and CAFs co-culture reduced RES-mediated cancer cell 
apoptosis which was rescued by simultaneous treatment with a TRPA1 
inhibitor. These results indicate that activation of CAF-expressed TRPA1 by 
RES promotes cancer progression by inducing HGF and VEGF expression 
regulating the TME. In contrast, RES acted as an inhibitor of wild type 
TRPA1, transiently expressed in HEK cells. In addition to that, RES 
responses were reduced in prostate CAFs co-expressing wild type TRPA1 
indicating a different version of TRPA1 in prostate CAFs. Sequencing 
analysis revealed a K539R mutation and two SNPs (Y69C and K186N), all 
located within the ARD of TRPA1, introducing for the first time the role of 
TRPA1 point mutations in cancer regulation. Indeed, those two 
polymorphisms have been associated with higher sensitivity to agonists 
(Vancauwenberghe et al., 2017). 
On the contrary, TRPA1 has also been associated with tumour prevention. 
Another study in 2016 that investigated the inflammation in the TME showed 
that methyl syrignate (MS), a TRPA1 activator, causes COX-2 
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downregulation in the lung cancer cell line A549. Hypoxic conditions that 
prevail in the TME of solid tumours induce increased levels of prostaglandins 
and COX-2 which eventually promote cellular migration and invasion. MS 
treatment reduced A549 invasion which was rescued by the use on TRPA1 
inhibitors suggesting the antitumor effect of TRPA1 (J. Park et al., 2016). 
Since TRPA1 is naturally involved in pain pathways, its role in cancer pain 
has also been noticed. Based on studies using oral squamous cell 
carcinoma mouse models, increased NGF is associated with cancer-related 
inflammation and NGF blockage reversed the effects by decreasing the 
expression of TRPV1 and TRPA1 in trigeminal ganglion neurons (Ye et al., 
2011). Similarly, elevated amounts of TRP-activating lipids in the saliva of 
oral cancer patients have been shown to induce pain-related behaviours in 
rat paws which were reversed by TRPV1 and TRPA1 inhibition (Ruparel et 
al., 2015). Lastly, chemotherapy-induced peripheral neuropathy (CIPN) has 
been linked to TRPA1 hypersensitivity by oxidative stress products. TRPA1 
antagonist systemic administration in mice prior to chemotherapy reversed 
TRPA1 hypersensitivity and alleviated pain suggesting TRPA1 antagonists 
as a novel strategy against CIPN (Trevisan et al., 2013). 
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1.4. Aims and Objectives  
Taken together, previous work has revealed the importance of the FGFR2 C-
terminal domain in FGFR2 signalling regulation through protein-protein interactions. 
Preliminary bioinformatics data by Dr. Zahra Timsah’s group proposed TRPA1 as a 
putative binding partner for the C-terminal domain of FGFR2. The aim of this project 
is to characterise the potential interaction between FGFR2 and TRPA1 and 
investigate the effects of this interaction on FGFR2 signalling. Thus, the specific 
objectives of this study are:  
 
1. to investigate the interaction between FGFR2 and TRPA1 in HEK293T cells 
2.  to investigate the interaction in a Lung Adenocarcinoma (LUAD) cell line 
3.  to map the binding sites on both proteins 
4.  to determine the complex stoichiometry 
5.  to examine the effect of TRPA1 binding on FGFR2 signalling 
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2. Chapter 2 
Material and Methods 
2.1. Mammalian cell culture 
2.1.1. Maintenance of cell lines, passaging, freezing and thawing 
All cell lines (Table 2.1) were cultured in Dulbecco's modified Eagle's high-glucose 
medium (DMEM), supplemented with 1% Gibco® Antibiotic-Antimycotic (Life 
Technologies™) and 10% v/v Gibco® foetal bovine serum (FBS, Life 
Technologies™). All cells were cultured in 75 or 25 cm3 flasks and incubated at 
37oC and 5% CO2. 
Table 2. 1: List of cell lines used in the project 
CELL LINE PROVIDER DESCRIPTION 
HEK-293T (CRL-3216™) ATCC® Human embryonic kidney cells 
expressing the T-antigen of 
adenovirus SV40 
CCL-204 (CCD-16Lu™) ATCC® Normal human lung fibroblasts 
HCC-44 (CSC-0C542) Creative Bioarray Human Lung adenocarcinoma 
HCC-515  Dr. Ignacio I. 
Wistuba 
Human Lung adenocarcinoma  
 
At 90% confluency, the cells were passaged to new flasks. Old medium was 
aspirated and the cells were detached by incubation with 1 x TrypLETM Express 
(GIBCO, UK) for ~3 minutes in the incubator (2ml for T-75, 1ml for T-25). Once all 
the cells were detached, trypsin was deactivated upon addition of fresh complete 
medium (at least 2 times the volume of trypsin) and the cell suspension was 
transferred to a 15ml tube. The cells were collected by centrifugation for 5 minutes 
at 600rpm. The supernatant was discarded and the cell pellet re-suspended in 
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warmed fresh medium (5-10ml depending on the passage ratio). Usually 0.5-1ml of 
re-suspended cells were added in a new flask containing fresh medium. 
For long term cell storage, 0.5ml of the cell suspension was mixed with 0.5ml of 
freezing medium (10% DMSO in DMEM) in cryovial tubes which were placed in Mr. 
Frosty box and kept in -80oC for 1-2 days prior to transferring into a liquid nitrogen 
tank.  
Recovery of cells involves quick thawing and transferring of cell suspension into a 
new flask with warmed fresh medium.  
2.1.2.  Transient transfection  
The cells were seeded in 6-well plates after passaging and cultured at 37oC and 5% 
CO2. At 80% confluence the cells were ready for transfection. Metafectene 
(Biontex) was used as a transfection reagent in 1:3 ratio (metafectene:DNA). Thus, 
2µg of DNA was mixed with Opti-MEM medium (100ul total volume) while 6ul of 
metafecten reagent was mixed in Opti-MEM medium (100ul total volume). The DNA 
mixture was added on top of metafectene drop by drop and incubated for 20 
minutes in room temperature (200ul total/per well). After the time elapsed, the DNA-
metafectene mixture was added to each well of the plate drop by drop. The plate 
was transferred into the incubator and 16-24h later the medium was replaced with 
fresh one.  
For the FGFR2 si-RNA knock down, RNAiMAX (Thermo Fisher) was used to 
transfect HEK-293T cells with FGFR2 si-RNAs (Assay ID: 118292, 1215, negative 
control ID: AM4611, Thermo Fisher). For a 6-well plate format, 30pmol of si-RNA 
and 9μL of RNAiMAX were diluted in 150μL OptiMEM and then combined in a total 
volume of 300μL per well. After 5 minute incubation the mixture was added to the 
cells.  
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2.1.3. Cell treatments 
The cells were serum starved (medium without FBS) for 2 hours prior to any 
treatment. Whenever needed, the cells were treated with 20ng/ml FGF9 for 30 
minutes, 100µM AITC for 5 minutes and 50µM HC-030031 for 5 minutes.  
2.1.4. Cell lysis 
Treated or just serum starved cells were washed 2 times with PBS and then 
mechanically lysed using the back of a pipette tip in 200ul of lysis buffer (Table 2.2). 
The mixture was transferred into an Eppendorf tube and centrifuged for 10 minutes 
at 13,000rpm to precipitate all the debris. The supernatant was transferred into a 
clean tube and used right after or kept in -80oC for future use.  
Table 2. 2: Cell Lysis Buffer recipe 
Reagent Final Concentration 
HEPES 50mM 
NaCl 150mM 
NaVO3 1mM 
NaF 10mM 
Glycerol 10% 
NP-40 1% 
 
2.2. Molecular Cloning techniques 
2.2.1. Bacterial transformation 
NEB® 5-alpha Competent E. coli High Efficiency bacteria were used for 
transformation based on the manufacturer’s instructions. BL21 bacteria were 
transformed in case protein expression and purification was needed. 1pg-100ng of 
plasmid DNA was added to an aliquot of bacteria and incubated on ice for 30 
minutes without vortex. Next, bacteria underwent a heatshock step for 30 seconds 
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at 42oC and then incubated on ice again for 5 minutes, prior to recovery on warm 
growth media for 1 hour at 37oC. Different amounts of bacteria suspension (100-
300μl) were spread on agar plates containing appropriate antibiotic and incubated 
overnight at 37oC. The next morning, bacteria colonies were screened for carrying 
the correct insert by plasmid purification and agarose gel electrophoresis.    
2.2.2. Agarose gel electrophoresis  
DNA agarose gel electrophoresis was used to detect correct PCR, digestion and 
miniprep product sizes and quality. Different percentage of agarose was used 
based on the DNA size that was being tested. For smaller fragments <1kb, 2% 
agarose was used while fragments >1kb were analysed in 1% agarose gels. 
Agarose was dissolved in 1x TAE buffer (MP Biomedicals). SYBR Safe (Invitrogen) 
was used to visualise DNA fragments in 1:10,000 dilution. The gels were left to set 
in the gel apparatus provided and then placed in the gel tank containing 1x TAE 
buffer. DNA samples were diluted in 6x Gel loading dye Blue (New England 
Bioloabs) prior to loading and 1kb or 100bp DNA ladder was also loaded on the gel 
as a size reference. Samples were run at 100V for approximately 1 hour.  
2.2.3. DNA gel extraction 
DNA fragments of interest were extracted from agarose gels using the GeneJet Gel 
Extraction kit (Thermo Fisher) following the manufacturer’s manual. In brief, the 
band of interest was removed from the gel using a scalpel under the UV light. The 
excised gel band was kept in an Eppendorf tube and weighed. Next, the binding 
buffer was added in a ratio of 1:1 (volume in µL : weight of gel band in mg), and 
incubated at 50-60oC with occasional vortexing until the gel is completely dissolved. 
The mixture was passed through a GeneJet purification column by centrifugation for 
1 minute. Another 100µL of Binding Buffer was passed through the column to 
improve the purity of the extracted DNA. The column was washed with 700µL Wash 
Buffer and then, centrifuged for an extra 1 minute to remove any excess buffer 
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remained in the column. The dried column was transferred into a clean Eppendorf 
tube and the DNA fragment was eluted with 50µL Elution buffer. The concentration 
of the extracted DNA was measured with a Nanodrop equipment.  
2.2.4. Small scale plasmid DNA extraction (miniprep) 
Recombinant plasmids from transformed DH5α bacteria (NEB® 5-alpha 
Competent E. coli High Efficiency) were purified using the QIAprep Spin Miniprep 
Kit (QIAGEN). Following bacterial transformation, single colonies were selected and 
inoculated into 5ml of dYT growth media containing appropriate antibiotic (ampicillin 
10μg/ml, kanamycin 50μg/ml) and incubated overnight at 37oC and 200rpm. 
Bacteria pellets were resuspended in 250μl P1 buffer, then lysed in 250μl P2 lysis 
buffer and then neutralised by adding 350μl P3 neutralisation buffer. The mixture 
was centrifuged at 13,000 rpm for 10 minutes and the supernatant was applied onto 
spin columns which bind the plasmid while other cellular components are eluted in 
the flow through. The spin columns were washed with ethanol containing wash 
buffer and lastly, the plasmids were eluted in 50μl Elution buffer. Plasmid 
concentration was measured using a Nanodrop spectrophotometer.  
2.2.5. Plasmids used in this project 
Table 2. 3: List of DNA plasmids 
Protein Construct  Provider 
TRPA1 pCMV6-AC-GFP Origene 
FGFR2-FLAG tag pCMV3-FGFR2-Flag Sino Biologicals 
TRPA1-Δ10 pCMV6-AC-GFP YouBio, Hunan, China 
FGFR2-C-58 pGEX4T1 Dr. Chin-Chuan Lin, 
University of Leeds 
FGFR2-STREP Tag pcDNA6B Dr. Chin-Chuan Lin, 
University of Leeds 
e-GFP pGFP-N3 Clontech 
FLAG Negative control pCMV3-C-FLAG  Sino Biologicals 
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vector 
 
2.1.1. TRPA1 truncations  
The pCMV6-AC-GFP vector from Origene (NM_007332, RG219290 clone) was 
used for full length TRPA1 mammalian cell expression. TRPA1-Δ10 (deletion of AR 
1-10) and TRPA1-Δ5 (deletion of AR 1-5) were made by YouBio, Hunan, China.  
2.2.6. C-58 mutations 
The C-58 Proline to Alanine mutations were introduced into the pGEX4T1-C58 
vector by using the Q5 site-direct mutagenesis kit (New England Biolabs).  The 
pGEX4T1-C58 vector was kindly provided by Dr. Chin-Chuan Lin, Ladbury’s group. 
Firstly, PCR was performed to generate the mutants by using the appropriate 
primer pairs containing the single nucleotide mutations (Table 2.4). Primer sets 
were generated using the online tool “NEBaseChanger” from New England Biolabs 
(https://nebasechanger.neb.com/).  
Table 2. 4: PCR primer list used for site directed mutagenesis of the C-58 
fragment (Proline to Alanine) 
Primer Sequence 5’-3’ Base substitution 
C58-P804A-Fw AGACCCCATGGCTTACGAACC CCT to GCT (C to G) 
C58-P804A-Rv GGAGAAAAAACAGAATCATCTCCTG n/a 
C58-P810A-Fw ACCATGCCTTGCTCAGTATCC CCT to GCT (C to G) 
C58-P810A-Rv TCGTAAGGCATGGGGTCT n/a 
C58-P813A-Fw TCCTCAGTATGCACACATAAACG CCA to GCA (C to G) 
C58-P813A-Rv AGGCATGGTTCGTAAGGC n/a 
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The PCR reaction mix and the cycling conditions used are shown below: 
Table 2. 5: PCR reaction 
Reagent Working concentration 
Reverse Primer 0.5μM 
Forward primer 0.5μM 
Q5 Hot Start High-Fidelity 2X Master Mix 1x 
Template DNA (1–25 ng/µl) 1-25 ng 
dNTPs 200μM 
Nuclease-free water Up to 10μL 
 
 
Table 2. 6: Cycling conditions 
Step Temperature  Time 
Initial Denaturation 98oC 30sec 
Denaturation 98oC 10sec 
Annealing  * 30sec 
Extension 35x cycles 72oC 2.5min 
Final extension  72oC 2min 
* Appropriate annealing temperatures were used according to the Tm values of the 
primer pairs. 
PCR efficiency was verified by agarose electrophoresis and the appropriate DNA 
fragment was extracted and purified using the GeneJET Gel Extraction Kit (Thermo 
Scientific) – see section 2.2.3. Following gel extraction, the PCR products were 
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incubated at room temperature for 5 minutes in a KLD reaction containing a mix of 
kinase, ligase and Dpn1 enzymes (Table 2.7). In this step, linear products are 
phosphorylated and ligated into circular plasmids. The initial template is removed by 
Dpn1 which targets methylated DNA.  
Table 2. 7: KLD reaction 
Reagent Volume (10μl) 
PCR product 1μl 
2X KLD reaction buffer 5μl 
10X KLD Enzyme Mix 1μl 
Nuclease-free water 3μl 
 
The last step includes bacteria transformation using the KLD reaction products (see 
2.2.1 section). The mutated plasmids were obtained by MiniPrep (section 2.2.4) and 
send for sequencing using appropriate primers to ensure the mutated sites were 
correct and the reading frame was intact.  
2.3. Immunofluorescence (IF) 
Cells were cultured on 10mm glass coverslips in 24-well plates and transfected or 
treated appropriately depending on the experiment. Fixation step was performed 
using 4% paraforlamdehyde (PFA) in PBS for 20 minutes at room temperature. The 
cells were washed 4 times with PBS and then blocked for 1 hour at room 
temperature with blocking buffer containing 8% Fetal Bovine Serum (FBS) and 
0.5% NP-40 in PBS prior to overnight incubation with primary antibodies (1:250) 
diluted in the same buffer at 4oC. After washing 3 times with PBS the cells were 
incubated with secondary antibodies conjugated with AlexaFluor fluorophores of the 
appropriate wavelength for 1 hours at room temperature in the dark. Next, the cells 
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were washed 3 times with PBS. The coverslips were lifted and placed with the cells 
facing down onto glass slides using mounting medium containing DAPI and sealed 
with nail polish. Fluorescent images were obtained using a confocal microscope.   
2.4. Protein biochemistry 
2.4.1. Protein expression and purification of C-58 WT and mutants 
The GST-tagged C-58 fragment of FGFR2 was expressed in BL21(DE3) strain of E. 
coli. This strain carries the T7 RNA polymerase gene which is regulated by the 
lacUV5 promoter and can be expressed followed IPTG stimulation. Once 
expressed, T7 RNA Polymerase can transcribe any gene under the control of the 
T7 promoter e.g. the gene of interest in the pGEX4T1 vector (Studier and Moffatt, 
1986).  
2.4.1.1. Recombinant protein expression in bacteria 
BL21(DE3) cells were firstly transformed with C-58 constructs and the colonies 
were screened to determine whether they were successfully transformed by 
performing diagnostic digestion with BamH1 on isolated plasmid DNA. The colonies 
whose DNA digestion produced the correct fragment size (successful 
transformation) could be used for further culture and induction of protein expression 
as well as stored in glycerol stocks for future use.  
Appropriately transformed BL21(DE3) bacteria from an overnight 5ml culture were 
inoculated in 250ml of dYT media containing ampicillin and cultured until optical 
density OD600=0.6.  At this point, 300μM of isopropyl-β-D-thiogalactopyranoside 
(IPTG) were used to induce the recombinant protein expression for 12h at 20oC. 
Next, the bacteria were pelleted at 4,000xg for 20 min at room temperature and 
stored at -20oC for future use.  
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2.4.1.2. GST-tagged recombinant protein batch purification 
Pelleted BL21(DE3) cells expressing the recombinant protein were re-suspended in 
Lysis buffer (50mM Tris pH 8, 100mM NaCl, 1mM β-mercaptoethanol and 0.1mM 
PMSF) prior to lysing with sonication (10sec x 5). The sonicated cells were 
centrifuged at 13,000xg at 4oC for 1 hour and the supernatant was applied onto 
400μl Glutathione Sepharose 4B GST-tagged beads (GE Healthcare) for 30 min at 
room temperature. GST beads have been washed in PBS to remove storage buffer 
and equilibrated with Lysis buffer. All bead centrifugations are performed at 500xg 
for 5 min. After 30 minutes, the beads were washed with 10 times bed volume lysis 
buffer 3 times and the protein of interest was eluted in 20mM glutathione in 50mM 
Tris-HCl. 20μl samples from each step were stored and analysed by SDS-PAGE.  
2.4.1.3. C-58-GST-beads production 
Purified C-58 FGFR2 fragments (wild type and 3 proline mutants) were incubated 
with washed and equilibrated GST beads for 2 hours at room temperature. Next, 
the C-58-GST-beads were washed 3 times in 10x bed volume 1x PBS and stored in 
PBS (50% beads) for future use in GST pull down assays.  
2.4.2. Determining protein concentration 
Following cell lysis (section 1.1.4), the total protein concentration contained in the 
cell lysates was determined by using the Bio-Rad Protein Assay Dye Reagent 
Concentrate (Biorad) which is based on the Bradford method. In brief, the acidic 
dye Coomassie Brilliant Blue G-250 binds to proteins present in the solution and 
changes absorbance from 465nm to 595nm. The detected absorbance is 
proportional to the protein concentration within a range. Bovine Serum Albumin 
(BSA) was used as a protein standard (linear range 0.2-0.9mg/mL) and the relative 
protein concentration of the samples can be determined by comparing with that of 
- 91 - 
the BSA standards. The Dye Reagent concentrate (Bio-Rad) was diluted 1:5 with 
deionised water and 1mL of the diluted dye was added in cuvettes (BRAND® UV 
cuvettes semi-micro, chamber volume 1.5). 2µL of the protein sample was added in 
the cuvette, mixed and then measured at 595nm.  
2.4.3. Sodium Dodecyl Sulphate–Polyacrylamide Gel (SDS-PAGE) 
SDS-PAGE was used to separate proteins from lysates based on molecular weight. 
The Biorad Mini-PROTEAN II System and the Tris-Glycine 4-20% pre-cast gels 
were used for SDS-PAGE. The protein samples were mixed with appropriate 
volume of 4x Laemmli SDS sample buffer and denatured at 95oC for 5 minutes. 
50μg of total protein were loaded for each sample on the gel together with a Pre-
stained Precision Plus Protein standards (Biorad) as a protein size marker. The 
samples were run in 1x Running buffer (0.025M Tris, 0.192M glycine and 0.1% 
SDS) at 120V for 1 hour and 15 minutes. Following electrophoresis, the gels were 
stained with Coomassie blue G-250 for 1 hour with gentle agitation to visualise all 
proteins. Alternatively, the gels were used in Western blots.    
2.4.4. Western blot 
Proteins separated in an SDS-PAGE gel were transfected onto PVDF membranes 
by semi-dry transfer. The equipment used for semi-dry transfer was the Trans-Blot® 
Turbo™ Blotting System from Bio-Rad. Pre-packed top and bottom stacks were 
purchased from Bio-Rad (Trans-Blot Turbo Transfer System Transfer pack – mini). 
Proteins were transferred from the gel to the membrane by running the pre-set 
standard protocol for all molecular weight proteins (25V for 30min).  
After the transfer was complete, the membranes were blocked in Blocking Buffer 
(5% non-fat dry Milk in Wash Buffer) for 1 hour at room temperature on a shaking 
platform. Next, the membranes were incubated with primary antibodies (1:1000 in 
Blocking Buffer) for 2 hours at room temperature or overnight at 4oC. The 
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membranes were then washed 3 times for 10 minutes with Wash Buffer (Table 2.8) 
and incubated with secondary antibodies (1:1000 in Blocking Buffer) for 1 hour at 
room temperature. The membranes were washed again 3 times for 10 minutes with 
Wash Buffer prior to imaging with chemiluminescence. SuperSignal™ West Pico 
PLUS Chemiluminescent Substrate (Thermo Scientific) was applied to the 
membranes for 1 minute and the results were imaged by a G-box machine from 
Syngene.  
Table 2. 8: Recipe for 1L of 10X Wash buffer 
10X Wash Buffer (TBS-T) 1L 
Tris-HCl 63.04g 
Tris-Base 12.11g 
NaCl 87.99g 
1mM EDTA 2.92g 
 
2.4.5. Quantification of western blots 
Western blot images were analysed by densitometry with Image J. A rectangle was 
drawn closely surrounding the band of interest and the signal intensity was 
determined with the “measure” function. The same rectangle was moved over the 
next band keeping the same surface area and the intensity of all protein bands was 
also determined. The output was copied to Excel or SPSS or Graph Pad where it 
was statistically analysed by Student’s t-test or Analysis of Variance (ANOVA).  
2.4.6. Membrane protein isolation 
HCC-515 cells from a T-75 flask were resuspended in 0.5ml of Solubilisation buffer 
(200 mM NaCl, 20 mM Tris.HCl, 1 mM PMSF, Protease Inhibitor Cocktail, pH 8). 
The cells were then sonicated for 5 seconds at 60% amplitude followed by a 10-
second break for 4 times. 10µL were kept for Western blot analysis. Next, the whole 
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cell lysate was centrifuged at 20,000 x  g for 20 minutes at 4oC. The supernatant 
was collected and the pellet was resuspended in 100µL Solubilisation Buffer and 
sonicated again. After the centrifugation step, the supernatants were combined and 
centrifuged in an ultracentrifuge at 100,000 x g for 1 hour at 4oC to pellet the 
insoluble material. 10µL of the supernatant (soluble/cytoplasmic fraction) were kept 
for Western blot analysis. The pelleted membranes were resuspended and 
incubated in 100 µL of Solubilisation Buffer containing 1% DDM (n-Dodecyl-B-D-
Maltoside) for 2 hours at 4oC. The solubilised membranes were then 
ultracentrifuged at 100,000 x g for 1 hour at 4oC and the supernatant was collected 
as the solubilised membrane fraction. All samples were analysed by Western blot 
(section 2.4.3 and 2.4.4).  
2.4.7. List of Antibodies used in this project 
Table 2. 9: List of primary and secondary antibodies  
Antibody Raised in Company Cat. No. 
Anti-TRPA1 mouse Santa Cruz Sc-166469 
Anti-FGFR2 rabbit Santa Cruz Sc-122 
Anti-FGFR2 rabbit Protein Tech 13042-1-AP 
Anti-TRPA1 rabbit Protein Tech 19124-1-AP 
Anti-TRPA1 rabbit MIllipore ABN1009 
Anti-pERK rabbit Cell Signalling 9101 
Anti-ERK rabbit Cell Signalling 4695 
Anti-β-actin rabbit Cell Signalling 4970 
Anti-p-PLCγ1 rabbit Cell Signalling 14008 
Anti-PLCγ1 mouse BD biosciences 610027 
Anti-mouse HRP Goat Cell Signalling 7076 
Anti-rabbit HRP Goat Cell signalling 7074 
Anti-mouse 
AlexaFluor555/488 
Goat, donkey Thermo Scientific A11029, A21202 
Anti-rabbit 
AlexaFluor555/488/594 
goat Thermo Scientific A11034, 
A11029, A11012 
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2.5. Protein interaction techniques 
2.5.1. Co-immunoprecipitation 
500-1000μg of total protein contained in 500μl of cell lysate were mixed with 20μl of 
Protein A/G plus Agarose beads (Santa Cruz) for 30 minutes at 4oC upon agitation 
to pre-clear the lysates from non-specific protein interaction with the beads. The 
beads were then spun down at 500 x g for 5 minutes and the supernatant was 
transferred into a clean 1.5ml tube where 5μl of the protein “prey” antibody was 
added (1:100) and incubated at 4oC for 1 hour under agitation. Next, 50μl of Protein 
A/G beads were added in the tubes and left overnight to incubate at 4oC under 
agitation. A step of 3 washes with 1ml 1x PBS was performed and after removing 
the last supernatant, 50μl of SDS sample buffer was added to the beads. The 
samples were boiled at 95oC for 5 minutes and the results were analysed by SDS-
PAGE and western blot.  
2.5.2. GST-pull down 
For GST pull down assay, 500μg of total protein contained in HEK cell lysate, wild 
type or overexpressing TRPA1, were mixed with 50μl of GST-C58 beads (25μl bed 
volume) overnight at 4oC. The beads were spun down at 600 x g for 5 minutes and 
the supernatant was discarded prior to washing with 1ml 1x PBS 3 times to avoid 
non-specific protein binding to the beads. After removing the last supernatant, the 
beads were mixed with 40μl of 4x Laemmli SDS sample buffer and boiled at 95oC 
for 5 minutes to break any protein interactions and denature protein structures. The 
results were analysed by SDS-PAGE followed by western blot.  
2.5.3. Microscale thermophoresis (MST) 
To investigate the direct interaction between FGFR2 and TRPA1, Microscale 
Thermophoresis (MST) was performed. The MST method utilises the 
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thermophoretic properties of molecules in order to determine binding affinities. 
Thermophoresis is the movement of molecules through a temperature gradient and 
it depends on the shape, charge and solvation energy of the molecule. MST is used 
for binding affinity determination for protein-protein, protein-small molecules, 
protein-DNA and enzyme-substrate interactions. MST offers great advantages over 
other methods (ITC – Isothermal Titration Colorimetry and SPR – Surface Plasmon 
Resonance) because 1) it allows for analysis of interactions in biological liquids 
such as blood or cell lysate which is closer to native conditions, 2) allows for 
analysis of strong interactions with a Kd as low as 1pM, and 3) does not require high 
sample consumption or molecule immobilisation on surfaces (Jerabek-Willemsen et 
al., 2014). 
The MST principle is described in Figure 2.1. We used the NanoTemper NT.115 
equipment located at the Faculty of Biological Sciences, Astbury Building with the 
help of Dr Iain Manfield. Purified full length TRPA1 and ΔN (Δ1-688 TRPA1, 
deletion of the N-terminal Ankyrin Repeat Domain), were kindly provided by Prof. 
Peter Zygmunt, Sweden. Purified human full length FGFR2 was bought from 
Origene (TP317098). Full length TRPA1 and ΔN were labelled with Alexa-Fluor488, 
passed through a NAP-5 column (GE Healthcare) to eliminate unincorporated dye 
and used at a constant concentration of 83nM. Purified FGFR2 was used in an 
increasing concentration. The FGFR2 titration series ranged from 0.1nM to 1.8µM 
(serial 1:1 dilution with PBS which was supplemented with 0.014% F-14 to keep 
membrane proteins solubilised). 10µL of 83nM TRPA1 or ΔN were mixed with 10 
µL of FGFR2 (serial concentrations) and incubated for 30 minutes prior to loading 
into the capillaries (4 µL). The experiment was performed at 10-50% LED and 40-
80% MST power. The data were analysed by Dr. Zahra Timsah using the the 
Monolith Software and GraphPAd Prism.  
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Figure 2. 1: Schematic of MST Principle. FGFR2 and TRPA1 mixtures are loaded 
into capillaries (4μl). The IR laser is focused on each capillary causing a localised 
temperature increase that makes the molecules move away (thermophoresis). 
Labelled TRPA1 is also excited by the IR laser emitting fluorescence signal. Initially, 
the molecules are equally diffused within the capillary and the fluorescent signal is 
steady. Thermophoresis is caused when the laser is turned on and a reduction in 
the fluorescence signal is detected. A steady fluorescence signal follows during 
which the molecules do not return to that initial location. When the laser is off, the 
molecules diffuse back increasing the fluorescence signal again. Thermophoresis 
depends on properties including shape, charge and size of the molecules. The 
binding of FGFR2 to TRPA1 changes the TRPA1 thermophoretic properties which 
are translated into changes in fluorescence and depend on the concentration of 
FGFR2 (different capillaries). 
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2.5.4. Proximity ligation assay 
The Proximity Ligation Assay (PLA) is used to study protein interactions in situ 
based on a template DNA amplification step that can be successful only if the 2 
protein targets are located within 40nm from each other (Söderberg et al., 2006). 
The Duolink® kit from Sigma was used for this experiment.  
This assay involves targeting of proteins of interest with primary antibodies raised in 
different species, followed by incubation with secondary antibodies specifically 
modified to carry an oligonucleotide DNA sequence, one “+” and the other one “-“. 
The next step involves the addition of connecting DNA sequences that hybridize to 
the PLA probes placed on the secondary antibodies, only if the 2 probes are 
located within 40nm (Figure 2.2). A ligase enzyme also added to the reaction 
ligates the sequence into a circular DNA template that can be amplified up to 1000-
fold through rolling-circle amplification by a DNA polymerase. The PLA probes 
serve as primers for the amplification step. Additional fluorescently-tagged 
oligonucleotides hybridise to amplified repeated sequences allowing the detection 
and localisation of the signal that is visualised as discrete spots using a confocal 
microscope. 
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Figure 2. 2: Schematic representation of PLA principle. a) binding of secondary 
antibodies that carry DNA sequences. b) Addition of DNA oligos complementary to 
DNA sequences conjugated to secondary antibodies. The Ligase enzyme ligates 
the oligos into a circular DNA template. DNA sequences serve as primers for a 
rolling cycle amplification by a DNA pol. c) Fluorescent probes complementary to a 
specific amplified sequence hybridise to it and generate the PLA signal (yellow).  
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Cells (HEK283T or HCC-515) were cultured in 10mm glass coverslips and stained 
with primary antibodies overnight following the regular immunofluorescence 
protocol. For the secondary antibody incubation, PLA(+) and PLA(-) probes were 
incubated for 1 hour in a humidified incubator. For each reaction (40ul) 8ul of 
PLA(+) and 8ul of PLA(-) were mixed in 24ul blocking buffer and placed on one 
10mm coverslip. Next, the cells were washed 3 times with PLA wash buffer A and 
incubated with the ligation reaction (40ul) that included 8ul ligation buffer and 1ul 
Ligase in 31ul dH2O for 30 min in a humidified incubator. The cells were washed 3 
times with PLA wash buffer A, and then incubated with the amplification reaction 
(40ul) that included 8ul amplification buffer and 0.5ul DNA polymerase in 31.5ul 
dH2O for 100 minutes in a humidified incubator. Lastly, the cells were washed 3 
times with PLA wash buffer A and 0.01% PLA wash buffer B for 10min. The 
coverslips were mounted in glass slides using a mounting medium containing DAPI. 
The results were visualised in a confocal microscope.  
Following image acquisition, PLA signals from each positive cell were manually 
counted for each condition and statistically analysed in SPSS. Normality test 
showed that the data was non-parametric thus, Kruskal Wallis, a non-parametric 
ANOVA test, and Mann Whitney (non-parametric post hoc) statistical analysis were 
performed.  
2.6. Calcium imaging 
Calcium Imaging experiments were performed with the help of Alex Hogea and 
Shihab Shah (members of Gamper Group). Calcium imaging was used as a 
functional assay for TRPA1 activity. HCC-44 or HCC-515 cells that were cultured 
on coverslips, were serum starved for 2 hours prior to imaging. Next, the cells were 
incubated with 1 μM Fura-2-AM (calcium indicator) and 0.01% pluronic acid in EC 
solution (160 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, and 
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10 mM Glucose) at 37 °C for 45 to 60 minutes. Following placement of coverslip 
chips in the perfusion chamber, the cells were washed with EC solution for 2 
minutes. Next, the cells were perfused with 100µM AITC for 5 minutes to activate 
TRPA1 channels prior to washing with EC for another 2 minutes. Ionomycin 
(Thermo Fisher Scientific) was used at the end of each recording as a positive 
control for calcium detection. HC-030031 was used at 50µM for 5 minutes before 
treatment with AITC to pre-block TRPA1 channels. Fura-2 was alternatingly excited 
at 340nm (calcium bound) and 380nm (calcium free) every 2 seconds and 510nm 
emission recordings were monitored. The calcium response was indicated by the 
ratio of fluorescence at 340nm/380nm (F340/F380).  
Experiments were performed in triplicates with 20-40 cells each. Firstly, all the data 
points were normalised against the first baseline value to overcome baseline 
variation between cells. The calcium response was calculated by subtracting the 
baseline (first EC wash right before stimulation) by the maximum response detected 
within the 5 minutes of AITC stimulation.  
An inverted Nikon Eclipse TE-2000 microscope, Polychrome V monochromator, 
IMAGO CCD camera, and TILLvision 4.5 software were utilised for this calcium 
imaging.  
2.7. Super resolution microscopy 
Image resolution using a regular confocal microscope is restricted to approximately 
half the size of the wavelength used, due to the diffraction limit of light. This results 
in a resolution limit of maximum 200nm laterally and 500nm axially that prevents 
detailed analysis of single molecules and cellular structures. An increase of 1.7 
times (max. 140nm laterally, 400nm axially) in resolution can be achieved by 
Airyscan imaging (Huff, 2015). Regular confocal imaging utilises a pinhole of 1 A.U. 
(Airy unit) because pinholes with diameter smaller than 1 A.U, even though achieve 
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higher resolution (0.2 A.U. = 1.4x resolution increase), result in signal loss up to 
95%. Airyscan utilises a novel detector composed of 32 smaller pinholes of 0.2 A.U. 
each, that combines the higher detection of a 1.25 A.U. pinhole with the resolution 
of a 0.2 pinhole, resulting in increased signal to noise ratio too (Huff, 2015). 
However, the 140nm maximum resolution is still way bigger than the size of 
biological complexes and molecules.  
The development of super resolution microscopy techniques such as d-STORM 
(direct-Stochastic Optical Reconstruction Microscopy) and PALM (PhotoActivated 
Localisation Microscopy) has managed to overcome the resolution limit by taking 
advantage of the photo-switchable properties of fluorophores (Schermelleh et al., 
2019). In brief, only a portion of the fluorophores are stochastically activated or 
“switched off” in sequential acquisitions. This results in separation of signals both in 
space as well as time. Superimposition of all the frames reconstructs the final 
image that can achieve resolution up to 20nm.  
An alternative method to overcome the diffraction limit of light and achieve higher 
resolution is Expansion Microscopy (ExM). ExM involves the physical expansion 
and thus magnification of the sample which is embedded into a swellable gel, 
resulting in separation of molecules and increase in resolution (Figure 2.3). In 
comparison to single-molecule super resolution microscopy techniques, ExM offers 
advantages such as use of inexpensive materials and equipment, simple and quick 
protocols as well as 3D imaging of thick specimens. However, due to the nature of 
the technique, live imaging is not feasible (Wassie et al., 2019).  
2.7.1. Expansion microscopy 
The Expansion microscopy experiments were performed in collaboration with Dr. 
Izzy Jayasinghe and Tom Sheard that provided an already validated protocol and 
assisted with data analysis. The ExM protocol involves a series of chemical 
reactions aiming to expand the sample isotropically (Figure 2.3). First, fluorophores 
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conjugated to secondary antibodies are attached to Acrylol X (AcX) which acts as a 
linker between the fluorophores and the polymer. Next, the samples are incubated 
with the Monomer solution that consists among others of Sodium Acrylate 
(monomer) and DMA (cross-linker). During polymerisation, a mesh of Solium 
PolyAcrylate is generated that is attached to the fluorophores through the anchors 
of AcX. Isotropic expansion requires digestion of the biological material through 
incubation with Proteinase K. Proteinase K digests all molecules, destroying any 
cellular structures. As a result, isotropic expansion of the swellable gel is achieved 
upon incubation in water due to osmosis and high charge of the electrolyte mesh. A 
4x expanded gel increases in volume 100 times. The expansion factor depends on 
the chemistry of the monomer solution and the concentration of the cross-linker 
(N,N′-Methylenebisacrylamide, DMA). For a 10X ExM, lower concentrations of DMA 
are used which results in greater expansion but also higher gel fragility (Wassie et 
al., 2019). The resolution depends on the expansion factor. A 4x expanded gel 
imaged with Airyscan confocal can achieve a resolution of 35nm, while a 10x 
expanded gel can achieve a resolution of 14nm.  
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Figure 2. 3: Schematic representation of Expansion Microscopy protocol. a) 
Anchoring step: Fluorophores (green), conjugated to antibodies targeting molecules 
(blue spheres), attach to anchors of Acryloyl X (AcX). b) Polymerisation step: 
Monomer solution containing the monomer (Sodium Acrylate) and the cross-liker 
(DMA) is applied to the sample. Upon APS (initiator) and TEMED (accelerator), 
Sodium Acrylate starts to polymerise and create a hydrogel mesh. AcX anchors 
attach fluorophores to the hydrogel mesh. c) Digestion step: the biological material 
is removed by digestion with Proteinase K that digests proteins. d) Physical 
expansion of the gel following incubation in water.  
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However, the fluorophores remain attached to the mesh. d) Upon water immersion, 
the gel is expanded. The attached fluorophores are now further apart and can be 
resolved under a confocal microscope.  
2.7.1.1. Immunofluorescence staining 
Cells were cultured in square glass coverslips (22mm x 22cm) within wells of a 6-
well plate and stained with primary and secondary antibodies following a regular 
immunofluorescence protocol (section 2.3). Alexa-Fluor488 and Alexa-Fluor594 
conjugated secondary antibodies were used for expansion since Dr Izzy 
Jayasinghe’s group has successfully been using those fluorophores in expansion 
microscopy. Next, the coverslips were attached to slides to create square chambers 
and imaged in a regular confocal microscope (Airyscan mode) to obtain pre-
expansion images of the cells.  
2.7.1.2. Anchoring 
Following PBS washes of the secondary antibody and pre-expansion imaging, the 
PBS is removed and replaced with the Anchoring Solution. The Anchoring Solution 
consists of Acryloyl X (AcX) in a final working concentration of 0.1mg/mL in PBS. 
Aliquots of 10mg/mL (1mg of AcX in 100µL DMSO) were diluted 1:100 in PBS and 
approximately 300µL were applied onto the cells overnight at 4oC. The slides were 
kept in a humidified box to keep cells from drying out. This anchoring method is the 
same for both the 4X and 10X expansion protocols.  
2.7.1.3. Monomer polymerization 
ExM 4X: 
The next day, the cells were washed with PBS and then incubated with Polymer 
Solution for 2 hours at 37oC. In brief, 282µL of (1.06% strength – Table 2.10) 
Polymer Solution was mixed with 12µL PBS, 3µL of Ammonium persulfate (APS, 
0.1% working concentration) and 3µL of N,N,N',N'-Tetramethylethylenediamine 
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(TEMED, 0.1% working concentration) to make 1x of 300µL final Volume. The 
solution was mixed avoiding air bubbles. Firstly, the coverslips were detached from 
the slides. New coverslips were cut lengthwise to create strips and placed on the 
two edges of the coverslips (with the cells) to serve as walls. The Polymer Solution 
was then applied to the cells and a new full-size coverslip was placed on top to seal 
the “chamber”.  
Table 2. 10: polymer recipe for ExM 4X 
Reagent Stock 
(g/100mL) 
Volume Working concentration 
(g/100ml) 
Sodium acrylate 38 0.5625  8.6 
Acrylamide 50 0.125   2.5 
N,N′-
Methylenebisacrylamide 
2 0.1875 0.15 
Sodium chloride 29.2 1   11.7 
PBS 10x 0.25    1x 
Water n/a 0.225  n/a 
Total Volume n/a 2.35mL n/a 
 
ExM 10X: 
The Polymer Solution for ExM 10X consists of 0.15875g Sodium acrylate (SA) and 
666µL Dimethylacrylamide (DMA) in water of 2.5mL total Volume (33% DMA and 
SA). The solution was bubbled with nitrogen gas for 1 hour at 4oC. 333µL of 
Potassium Persulfate (KPS, 27mg/mL stock concentration) was added in 2.166mL 
of Polymer Solution and bubbled with nitrogen gas for another 15 minutes.in the 
meantime, the cells were washed with PBS and coverslip walls were in place. 
375µL of Polymer Solution containing KPS were mixed with 1.5µL TEMED (0.4% 
working concentration) and applied to the cells. A new coverslip was placed on top 
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to seal the “chamber”. The cells were incubated with the Polymer Solution overnight 
at room temperature.  
 
2.7.1.4. Digestion 
Following Polymerisation, the remaining tissue embedded in the gel is dissolved 
with a Proteinase K incubation step which is the same for both 4X and 10X 
expansion protocols. Firstly, the gel is removed from the chamber by carefully 
separating the coverslips and cutting excess gel. The shape and dimensions of the 
gel are recorded. Next, the gel was placed in a well of a 6-well plate and 2mL of 
Digestion Solution (Table 2.11) is applied. 100uL of Proteinase K (8units/mL 
working concentration) was mixed with 10mL of Digestion Solution (1:100) and the 
gel was incubated for 12-16hours overnight at room temperature.  
Table 2. 11: Digestion Buffer recipe for 100mL 
Reagent Stock Working concentration Amount used 
EDTA 01M 1mM 1mL 
Tris pH 8 1M 50mM 5mL 
Triton X-100 100% 0.5% 0.5mL 
Guanidine HCl n/a 0.8M 7.6424g 
Water  n/a n/a Up to 100mL 
HCl  10% n/a Up to pH 8 
 
2.7.1.5. Expansion  
The next day, the Digestion Solution was removed and the gel was transferred to a 
container that was big enough to fit the expanded gel. The gel was incubated with 
30-100mL of deionised water which was changed every 30 minutes to 1 hour until 
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the expansion plateaued. At this point, the new dimensions of the gel were 
recorded and divided by the initial dimensions to determine the expansion factor. All 
the incubations were performed in a dark room to avoid photobleaching.  
2.7.1.6. Imaging and analysis 
The gel was cut into squares that would fit in square chamber slides for imaging. To 
avoid gel drifting while imaging, the square chamber slides were coated with 0.1% 
poly-L-lysine for 30 minutes and then washed with water prior to placing the gel. A 
few drops of PBS were added on top of the gel to prevent it from drying and 
shrinking during imaging. Fluorescent images were obtained at 63x magnification 
and by using the Airyscan mode in a confocal microscope. Airyscan processed 
images were inserted into Image J. A threshold (usually “ISODATA” was applied to 
areas of interest and the images were analysed with the Mander’s Colocalisation 
Analysis. The obtained values were copied to Excel and statistically analysed.  
2.8. Statistical Analysis 
Statistical analysis was performed on data obtained from at least three repetitions. 
Throughout the thesis, the data are presented in bar graphs as the average of all 
repetitions. The error bars represent the S.E.M. (standard error of the mean). 
Statistical significance between 2 groups and more than 2 groups was analysed by 
Student’s t-test in Excel and ANOVA (analysis of variance) in SPSS or GraphPad, 
respectively. Statistical significance is shown by asterisks (*).  
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3. Chapter 3 
Characterisation of the FGFR2-TRPA1 complex 
3.1. Introduction 
Protein-protein interactions are necessary for multiple cellular processes, including 
signal transduction. Intermolecular and intramolecular protein interactions are 
mediated through specific recognition and reversible binding between structural 
motifs found on the protein molecules. There are numerous protein domains that 
are implicated in target recognition based on protein motifs. The SH2 domains, for 
instance, bind to phosphorylated tyrosine residues on target proteins and the FHA 
(Fork-head Associated) domains recognize phosphorylated threonine and serine 
residues on targets (Ball et al., 2005).  
As a Tyrosine Kinase Receptor, FGFR2 forms direct interactions with downstream 
adaptor and effector proteins (substrates for phosphorylation) resulting in signalling 
cascades. One of the most significant protein interactions involves recognition of 
FGFR2 phospho-tyrosine residues by SH2-containing proteins. The n-SH2 domain 
of PLCγ1, for instance, recognises phospho-tyrosine 769 (pY769) on the FGFR2 C-
terminal region which results in PLCγ1 phosphorylation and activation by the 
receptor (Huang et al., 2016). Another substrate of FGFR is FRS2 (FGFR-related 
substrate-2) which is constitutively bound and interacts through its PTB domain 
(phospho-tyrosine binding domain) that recognises non-phosphorylated residues on 
the FGFRs juxtamembrane region (residues 419, 422, 423 and 425 of human 
FGFR1) (Gotoh, 2008). There is evidence that phosphorylated serine residues on 
FGFR2 (S779) can also serve as interaction sites for the 13-4-4 group of proteins 
which can activate pathways including the MAPK however, the specific mechanism 
of signalling activation through phospho-serines remains elusive (Lonic et al., 
2008).  
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An additional form of interaction that is shown to be vital for the FGFR2 signal 
regulation, especially under non-stimulating conditions, occurs through its C-
terminal proline-rich motif. In general, Proline-rich motifs are recognised by SH3 
domains and so far, there are two SH3-containing binding partners that have been 
described for FGFR2: the adaptor protein GRB2 and the phospholipase PLCγ1 
(Ahmed et al., 2010; Timsah et al., 2014). 
There is evidence of a direct interaction between proline-rich motifs and Ankyrin 
repeat domains (ARD), another common protein motif. According to Rader et al, the 
mouse Ankyrin-repeat family A protein (ANKRA) interacts with the proline-rich 
motif-containing cytoplasmic domain of the rat megalin (a low-densitty lipoprotein 
receptor found in epithelial kidney cells) through its ankyrin repeats (Rader et al., 
2000). Based on this evidence, there could be other possible ankyrin repeat-
containing binding partners for the proline-rich motif of FGFR2. Following 
bioinformatics analysis performed by Dr. Zahra Timsah’s group (unpublished data), 
one of those potential binding partners is the ion channel TRPA1. 
TRPA1 is a non-selective cation channel with an extended N-terminal domain that 
carries 16 ankyrin repeats. The primary module of the TRPA1 ARD (AR12-16) is 
responsible for electrophilic ligand recognition which mainly includes Cysteine 621, 
641 and 665, however, no protein-based ligand has been proven to bind directly on 
the ARD so far. This raises the question of what is the actual function of the rest of 
the ARs (Paulsen et al., 2015). Given the large number of ARs compared to other 
TRP channels, TRPA1 could interact with other membrane-bound or cytoplasmic 
proteins. For example, Tmem100, a two-transmembrane protein, forms complexes 
with both TRPA1 and TRPV1, individually, regulating TRPA1 activation. However, 
the binding region on either of the channels has not been further determined.  
To the best of our knowledge, the direct interaction between a TRP channel and an 
RTK has never been reported, especially in the context of cancer. This Chapter 
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aims to characterise the possible interaction between FGFR2 and TRPA1 in a 
cellular overexpression system as well as map the interaction sites on both proteins 
by utilising protein interaction techniques including pull-downs, PLA and biophysical 
methods. Physiological complex formation is also studied in a human LUAD cell 
line. Further characterisation and stoichiometry of the FGFR2-TRPA1 complex is 
studied by Expansion Microscopy, a super-resolution microscopy technique.   
This set of data led to a publication in 2017 by Dr Zahra Timsah’s group (Berrout et 
al., 2017) however, additional controls, repeats and further experiments have been 
conducted and included in the present chapter.  
 
3.2. Results 
3.2.1. FGFR2-TRPA1 complex formation in transfected HEK-293T cells 
To assess the binding between FGFR2 and TRPA1, HEK-293T cells transiently 
transfected with plasmids containing tagged proteins (tGFP-TRPA1 and FGFR2-
FLAG), (tGFP = turbo GFP), were lysed and used for co-IP experiments. It was 
crucial to incubate the cells in serum-free media for 2 hours prior to lysis to avoid 
any stimulation of FGFR2. Transfection efficiency and simultaneous expression 
was confirmed by Immunofluorescence staining using anti-FGFR2 and anti-TRPA1 
antibodies (Figure 3.1). The expression of both proteins in HEK-273T cells confirms 
both plasmids are functional, and that this system can be utilised for studying the 
interaction between FGFR2 and TRPA1 
Lysates from HEK-293T cells transfected with tGFP-TRPA1 and/or FGFR2-FLAG 
were used in co-IP experiments in which either FGFR2 (Figure 3.2a) or TRPA1 
(Figure 3.2b) served as “bait” protein and the results were analysed by western blot. 
FGFR2 successfully pulled down TRPA1 (a, lane 4) and vice versa, TRPA1 pulled 
down FGFR2 (b, lane 3) suggesting complex formation between the two proteins. 
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Minimal amounts of protein were detected in negative control cells expressing only 
the protein “prey” verifying the specificity of the results (a and b lane 2).  
Even though the tGFP tag is connected to the N-terminal of TRPA1 and the FLAG 
tag is linked to the C-terminal of FGFR2, both regions are located in the cytoplasm.   
In order to eliminate the possibility of interaction through the tags, co-IP 
experiments were performed in HEK-293T cells expressing negative control 
vectors. The ability of tags to pull down the protein “bait” was examined in western 
blots (Figure 3.3). Firstly, the anti-FLAG antibody was not able to pull down TRPA1 
in the absence of FGFR2 (Figure 3.3a, lane 2, tGFP-TRPA1+empty FLAG vector) 
excluding the possibility of interaction through the FLAG tag of the receptor. 
However, the anti-FLAG antibody pulled down TRPA1 when the cells were double 
transfected with tGFP-TRPA1 and FGFR2-FLAG confirming the interaction 
between the two proteins once again.  
Similarly, an anti-FGFR2 antibody on HEK-293T cells co-expressing FGFR2-FLAG 
and an empty GFP vector failed to precipitate GFP (Figure 3.3b, lane 1) eliminating 
the possibility of interaction of FGFR2 with GFP tag. However, the pGFP-N3 vector 
(Clontech) was used in this co-IP due to lack of tGFP (turboGFP) negative control 
vector. Nevertheless, this experiment showed that there was no interaction between 
FGFR2 and GFP, confirming the specificity of FGFR2-TRPA1 interaction (at least in 
the context of the above controls). TRPA1 could not be recognised by a regular 
anti-GFP antibody in the presence of FGFR2, neither in the co-IP nor the lysates 
blot (Figure 3.3b, lanes 2 and 4), even though it was recognised by the anti-TRPA1 
antibody (same lanes). This is because a specific anti-tGFP antibody is required for 
tGFP recognition. 
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Figure 3. 1: Efficiency of transfection for FGFR2 and TRPA1 in HEK-293T 
cells. Immunofluorescence staining with anti-FGFR2 (Santa Cruz) and anti-TRPA1 
(Santa Cruz) antibodies to verify successful expression of the proteins in HEK-293T 
cells. Scale bar equals 20µm. 
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Figure 3. 2: Co-Immunoprecipitation experiments confirming the interaction 
between overexpressed FGFR2 and TRPA1 in HEK-293T cells. a) Co-IP with 
anti-FGFR2 antibody (Santa Cruz) and b) with anti-TRPA1 antibody (Santa Cruz) 
on HEK-293T cells transfected with FGFR2-FLAG and tGFP-TRPA1. Un-
transfected (UT), tGFP-TRPA1- and FGFR2-FLAG-transfected cells were used as 
negative controls. Left panels = co-IP, right panels = expression levels for the 
proteins of interest. The IgG heavy chain band and β-actin are used as loading 
controls for the IP and Western blot, respectively. Representative blots are shown 
(n=3). 
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Figure 3. 3: Co-Immunoprecipitation experiments to control for binding 
through the epitope tags. a) Co-IP with the anti-FLAG antibody on HEK-293T 
cells transfected with FGFR2-FLAG + tGFP-TRPA1 (positive control), Un-
transfected (UT) and tGFP-TRPA1+FLAG vector (negative controls). b) Co-IP with 
the anti-FGFR2 antibody (Santa Cruz) on HEK-293T cells overexpressing FGFR2-
FLAG + tGFP-TRPA1 (positive control) and FGFR2-FLAG + GFP (negative 
control).  Left panels = co-IP, right panels = expression levels for the proteins of 
interest. The IgG heavy chain band and β-actin are used as a loading controls for 
the IP and Western blot, respectively. Representative blots are shown (n=3). 
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In the next series of experiments, Proximity ligation assay (PLA, see Chapter 2 for 
details) was also performed to confirm the interaction between overexpressed 
FGFR2 and TRPA1 in HEK-293T cells. The PLA assay was performed using 
antibodies against FGFR2 and TRPA1 proteins.  
Confocal analysis of the PLA experiment showed that the PLA signal was 
significantly higher (p<0.05, Mann Whittney, mean = 23 puncta per cell) in cells 
overexpressing FGFR2-FLAG and t-GFP-TRPA1 compared to cells overexpressing 
only tGFP-TRPA1 (mean = 4.7 puncta per cell) which served as a biological 
negative control because only one of the proteins was overexpressed (Figure 3.4 
and 3.5). PLA signal is created only when the two PLA probes are located within 
40nm apart which suggests a high chance of physical interaction between FGFR2 
and TRPA1, therefore, verifying the co-IP results.  
Interestingly, a low PLA signal was observed in un-transfected cells (mean = 2 
puncta per cell), which could be the result of either a “noise” signal created by the 
“by chance” colocalization of non-specifically bound antibodies or interactions 
between endogenous FGFR2 and TRPA1 proteins, potentially expressed in HEK-
923T cells at low levels, or even a combination of the above. The tGFP-TRPA1-
expressing cells in which FGFR2 was not over-expressed had a significantly higher 
TRPA1-FGFR2 PLA signal compared to the wild type cells (Figure 3.5). This 
increase in PLA signal upon over-expression of TRPA1 could be due to interactions 
between exogenous TRPA1 and minimal amounts of endogenous FGFR2.  
Nevertheless, the PLA signal was significantly higher in double- compared to 
single-transfected cells indicating signal specificity.  As an additional negative 
control, PLA was performed without primary antibodies added to double transfected 
cells, which showed no PLA signal. Two TRPA1 antibodies raised in different 
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species were used as a technical positive control in cells overexpressing only tGFP-
TRPA1 (mean = 9.5 puncta per cell) (Figure 3.4).  
TRPA1 is fluorescently tagged, which facilitates the visualisation and confirmation 
of protein presence in the examined cells. On the other hand, there was no 
fluorescent tag for FGFR2 - thus, the presence of the protein could not be verified 
at the time of PLA imaging. However, based on the PLA principle, to visualise a 
PLA signal the proteins should be expressed in the same cell, so PLA signal was 
automatically linked to double expression. Indeed, the PLA signal was present in 
GFP cells (co-expressing FGFR2) and not in non-GFP cells (wild type or only 
FGFR2 expression) (Figure 3.4). It was also observed that the PLA signal varied 
from 6 to 72 in 127 cells overexpressing both proteins which can be explained by 
the differences in protein expression levels between cells following transfection.  
Next, to eliminate the possibility of increased PLA signal because of protein 
overexpression and “random” co-localisation due to abundance, rather than due to 
actual physical association of the targets, an additional PLA assay was performed 
on cells transfected with a negative control empty GFP vector and FGFR2-FLAG. In 
theory, this combination should not have higher PLA signal than the FGFR2-FLAG 
and tGFP-TRPA1 combination because GFP does not interact with FGFR2 or 
FLAG. PLA signal was significantly higher in this negative control (mean = 62 
puncta per cell) compared to the FGFR2+TRPA1 condition (Figure 3.6). In this 
experiment, a different pair of antibodies had to be used: anti-GFP and anti-
FLAG, which means that this is not an “ideal” negative control. However, it 
shows that PLA can be affected by protein over-expression.   
Therefore, the PLA experiment in Figure 3.5 is an indication of FGFR2 and TRPA1 
close proximity / physical association and not a definite proof of interaction due to 
the fact that the proteins were overexpressed and as a result present at high levels. 
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Further interpretation of PLA results is considered in the Discussion section of this 
chapter.  
Taken together, both co-IP and PLA experiments could suggest complex formation 
between TRPA1 and FGFR2 in overexpressing HEK-293T cells.  
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Figure 3. 4: PLA assay on transfected HEK-293T suggests close proximity of 
FGFR2 and TRPA1. Protein overexpression is indicated on the left and each row 
represents a different assay condition. ‘TRPA1+FGFR2-ve’ = no primary antibodies. 
‘TRPA1+ve’ = TRPA1-transfected cells and the use of two TRPA1 antibodies raised 
in different species (Santa Cruz and Protein Tech). ‘UT’ = Un-transfected. TRPA1 is 
tGFP-tagged and FGFR2 is FLAG-tagged. TRPA1 presence is verified with GFP. 
PLA signal is visualised with Texas Red. DAPI stain is used for nuclear staining. 
Representative images are shown (n=4). ‘Merge’ for DAPI, GFP and Texas Red.  
- 119 - 
 
 
 
 
Figure 3. 5: PLA quantification. Scatter plot illustrating PLA puncta per cell in four 
different conditions. There was a significant difference between the groups as 
analysed with non-parametric Kruskal Wallis test on OriginPRO. Significant 
differences are shown as * (p≤0.05, Mann Whitney, non-parametric post hoc). 
FGFR2-FLAG + tGFP-TRPA1 = 127 cells and mean = 23 puncta per cell, UT = 74 
cells and mean = 2 puncta per cell, TRPA1-only (negative control) = 18 cells and 
mean = 4.7 puncta per cells, TRPA1-TRPA1 (positive control) = 8 cells and mean = 
9.5 puncta per cell. Statistical analysis of Figure 3.4. UT = Un-transfected.  
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Figure 3. 6: PLA signal is affected by protein abundance. a) Representative 
images of PLA assay on HEK-293T cells transfected with FGFR2-FLAG + GFP as 
a negative control. TRPA1 = GFP, PLA = Texas Red, cell nuclei = DAPI. b) 
Statistical analysis. Scatter plot illustrating the PLA puncta per cell in two groups. 
FGFR2-FLAG + GFP = 3 cells, FGFR2-FLAG + tGFP-TRPA1 = 127 cells. 
Significant differences are shown as *** (p≤0.001, Mann Whitney, non-parametric, 
OriginPRO). Error bars of the mean are shown in black. 
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3.2.2. TRPA1 directly binds to FGFR2 through the Ankyrin Repeat Domain 
(ARD) 
At this point, co-IP and PLA experiments suggest complex formation between 
FGFR2 and TRPA1. However, direct interaction between the two proteins has not 
been confirmed. For this reason, a biophysical method called Microscale 
Thermophoresis (MST) was performed using purified proteins to study protein 
interaction in vitro. Purified TRPA1 labelled with Alexa-Fluor488 was used at a 
constant concentration of 83 nM while purified FGFR2 was used in an increasing 
concentration (0.1-1800 nM). A binding curve was constructed after raw data 
analysis using the Monolith software, performed by Dr. Zahra Timsah, which 
revealed protein interaction between the proteins. The dissociation constant (Kd) 
was calculated as 122.8 ± 23.4 nM that indicates the concentration at which the two 
proteins exist in an equilibrium of bound and unbound state (Figure 3.7b). 
The N-terminal Ankyrin Repeat Domain (ARD) of TRPA1 is an appropriate 
candidate for protein interactions since ARD are involved in protein interactions. To 
investigate the potential role of the ARD in the interaction with FGFR2, MST was 
performed with a truncated version of TRPA1 (Δ1-688 or Δ16) in which the 16 N-
terminal Ankyrin repeats have been deleted (Figure 3.7a). In this case, a binding 
curve could not be created suggesting that TRPA1 cannot interact with FGFR2 in 
the absence of the ARD domain (Figure 3.7b).  
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Figure 3. 7: Direct interaction of FGFR2 and TRPA1 through the ARD as 
suggested by MST analysis of purified proteins. a) Western blot of purified 
samples of TRPA1 full length (FL) and Δ16. Bands of interest are specified with 
arrows. TRPA1 full length = 130 kDa and TRPA1-Δ16 = 50 kDa. Purified TRPA1 
and Δ16 were kindly provided by Prof. Peter Zygmunt, Sweden. b) Dose-response 
curve of TRPA1 bound to increasing concentrations of FGFR2. Error bars = 
standard error of the mean (n = 7). Delta N-F2 = Δ16. Dissociation constant KD = 
122.8 ± 22.4 nM.  
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To further examine the involvement of the TRPA1 ARD domain in the interaction 
with FGFR2 within cells, truncated versions of TRPA1 missing either the first 10 
(Δ10) or the first 5 (Δ5) ankyrin repeats were co-expressed with FGFR2 in HEK-
293T cells and protein interactions were studied by co-IP (Figure 3.8 and 3.9). 
Firstly, the transfection efficiency of the Δ10 and Δ5 constructs in HEK-293T cells 
was examined by western blot using an anti-TRPA1 antibody that recognises 
epitopes outside the ARD. As shown in Figure 3.8a, the Δ10 construct was 
successfully transfected and expressed in HEK-293T cells. The predicted molecular 
weight of 124 kDa matches the weight of the Δ10 band. Unfortunately, the 
transfection of the Δ5 construct was not successful after a number of attempts, 
therefore making the further analysis of the role of specific repeats between 1 and 
10 not feasible (Figure 3.8a).  
Interestingly, co-expression of Δ10 with FGFR2 was difficult. When transfected 
together, the expression levels of both proteins were significantly lower (Figure 
3.9a, lane 3) compared to the full length TRPA1 and FGFR2 combination (Figure 
3.8b). Δ10 protein levels are absent in double-transfected cells compared to lane 2 
in which cells were transfected with Δ10 only. An example of an inconclusive co-IP 
experiment is shown in Figure 3.9b. The fact that Δ10 did not pull down FGFR2 
(lane 3) like full length TRPA1 did (positive control - lane 2), could be due to the 
failed co-expression of FGFR2. Therefore, co-IP experiments could not be 
performed accurately (Figure 3.9b). 
To solve this complication, GST pull-down assays were performed instead, which 
are explained in the next section.  
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Figure 3. 8: Protein expression of full length, Δ10 and Δ5 TRPA1 by western 
blot and immunofluorescence. a) Western blot analysis of un-transfected (UT), 
TRPA1 full length, TRPA1 Δ10- and Δ5-transfected cells. Full length TRPA1 = 150 
kDa. Δ10 = 124 kDa. Δ5 = 143 kDa. β-actin was used as a loading control. b) 
Immunofluorescence staining on FGFR2-FLAG + tGFP-TRPA1 full length or Δ10. 
FGFR2 = red. TRPA1 = green. (Anti-TRPA1 and anti-FGFR2 antibodies from Santa 
Cruz) 
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Figure 3. 9: Co-IP experiment to examine the binding capacity of Δ10 to 
FGFR2. a) Western blot analysis to verify the co-expression efficiency of FGFR2-
FLAG and tGFP-TRPA1-Δ10 (Santa Cruz antibodies). b) Co-IP experiment with 
anti-TRPA1 antibody (Santa Cruz) on HEK-293T cells. FGFR2-FLAG + tGFP-
TRPA1 cells were used as positive control. FGFR2-FLAG-transfected cells were 
used as negative control. tGFP-TRPA1-Δ5 was not expressed at all. IgG heavy 
chain was used as loading control. UT = un-transfected cells. 
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3.2.3. The FGFR2 C-terminal domain mediates direct interaction with the 
TRPA1 ARD 
The C-terminal region of FGFR2 has been implicated in protein-protein interactions 
with downstream signalling proteins and therefore it was hypothesised that it could 
also be involved in the interaction with TRPA1. To examine the role of the FGFR2 
C-terminal region in this interaction, a fragment containing the last 58 amino acids 
of FGFR2 (C-58) was tagged with GST (34 kDa total molecular weight), expressed 
in E.coli and purified by GST affinity purification (Figure 3.10a). 
Cell lysates were prepared from un-transfected HEK-293T cells as well as cells 
transfected with the TRPA1 construct. These lysates were then utilised in pull-down 
assays using the GST-C-58 conjugated beads and the results were visualised by 
western blot (Figure 3.11a,b, lane 2). Furthermore, the un-transfected HEK-293T 
lysate was mixed with standard GST beads as a control for non-specific binding 
(Figure 3.11b, lane 1). As shown in Figure 3.11b, TRPA1 was pulled down by the 
C-58 fragment but not by the empty GST beads suggesting that the last 58 C-
terminal residues of the receptor are involved in the interaction with TRPA1. The 
ability of C-58 to pull down endogenous PLCγ1 was used a positive control since 
the interaction between the two has been reported before (Timsah et al., 2014). As 
expected, PLCγ1 was pulled down both in wild type and TRPA1-expressing cells 
(lane 2, 3).  
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Figure 3. 10: C58 fragment purification. SDS-PAGE stained with Coomassie 
staining (left panels) and Western blots probed for total FGFR2 antibody (Protein 
Tech) (right panels). Samples from different stages of the purification process were 
loaded: Input (I), Pellet (P), Flow Through (FT), Wash 1,2 and 3 (W1,2,3), Elution 1 
and 2 (E1 and 2) and beads. a) C58-WT. Proline (P) to Alanine (A) mutation on 
sites b) 804, c) 810 and d) 813. Purified corresponding bands are indicated with 
arrows. The molecular size of GST-C58 fragments is 34 kDa (26 kDa GST + 8 kDa 
C58).  
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Figure 3. 11: TRPA1 binds to the C-terminal domain of FGFR2. a) Schematic 
representation of the GST pull-down assay. GST-tagged C-58 fragment is attached 
to the Glutathione beads and pulls down binding partners that are detected by 
western blot. b) GST pull down assay to assess the interaction of TRPA1 with the 
C-terminal 58 amino acids of FGFR2. Lysates from tGFP-TRPA1-transfected cells 
were mixed with the GST-C58 beads as well as uncoupled GST-beads (negative 
control). Un-transfected (UT) cell lysate mixed with GST-C58 beads was used as a 
negative control. C-58 FGFR2 levels were used as a loading control (ponceau 
staining). PLCγ1 binds to the C-terminal domain of FGFR2 and therefore it was 
used as a positive control. A representative blot is shown here (n=4). GST = 
Glutathione S-transferase.  
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Following some difficulties in co-express TRPA1-Δ10 and FGFR2 constructs, GST 
pull down assays were performed instead to examine the role of the ankyrin repeats 
in the interaction (Figure 3.12). Lysates from HEK-293T cells expressing full length 
TRPA1 or Δ10 were subject to pull down assay with GST-C-58 beads and the 
ability of C-58 to pull down Δ10 was compared to the full length protein. Indeed, 
Δ10 was pulled down approximately 80% less than the full length TRPA1 (0.23 ± 
0.06 a.u., p = 0.0002, Student t-test) which indicates that the first ten ankyrin 
repeats of TRPA1 are crucial for the binding to the FGFR2 C-terminal fragment 
(Figure 3.12).  
To further determine the specific binding site on FGFR2, site-directed mutants of 
the C-58 fragment were constructed. The proline-rich motif at the C-terminal of 
FGFR2 is involved in protein-protein interactions with SH3-domain-containing 
downstream proteins (Ahmed et al., 2010, Timsah et al., 2014). Even though 
TRPA1 does not contain SH3 domains, the ability to bind to the proline-rich motif 
was still investigated. Three purified C-58 mutants (Proline to Alanine) were used in 
GST pull down assays: P804A, P810A and P813A (Figure 3.10b, c, d). 
Endogenous PLCγ1 pull down was used as a positive control since it interacts with 
that proline-rich motif through the SH3 domain. Indeed, PLCγ1 pull down was 
reduced when P810 and P813 were mutated (n = 1). However, there was no 
decrease in the ability to pull down TRPA1 between the wild type and mutant 
fragments in this set of experiments (n = 2) (Figure 3.13).  
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Figure 3. 12: Mapping out the FGFR2 binding site on TRPA1 by GST pull 
down. a) TRPA1 full length and Δ10-expressing cell lysates were subject to GST 
pull down assay with GST-C58 beads. GST pull down (left panel) and Western blot 
to determine protein expression (right panel). C-58 levels were used as a loading 
control (Ponceau staining). PLCγ1 binds to the C-terminal domain of FGFR2 and 
therefore it was used as a positive control. b) Quantification of the GST pull down 
by densitometry on ImageJ. Bar graph showing the normalised densitometry values 
of TRPA1 and Δ10 conditions against TRPA1. Densitometry values were initially 
normalised against C58 (loading control). A significant difference is indicated by *** 
(p ≤ 0.001, Student t-test). Error bars represent the standard error of the mean (n = 
3). GST = Glutathione S-transferase.  
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Figure 3. 13: Mapping out the binding site on FGFR2 C-terminal domain. a) 
schematic representation of FGFR2 cytoplasmic domain. C-58 consists of residues 
763 to 821. Mutated Prolines are indicated in red. PLCγ1 binds to prolines P810 
and P813 through the SH3 domain. Phosphorylated Tyrosine 769 (pY769) is the 
binding site for PLCγ1 SH2 domain. b) GST pull down assays with tGFP-TRPA1-
expressing cell lysates and wild type and three individual Proline mutations of C-58. 
PLCγ1 was used as a positive control and GST-C58 was used as a loading control 
(ponceau staining). c) and d) Quantification of the GST pull down by densitometry 
on ImageJ. Bar graphs showing the normalised densitometry values of TRPA1 (n = 
2) and PLCγ1 (n = 1) in four conditions against the wild type C58. Densitometry 
values were initially normalised against C58 (loading control). Error bars in c 
represent the standard error of the mean (n = 2). GST = Glutathione S-transferase.  
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3.2.4. Endogenous FGFR2-TRPA1 complex formation in HCC-515 LUAD cells 
Hitherto, I have established that FGFR2 and TRPA1 can interact when 
overexpressed. However, in order for this interaction to play a physiological role, it 
is crucial to show that the interaction of endogenous FGFR2 and TRPA1 proteins 
occurs in a physiologically relevant system like cancer cells. The FGFR2 role in 
Lung Adenocarcinoma progression through protein-protein interactions has already 
been described before (Timsah et al., 2015) and thus, LUAD cell lines were 
selected as a tool to assess the interaction in cancer.   
Firstly, the protein expression pattern of FGFR2 and TRPA1 in human LUAD 
tissues was determined by immunohistochemistry, performed by Michael Shires 
(St. James’s Hospital, Leeds). A commercially available tissue microarray (TMA, 
Pantomics, Richmond, USA) with 102 normal and LUAD tissue sections was 
utilised and stained with anti-FGFR2 and anti-TRPA1 antibodies. The expression 
levels were semi-quantified by a specialised pathologist, Mihai Gagea (MD 
Anderson, USA), using a scoring system from zero 0 to 3+ (arbitrary units), with 0 
representing absence of protein expression and 3+ representing maximum protein 
expression. As shown in Figure 3.14, both FGFR2 and TRPA1 are overexpressed 
in LUAD compared to the healthy tissue, with approximately 70% of all LUAD 
tissues being scored as 3+ for both proteins.  
Next, the protein levels of FGFR2 and TRPA1 were studied by western blot in two 
human LUAD cell lines (HCC-44 and HCC-515) and one normal lung fibroblast cell 
line (CCL-204). HCC-515 cells express both proteins of interest (Figure 3.15, lane 
3) and therefore, it was chosen for further interaction experiments. HCC-44 cells 
express only FGFR2 (Figure 3.15, lane 2) and CCL-204 normal lung fibroblasts 
express neither FGFR2 or TRPA1 (Figure 3.15, lane 1). Protein expression was 
also verified by immunofluorescence (Figure 3.16) to ensure PLA experiments 
could be performed.  
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Figure 3. 14: Protein expression of FGFR2 and TRPA1 in human healthy and 
LUAD tissue microarray analysed by Immunohistochemistry.  Hematoxylene 
and Eosin (H&E) staining on normal and LUAD tissue (left panels). Representative 
images of IHC staining with anti-FGFR2 and anti-TRPA1 antibodies show increased 
protein expression in LUAD tissues for both proteins.  (scale bar=10µm). Protein 
levels are shown as brown staining. Yellow boxes show details on different cell 
types: red arrows indicate neoplastic cells which are strongly positive for both 
proteins, green arrows indicate infiltrated inflammatory cells which are also positive 
for both proteins and the black arrow indicates the supporting stroma that is 
negative for both proteins. The bar graph illustrates the semi-quantified results of 
IHC. Around 70% of LUAD tissues express high levels of FGFR2 and TRPA1 as 
scored by a specialised pathologist, Mihai Gagea (MD Adnerson Cancer Centre, 
Houston, USA). IHC was performed by Michael Shires (St. James’s Univeristy 
Hospital, Leeds, UK). Figure taken from our publication (Berrout et al., 2017). 
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Figure 3. 15: Protein expression levels of TRPA1 and FGFR2 in normal and 
LUAD cell lines. Western blot analysis of the endogenous expression of FGFR2 
(Santa Cruz) and TRPA1 (Millipore) in normal CCL-204 and LUAD HCC-515 and 
HCC-44 cells. Band density was quantified by ImageJ and the values were 
normalised against β-actin (loading control). Representative western blot is showing 
(n=3).  
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Figure 3. 16:  Immunofluorescence staining for FGFR2 and TRPA1 in HCC-515 
cells. Specific antibodies for each protein were used in independent staining 
experiments. Alexa_Fluor555-conjugated secondary antibodies were used to 
visualise the staining. Primary antibodies were excluded from the negative controls. 
Anti-TRPA1 from Protein Tech, anti-FGFR2 from Santa Cruz.   
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The presence of FGFR2 and TRPA1 proteins on the plasma membrane of HCC-
515 cells was verified by cellular fractionation. Both FGFR2 and TRPA1 were 
detected in the membrane fraction (Figure 3.17a). The FGFR2–TRPA1 interaction 
was confirmed in HCC-515 cells by Co-IP experiments in which FGFR2, protein 
“bait”, successfully pulled down TRPA1 (protein “prey”) (Figure 3.17b, lane 2).  
PLA experiments in HCC-515 cells further supported complex formation. In these 
experiments, FGFR2 was knocked down with siRNA and the efficiency of knock 
down was verified by western blot at 35% (Figure 3.18b). PLA levels of FGFR2 
knock-down cells was significantly lower compared to scrambled siRNA / control 
cells (p-value = 0.000001) suggesting that endogenous FGFR2 and TRPA1 
proteins are in close proximity in HCC-515 cells and could be physically associated 
(Figure 3.18c). Due to the lack of time, this PLA experiment was only performed 
once. 
To further investigate the activity of TRPA1 in the LUAD cell lines used in this 
chapter, calcium imaging experiments were performed using AITC as a TRPA1 
agonist. As shown in Figure 3.19a, b and c, HCC-515 cells had a borderline 
response to AITC while HCC-44 cells had a much higher response. When HCC-44 
cells were pre-treated with HC-030031, a specific TRPA1 inhibitor, there was a 
nearly 7-fold reduction in the calcium response indicating the signal detected in 
these cells was specific to TRPA1 (Figure 3.19d and e).  
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Figure 3. 17: Co-IP experiment suggesting FGFR2 and TRPA1 complex 
formation in HCC-515 cells. a) Western blot analysis of the FGFR2 (Protein Tech) 
and TRPA1 (Protein Tech) protein levels in a membrane fraction and total cell 
lysate. Proteins of interest are present in the membrane fraction, as expected. JNK 
and β-actin were used as a control for the cytosolic fraction. b) co-IP experiment to 
determine complex formation between FGFR2 and TRPA1 in HCC-515 cells. An 
anti-FGFR2 (Santa Cruz) antibody was used to precipitate FGFR2 and the 
presence of TRPA1 (Protein Tech) was detected by western blot. Total cell lysate 
was loaded on the left as a verification of correct band sizing. TRPA1 band in the 
cell lysate was visible only in higher exposure times that overexposed/saturated the 
band in the IP lane.  (SC = Santa Cruz) 
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Figure 3. 18: PLA experiment on scrambled and FGFR2 siRNA-tranfected 
HCC-515 cells. a) Representative PLA images in scrambled and siRNA HCC-515 
cells. b) Western blot verifying the efficiency of FGFR2 knock-down in HCC-515 
cells used for PLA experiments. Protein levels were quantified by densitometry on 
Image J. β-actin was used as a loading control.  siRNA#2 decreased FGFR2 
protein levels by 35%. UT = un-transfected. c) Bar graph illustrating the PLA puncta 
per cell in scrambled (SCR) and FGFR2 knock down cells. Error bars = S.E.M. SCR 
n = 12 cells, siRNA n = 10 cells. N = 1. Significant differences are shown as *** (p-
value ≤ 0.001 with unpaired students t-test). 
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Figure 3. 19: Calcium imaging experiments on LUAD cell lines. a) and b) 
Normalised to baseline average calcium response after a 5-minute AITC perfusion 
shown as a ratio of Fura-2 fluorescence intensity at 340/380 nm. Error bars = S.E.M 
(n = 4). (Absolute baseline fluorescence ratio: HCC-44 = 709 ± 50.6, HCC-515 = 
699.6 ± 7). c) Quantification of maximum calcium response from a and b. HCC-44 
cells had a significantly higher response (p ≤ 0.05 by Student’s T-test) compared to 
HCC-515 cells. Error bars = S.E.M. d) Normalised average calcium response after 
a 5-minute HC030031 followed by an AITC + HC030031 perfusion shown as a ratio 
of Fura-2 fluorescence intensity at 340/380 nm. Error bars = S.E.M (n = 3). e) Bar 
graph representing the calcium response of HCC-44 cells after AITC perfusion in 
the absence and presence of HC030031. Calcium response is calculated as the 
difference between the maximum F340/F380 within the 5 minutes of AITC perfusion 
and the F340/F380 prior to perfusion initiation (baseline). Error bars = S.E.M and p 
= 0.0119 (*) by student’s t-test, n = 3. 
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3.2.5. FGFR2-TRPA1 complex characterisation by Expansion Microscopy 
(ExM) 
To further characterise the FGFR2-TRPA1 interaction in the nanometre scale, 
Expansion Microscopy (ExM) was performed on HEK-293T cells that were 
transfected with FGFR2 and TRPA1 constructs. ExM allows for super-resolution 
image acquisition and therefore, detailed analysis of molecules of interest.  Firstly, 
FGFR2-FLAG + tGFP-TRPA1-expressing cells underwent a 4-times and a 10-times 
expansion (Figure 3.20). The expansion factor was calculated by manual 
measurement of the gel size right before image acquisition (final size divided by 
initial size). For the 4x expansion, the expansion factor was exactly 4, while for the 
10x expansion, the expansion factor was calculated to be approximatelly 8.5. 
Considering the maximal Airyscan lateral resolution is 140 nm (480 nm laser), a 4x 
and an 8.5x expanded sample will give a theoretical resolution of 35 nm and 16.4 
nm, respectively which enables the visualisation of individual protein complexes 
(Fouquet et al., 2015, Sheard et al., 2019, Truckenbrodt et al., 2018). Figure 3.20 
illustrates the increase in the resolution as the expansion factor increases from 1x 
to 10x. It looks like both FGFR2 and TRPA1 are located in membrane structures 
such as the plasma membrane and the Endoplasmic Reticulum however, this is not 
certain since no membrane markers were used in this experiment.  
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Figure 3. 20: Improvement in optical resolution as obtained by increasing the 
expansion factor. a) Regular Airyscan confocal image (estimated resolution 140 
nm) b) ExM 4x (estimated resolution 35 nm), c) ExM 10x (estimated resolution 16.5 
nm). All scale bars indicate 5 μm.   
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Next, images of 4x expanded cells were obtained from two different focal planes 
and analysed for FGFR2 and TRPA1 co-localisation by ImageJ. Since the area of 
interest for the FGFR2 and TRPA1 interaction is the plasma membrane, the two 
focal planes were focused on membrane areas. Focal level 1 includes images of a 
flat membrane surface and away from the nucleus (edge of the cell) and focal level 
2 includes images above the membrane surface (cell interior) (Figure 3.21). Due to 
lack of membrane markers, the bottom membrane surface was considered to be 
the first plane in which signal was detected. Co-localisation was quantified by 
performing a Mander’s co-localisation analysis which calculates the Mander’s 
values M1 and M2 that represent the percentage of co-localisation for each protein 
(Zinchuk et al., 2007). Analysis of images similar to these shown Figure 3.20 
revealed that, 31.2% ± 5.7% of FGFR2 molecules co-localise with TRPA1 and 
49.3% ± 3.1% of TRPA1 co-localise with FGFR2 on a vertical membrane area – cell 
periphery (above bottom surface – Figure 3.22a). On the other hand, FGFR2 M1 
equals 18.8% ± 3.9% and TRPA1 M2 equals 33.1% ± 6.5% on a flat membrane 
surface (Figure 3.22b). The percentages of co-localisation do not significantly differ 
between the two focal planes, suggesting consistency in data acquisition. However, 
the focal plane 1 was chosen as a more suitable way of analysing co-localisation 
due to the higher amount of molecules that can be detected in one surface area. 
Moreover, the theoretical resolution in this 4x ExM experiment is around 35nm, 
meaning that objects located in a shorter distance could not be separated. The fact 
that FGFR2 co-localises with TRPA1 indicates that they are in close proximity (less 
than 35 nm apart).  
Next, a 10x ExM images were analysed. The 10x Mander’s co-localisation values 
were compared to the 4x ones. In 10x, FGFR2 M1 was reduced to 11.2% ± 1.1% 
(~60% reduction) and TRPA1 M2 was reduced to 23.7% ± 3.6% (~30% reduction) 
(Figure 3.23). When imaging close to single molecule level, Pauli’s exclusion law, 
stating that two molecules cannot be at the same spot at the same time, should be 
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taken into consideration (Aaron et al., 2018).  Therefore, this result would be 
expected as the resolution has been increased to 16.4 nm, visibly separating all 
molecules further (even those that interact), resulting in lower co-localisation signal.  
 
 
Figure 3. 21: Schematic illustrating the two membrane focal planes analysed 
in ExM 4x. Focal level 1 is located right at the bottom cell surface that is attached 
to the coverslip creating a relatively flat membrane. Focal level 2 is located above 
the bottom membrane surface and includes cellular compartments such as ER, 
organelles and nucleus. In this plane, the plasma membrane signals originate form 
a line of membrane that surrounds the cell.  
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Figure 3. 22: Mander’s values from FGFR2 and TRPA1 co-localisation 
analysis do not differ in two different focal planes. Representative image of a 
4x expanded cell in focal plane 2 (a) and focal plane 1 (b) (left). White boxes 
indicate representative analysed areas. Zoomed in area that was used in the 
analysis (right top) and image after threshold (right bottom). FGFR2 = red, TRPA1 = 
green. c) Quantification of Mander’s M1 and M2. No significant difference was 
observed between the groups (p-value = 0.242 and 0.597 for FGFR2 and TRPA1, 
respectively).  
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Figure 3. 23: Reduced Mander’s co-localisation values in 10x compared to 4x 
ExM. Representative image of a (a) 10x ExM and (b) 4x ExM for FGFR2 (red) and 
TRPA1 (green) at 16.4nm and 35nm resolution, respectively (left). Same image 
following threshold implementation (right). White circles indicate co-localisation 
events at 10x. White box indicates enlargement of one co-localisation event.  
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Detailed observation of complexes detected in 10x ExM would be beneficial to 
understand the complex formation between FGFR2 and TRPA1 as well as for 
future attempts to determine the stoichiometry of the complex. For this reason, it 
was crucial to set some nanoscale measurements and determine protein and 
theoretical complex sizes.  
The TRPA1 channel (4 subunits) is 10.4 nm wide (parallel to membrane) and 12.3 
nm long (vertical size) as revealed by the cryo-EM structure (Paulsen et al., 2015). 
The orientation of the ARD remains unresolved yet, the estimated size (AR1-11) is 
around 10nm each, increasing the radius of TRPA1 at 10 nm. Thus, the total 
TRPA1 channel diameter could be estimated at 20 nm minimum (Figure 3.24a) 
which is higher than the estimated resolution of 16.4 nm indicating that individual 
TRPA1 channels can be resolved. Moreover, a monoclonal antibody recognising 
the C-terminal region of TRPA1 was used in this experiment. Based on the location 
of the C-terminal domains, it could be speculated that only one antibody would have 
access to this area due to limited space.  
The size of the FGFR2 dimer in complex with FGF9 ligand is around 5nm meaning 
that a single FGFR2 molecule has a width of 2.5 nm (Goetz and Mohammadi, 
2013). These measurements represent the width of the complex in the extracellular 
space however, it would be expected that the FGFR2 dimer would have a similar 
size in the intracellular C-terminal region (Figure 3.24b and c). A polyclonal 
antibody against the C-terminal region of FGFR2 was used in this experiment, 
which, in combination with the secondary antibody, adds 20-30 nm to the size of the 
receptor complex visualised via the immunofluorescence 
Furthermore, the error generated by the detection method, i.e. primary and 
secondary antibodies, should also be calculated and taken into consideration. An 
antibody average size is between 10-15 nm, which sets the error to 20-30 nm for 
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primary and secondary antibody combined (Figure 3.24) (Sheard et al., 2019).  In 
other words, the spot at which a fluorescent signal is detected, does not represent 
the actual location of the molecule, which, in reality, can be located anywhere 
around a 30 nm radius.  
Taken together, by summing up the error generated by the detection of both 
FGFR2 and TRPA1, the estimated maximum size of a complex would be in the 
range of 50-70 nm. This is because the interaction occurs through the ARD of 
TRPA1 which is 10 nm long, plus 2-times the antibody error (Figure 3.24d). 
Representative images of FGFR2-TRPA1 “complexes” within 70 nm are shown in 
Figure 3.25 and Appendix.  
Based on observations on the “complexes”, it appears that TRPA1 exists in 
complex with one or two FGFR2 molecules at a time (Figure 3.25a and b, 
Appendix). However, it is not possible to determine whether both FGFR2 molecules 
are in direct contact with the channel or whether they form a dimer that interacts 
with TRPA1 through one of them. The resolution of two FGFR2 molecules within a 
dimer is possible by 10x ExM because the secondary antibodies labelling each 
molecule would be at least 20 nm apart. This means that each red signal 
represents one FGFR2 molecule, in theory. However, placing two FGFR2 
molecules close together could initiate their dimerization anyway, assuming that 
interactions through the ARD are flexible enough to allow these movements. 
The interaction of TRPA1 with 3, 4 or more FGFR2 molecules has not been clearly 
observed, suggesting that it probably creates complexes in 1:1 or 1:2 (single or 
dimers) stoichiometry. However, the possibility of TRPA1 to form higher order 
complexes by interactions with multiple FGFR2 molecules cannot be completely 
excluded at present. There have been locations with higher density of molecules 
that cannot be fully interpreted (Figure 3.25c). An additional point to consider is the 
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fact that these are 2D images thus, molecules from different planes that are 
projected into the 2D image result in artefacts. 
 
 
 
 
Figure 3. 24: Schematic representation of estimated distances in FGFR2 and 
TRPA1 complex. a) TRPA1 tetrameric channel dimensions with antibody error. 
ARD = Ankyrin Repeat Domain. b) monomeric FGFR2 dimensions with antibody 
error. c) dimeric FGFR2 with antibody error. d) Maximum distance between green 
(TRPA1) and red (FGFR2) signal in which an interaction can theoretically occur 
including antibody error.  
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Figure 3. 25: Representative images of FGFR2 and TRPA1 complexes as 
obtained by ExM 10x in transfected HEK-293T cells. a) FGFR2-TRPA1 complex 
in 1:1 stoichiometry. Signals partially overlap. b) FGFR2-TRPA1 complex in 1:1 or 
possibly 2:1 stoichiometry. Signals do not overlap but are located within maximum 
complex distance of 50-70 nm. c) Higher density of FGFR2 and TRPA1 signals in a 
localised area. Chance of higher order complexes. Representative images are 
shown.  
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3.3. Discussion 
3.3.1. Complex formation between FGFR2 and TRPA1 
3.3.1.1. Co-Immunoprecipitation (Co-IP) controls 
Co-IP results in this chapter suggest for the first time that TRPA1 is a novel 
interaction partner for FGFR2. Since the proteins of interest were tagged and 
overexpressed in HEK-293T cells, the use of appropriate controls was attempted to 
discard the possibility of interaction through the tags (Figure 3.2 and 3.3).  
First, an empty FLAG tag (negative control) was not able to pull down TRPA1 
eliminating the possibility of interaction of the FLAG tag with TRPA1 or the 
TurboGFP tag of TRPA1 (Figure 3.3a, lane 2). However, due to the small size of 
the FLAG tag (8 amino acids = 1kDa estimated), no band was visible in the western 
blot (lane 5) and thus, the efficiency of transfection for the negative vector was not 
verified.  
On the other hand, the appropriate TurboGFP negative control vector was not 
available at the time and therefore, an empty eGFP vector was used instead as an 
alternative option to eliminate the possibility of interaction occurring through the 
TurboGFP tag of TRPA1 and indeed, eGFP did not precipitate FGFR2. TurboGFP 
is an optimised variant of ppluGFP (from Pontellina Plumata) that is brighter and 
has faster maturation kinetics compared to eGFP and therefore, it is highly 
applicable in gene expression analysis (Evdokimov et al., 2006).  
TurboGFP-tagged proteins have been used in Co-IP experiments in the past that 
showed no interaction through the tag, indicating that TurboGFP tags are suitable 
for protein interaction experiments (Lu et al., 2014, Penicud and Behrens, 2014). 
Additionally, FLAG tag proteins have repeatedly been used in interaction 
experiments and have been shown to be suitable for Co-IP (Hu et al., 2018, Sun et 
al., 2011). All this evidence suggests that the observed TRPA1-FGFR2 interaction 
is highly unlikely occurred through the epitope tags. This conclusion is additionally 
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supported by the pull-down assays and biophysical methods (MST) utilising purified 
proteins (Figures 3.7 and 11).  
3.3.1.2. Proximity Ligation Assay (PLA) limitations 
PLA experiments were utilised as an additional method to investigate FGFR2 and 
TRPA1 complex formation. PLA was introduced as a simple and easy modification 
of a conventional immunofluorescence method to assess protein 
proximity/interaction for any pairs of antigens for which specific antibodies can be 
produced (Soderberg et al., 2006). This flexibility allows the investigation of not only 
protein complexes but also receptor dimerization and post-transcriptional protein 
modifications like phosphorylation (Chen et al., 2013, Elfineh et al., 2014, Gajadhar 
and Guha, 2010, Gomes et al., 2016, Iwabuchi et al., 2017). By principle, PLA 
signal is generated only when the PLA probes are located within maximum of 40nm 
(suggesting close proximity and possible interaction) which is lower than the optical 
resolution limit allowing for localisation analysis in the nanometre scale. As shown 
in Figure 3.4 and 3.5, significantly higher PLA signal was observed in the presence 
of both proteins of interest compared to negative controls (omission of primary 
antibodies and overexpression of only one of the proteins). However, these data 
should be interpreted with caution because PLA can produce “false positive” signal 
(Alsemarz et al., 2018), ( see below).  
One of the most significant limitations of PLA is the use of appropriate controls that 
not only reference for antibody specificity but also for proximity specificity. Regular 
negative controls such as omission of primary antibodies or absence of one of the 
epitopes (e.g. si-RNA knock down) correct only for the non-specific binding of the 
secondary antibodies, which is generally low, and therefore controls like that always 
produce negligible amounts of signal (as seen in Figure 3.4 and 3.5). Last year, 
Alsemarz, A., et al., proposed that PLA is prone to false positive signal that is 
roughly proportionate to the antibody density/abundance of antigens by comparing 
signals from antigens that are known to be interacting as well as non-interacting 
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proteins. At high protein abundance, the PLA signal was not significantly different in 
cases of non-interacting proteins (e.g. E-cadherin/membranous-GFP, E-
cadherin/soluble-GFP, β-tubulin/soluble GFP) compared to known interacting 
proteins (e.g. E-cadherin/β-catenin). These data suggest that significant PLA signal 
can be detected provided that the primary antibodies have bound close enough, in 
other words, high abundance of the two antigens in a localised area (e.g. 
membrane or microtubules) which generates the “specificity” artefact (Alsemarz et 
al., 2018).  
As an attempt to correct for any exaggerated signal due to the overexpression of 
the proteins in HEK-293T cells, FGFR2-FLAG + eGFP expressing cells were 
utilised as a negative overexpression control. Considering that a different pair of 
antibodies was used in this negative control (anti-GFP and anti-FLAG), a 
comparison with PLA signal generated by the anti-TRPA1 and anti-FGFR2 pair 
would not be fair. Therefore, even though FGFR2-FLAG+eGFP cells had higher 
PLA signal compared to FGFR2-FLAG+TRPA1-tGFP (Figure 3.6), it does not 
indicate that PLA generated by FGFR2 and TRPA1 antibodies is an artefact. In 
order to compare between PLA results, the same set of primary and secondary 
antibodies should be utilised.  
Nevertheless, PLA can be an informative tool, given the proper experimental design 
and uses of appropriate controls. Gajadhar, A., et al., for instance, studied the 
ligand-induced EGFR dimerization in cells overexpressing two different epitope-
tagged EGFRs. In this example, both antibody specificity (primary antibody 
omission or lack of one of the antigens) and proximity specificity controls 
(dimerization mutant) were implemented. The dimerization mutant showed similar 
localisation and expression levels compared to the wild type version and therefore, 
would be an appropriate negative control for this PLA experiment (Gajadhar and 
Guha, 2010).  
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In the present study, a mutated variant of TRPA1 or FGFR2 that impairs the 
interaction would be an acceptable negative control. However, as mentioned in the 
results section, TRPA1-Δ10 and full length TRPA1 were not expressed in similar 
levels especially when co-expressed with FGFR2 and therefore, PLA experiments 
would still remain inconclusive (Figure 3.9a).  
In conclusion, PLA results in Figures 3.4,5 and 6 are not a conclusive evidence of 
an interaction but rather an indication of close proximity between FGFR2 and 
TRPA1.  
 
3.3.2. The C-terminal region of FGFR2 directly interacts with the Ankyrin 
Repeats 6-10 of TRPA1 
 
3.3.2.1. Direct interaction between FGFR2 and TRPA1 ARD as shown 
by MST 
Co-IP and PLA experiments suggest a protein interaction between FGFR2 and 
TRPA1; however, this approach could not verify the direct binding of the two 
proteins. To investigate whether FGFR2 and TRPA1 interact directly and to further 
characterise the binding affinity and identify the TRPA1-binding site, a biophysical 
method, Microscale Thermophoresis (MST), was performed. The output from the 
MST assays is a binding curve. The dissociation constant is defined as the 
concentration in which the first protein occupies half of the sites on the second 
protein in equilibrium. Subsequently, the lower the dissociation constant (Kd), the 
higher the binding affinity is (Kastritis and Bonvin, 2013). For instance, the 
dissociation constant of monoclonal antibodies, that are very specific and show high 
affinity for their target antigens, has been measured to be in the range of 20 to 200 
pM which is very strong (Landry et al., 2015).   
Indeed, MST revealed that FGFR2 and TRPA1 interact directly with a dissociation 
constant (Kd) of 122.8 ± 23 nM. It also revealed that the interaction is mediated 
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through the ankyrin repeat domain of TRPA1 since no binding curve was acquired 
with the TRPA1-Δ16 truncation.  
It could be agreed that a Kd of 122 nM is a relatively strong interaction and is in the 
range observed for other FGFR2 interactions. The cSH2 domain of PLCγ1, for 
example, interacts with the pY769 of FGFR2 with a dissociation constant of 100nM, 
as measured by Surface Plasmon Resonance (SPR) (Huang et al., 2016). The SH3 
domain of PLCγ1 binds to the C-terminal 23 amino acid fragment of FGFR2 with a 
dissociation constant of 40 µM and the SH3 domain of GRB2 binds to the same site 
with a dissociation constant of 100 nM for a 2:1 complex and 25 µM for a 2:2 
complex (by ITC) (Timsah et al., 2014, Lin et al., 2012). Notably, differences up to 
4-fold are expected when comparing dissociation constants as measured by 
different methods (Landry et al., 2015). In general, interactions studied with full 
length proteins (like here) are more accurate, as fragments do not represent the 
original folding in synergy with the rest of the protein.   
This MST experiment shows for the first time the involvement of the TRPA1 ARD in 
the interaction with FGFR2. The Kd of this interaction (122 nM) also lies between 
the range of previously reported interactions mediated by ARDs. For example, the 
ankyrin repeat domain of the oncoprotein gankyrin binds to the C-terminal portion of 
the S6 ATPase from the 26S proteasome with a dissociation constant of 67 nM, the 
first two repeats of the ARD of Iκ-Bα interacts with the N-terminal domain of NF-κB 
with a Kd of 40 pM and the p53-BP2 ARD binds to the L2 loop of p53 with a Kd of 
0.5-5 µM (Chapman et al., 2014, Patel et al., 2008, Bergqvist et al., 2009).  
Further studies to identify the binding site contained in the TRPA1 ARD by Co-IP 
were not accomplished in this study because, upon co-expression, the protein 
levels of TRPA1-Δ10 and FGFR2 were very low (Figure 3.10). The decrease in 
protein levels could be explained as possible competition for the transcriptional 
machinery since both genes are under the control of pCMV promoters. The TRPA1-
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Δ10 efficiency of transfection is much lower than the full length TRPA1 and this 
could have magnified the effect of this competition. Due to protein expression level 
problems, the Co-IP between full length and truncated TRPA1 would not be a fair 
comparison.  To overcome this issue, GST-pull down assays were performed as 
discussed below.  
3.3.2.2. FGFR2 and TRPA1 interaction is mediated through the C-
terminal domain of FGFR2 
Firstly, the evidence that the C-terminal Proline-rich fragment of FGFR2 is involved 
in the interaction with the ARD binding site of TRPA1 came from additional GST-
pull down assays (Figure 3.11b). The bacterial expression system for FGFR2-C58 
was chosen due to higher protein yield compared to mammalian systems. 
Moreover, the absence of post-transcriptional modifications on the fragment allows 
for use of bacterial expression systems. Appropriate negative controls, including 
empty beads or use of wild type cell lysate, failed to pull down TRPA1 which verifies 
the specificity of the signal. However, these controls do not test for the possibility of 
interaction through the GST tag and therefore, an additional control with GST-
conjugated beads would be more suitable to eliminate this likelihood.  
GST-pull down assays with amino acid substitution mutations from Proline to 
Alanine located in the C-terminal region of FGFR2 did not show any reduced 
binding between C58 and TRPA1 (Figure 3.13). That was an attempt to map the 
specific residues involved in the interaction with the TRPA1 ARD. The reason 
behind mutating these particular residues comes from previous studies on FGFR2 
C-terminal interactions with SH3-contaning proteins which reveal Proline 810 and 
813 as a Proline-rich binding site (Ahmed et al., 2010, Lin et al., 2012, Timsah et 
al., 2014). The data presented here (Figure 3.13) could suggest that P810 and 
P813 are not involved in the interaction with TRPA1 however, additional repeats are 
needed to achieve certainty in regards to the involvement of the prolines in 
question. The PLCγ1 positive control was performed in one replicate and showed 
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reduction of PLCγ1 binding to P810 and P813, as shown in the literature, however, 
this control should be implemented in all GST pull down experiments involving 
proline mutations to ensure the validity of the experiment.  
Based on the published study from our lab, Proline 810 and 813 are involved in the 
interaction with the ARD. Notably, these substitutions did not entirely abolish the 
binding; some TRPA1 binding was still detectable, suggesting that Proline 810 and 
813 are not the only residues comprising the FGFR2 binding site. In fact, ARDs 
differ from other common motifs like SH2 or SH3, which bind to a well determined 
sequence, because they can recognise a wide variety of sequences. ARD-mediated 
interactions involve diverse targets in which discontinuous areas of residues along 
the interaction interface are recognised. A number of factors regulate the specificity 
of ARDs. Even though ankyrin repeats are highly conserved (e.g. TPLH 
tetrapeptide in the first helix), several amino acid substitutions confer target 
specificity. The number of repeats can also affect the recognition since the higher 
the number of repeats the more concave and compact the interaction surface 
becomes. The specificity can also be influenced by the presence of additional 
domains in the protein (Li et al., 2006, Islam et al., 2018). Therefore, the possibility 
of a more extended binding site on the FGFR2 C-terminal region cannot be 
excluded.  
3.3.2.3. AR 6-10 mediate the interaction between TRPA1 and C-terminal 
domain of FGFR2 
Using FGFR2-C58 conjugated GST beads determined that the FGFR2-binding site 
of TRPA1 is located within the first ten ankyrin repeats, since TRPA1-Δ10 showed 
an approximately 80% reduction in interacting with FGFR2-C58 (Figure 3.12). 
Based on the cryo-EM structure of TRPA1, the last five ankyrin repeats (12-16) are 
fully resolved and incorporated into the “stem” of the channel together with the C-
terminal Coiled-coil domains. The remaining 11 ankyrin repeats (1-11), that form a 
crescent-shaped density around the “stem” of the channel, are not fully resolved 
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because their positions are more flexible.  However, a “propeller” orientation is 
more favourable. This structural conformation and flexibility would make the first 
eleven ankyrin repeats more accessible and facilitate protein interactions (Paulsen 
et al., 2015).  
Serial ankyrin repeat truncations and subsequent amino acid substitutions are 
needed to completely map the exact binding site within the first ten ankyrin repeats 
of TRPA1.  
At this point it is crucial to ensure that the truncated TRPA1 is still a functional 
membrane channel and that the decrease in the interaction with FGFR2 C-terminal 
domain is not due to membrane traffic failure. Therefore, calcium imaging 
experiments to assess the activity of the transfected full length TRPA1 as well as 
Δ10 would be ideal to ensure proper membrane localisation and function of the 
channels. Notably, TRPA1 has been found to be fully functional and respond to cold 
temperatures as well as electrophilic compounds even in the absence of the N-
terminal ARD (Moparthi et al., 2014) suggesting that Δ10 is more likely to also be 
functional in the present study. 
3.3.2.4. Interplay between TRP channels and RTKs 
This study is the first to document a direct interaction between FGFR2 and TRPA1. 
In general, crosstalk between TRP channels and RTKs has been investigated 
before yet, the exact mechanisms remain elusive. Those mechanisms usually 
involve PLC proteins or additional mediators like calcium (Tajeddine and Gailly, 
2012, Veldhuis et al., 2015).  
In 2016, the role of TRPC3 in indirect EGFR activation (transactivation) was 
described and implicated in hypertension-induced vascular smooth muscle cell 
(VSMC) growth and the subsequent possibility of stroke. Angiotensin II, a 
vasoconstrictor and VSMC growth activator, transactivates EGFR through 
activating ADAM17, a metalloproteinase involved in ectodomain shedding of pro-
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HB-EGF (pro-heparin-binding epidermal growth factor). ADAM17 activity is calcium-
dependent and complex formation between ADAM17 and TRPC3 results in its 
activation due to localised calcium influx indicating the role of TRPC3 in EGFR 
transactivation and cerebrovascular remodelling (Wang et al., 2016). 
Notably, there is evidence of complex formation between TRP channels and RTKs 
however, detailed follow-up studies have not been performed. Firstly, in 1999, 
Wang and colleagues showed that TRPC3 and the neurotrophic receptor TrkB (an 
RTK) share common spatial and temporal expression in the central nervous system 
of foetal and neonatal rats and that TRPC3 was co-immunoprecipitated with Trk 
receptors, possibly forming a complex that explains the Calcium-dependent current 
after BDNF treatment (Li et al., 1999).  
Another example is the functional interaction between TRPV3 and EGFR in 
keratinocyte differentiation and hair formation (Cheng et al., 2010). In this study, 
TRPV3 and EGFR co-immunoprecipitated. Interestingly, TRPV3 was not 
immunoprecipitated with either FGFR2 or ADAM17, a known metalloprotease 
responsible for TNF-α shedding (EGFR ligand). EGFR is involved in epidermis 
renewal by controlling keratinocyte proliferation and terminal differentiation thus, 
EGFR deficiency is coupled with the wavy hair phenotype and skin problems. 
Similarly, TRPV3 knock-out mice demonstrated the same phenotypes. Cheng and 
colleagues (Cheng et al., 2010) suggested a model, whereby unknown signals 
(most likely 32oC on skin surface) activate TRPV3 in basal levels that cause 
calcium influx and activation of metalloproteinases and glutaminases (ADAM17 and 
TGase1, 2) that increase TNF-α/EGFR activation and downstream signalling 
pathways including PLCγ, MAPK and PI3K. Activation of EGFR potentiates TRPV3 
either by the direct interaction (TRPV3 phosphorylation) or through PLCγ and ERK, 
creating a positive feedback loop that enhances EGFR signalling even more. 
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These examples use co-immunoprecipitation experiments to suggest complex 
formation, yet direct interactions between the components have not been 
investigated in these studies. Nevertheless, they implicate TRP and RTK interplay 
in physiological processes.  So far, TRP/RTK complex formation has not been 
described in the context of cancer. The present study investigates the direct 
interaction between FGFR2 and TRPA1 and their implications in cancer signaling. 
Taken together, the fact that TRPA1 interacts with the C-terminal domain of FGFR2 
and more likely masks specific key residues for signalling raises questions such as 
possible competition with PLCγ1 and GRB2 which share the same Proline-rich 
binding site and subsequent effects on general FGFR2 signalling. This 
automatically highlights the role of TRPA1 in FGFR2-related skeletal diseases and 
cancer (Ornitz and Marie, 2015). The effect of this interaction on FGFR2 signalling 
is investigated in Chapter 4. 
3.3.3. FGFR2 and TRPA1 complex formation in LUAD 
 
3.3.3.1. Overexpression of FGFR2 and TRPA1 in human LUAD tissues 
Apart from the over-expression system, the FGFR2-TRPA1 interaction was also 
studied in a physiologically relevant system to confirm that the interaction occurs in 
native conditions such as within cancer cells. Dysregulated FGFR2 signalling has 
been implicated in malignancies and therefore, cancer cells would be a suitable 
system to confirm TRPA1 interactions that could affect FGFR2 signalling (Sme 
Theelen et al., 2016, Timsah et al., 2015). Firstly, IHC staining confirmed that 
TRPA1, as well as FGFR2, are overexpressed in human LUAD compared to 
healthy tissues which is consistent with previous studies. For instance, Takahashi, 
et al, in 2018, investigated the protein expression of TRPA1 in a series of cancer 
types and revealed that TRPA1 levels were significantly elevated in a panel of 
Breast and Lung cancer (LUSC and LUAD) tissues by IHC as well as in selected 
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cell lines by western blot (Takahashi et al., 2018). Moreover, high levels of FGFR2 
have also been detected in lung malignancies including squamous cell carcinoma 
and adenocarcinoma and have been associated with overall survival and 
recurrence-free survival (Chang et al., 2014, Behrens et al., 2008, Timsah et al., 
2015). Therefore, LUAD cell lines were utilised to investigate the interaction in a 
native system. 
3.3.32. FGFR2-TRPA1 complex formation in HCC-515 cells 
Western blot analysis and immunofluorescence experiments have verified the 
expression of both proteins in the HCC-515 human LUAD cell line (Figure 3.15 and 
16). In particular, immunofluorescence images show a dense nuclear localisation of 
FGFR2, a phenomenon that has been described in the past for FGFR1,2 and 3 yet, 
little is known about their actual mechanism of action in the nucleus (Salva et al., 
2019, Zhou et al., 2015). Studies seem to converge on the transcriptional role of 
FGFRs which, in turn, have an effect on cancer cell phenotype. For instance, the 
intracellular domain of FGFR1 is cleaved following FGF10 stimulation in breast 
cancer cells and translocates to the nucleus where it orchestrates an invasive gene 
expression signature (Chioni and Grose, 2012). On the other hand, FGFR2 has 
been found to translocate to the nucleus and physically interact with and negatively 
regulate HIF-1 and HIF-2 inhibiting hypoxia-induced cell invasion in pancreatic 
cancer cells (Lee et al., 2019). The presence of FGFR2 in the nucleus of HCC-515 
cells has been acknowledged but not investigated further as it exceeds the 
objectives of this study. However, isolation of membrane proteins and analysis by 
western blot confirmed the localisation of both FGFR2 and TRPA1 at the cellular 
plasma membrane of HCC-515 cells and therefore, FGFR2-TRPA1 membrane 
complex formation could be studied (Figure 3.17a).   
Co-IP experiments with an anti-FGFR2 antibody confirmed that endogenous 
FGFR2 can pull down endogenous TRPA1 and that this interaction can occur 
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naturally in cells (Figure 3.17b). An additional sample utilising a cell line that 
expresses only one of the proteins such as the HCC-44 cells would be an ideal 
negative control in this situation. PLA experiments were also performed as 
supporting evidence in which PLA signal from wild type and FGFR2-siRNA knock-
down cells were compared (Figure 3.18). Indeed, the PLA signal was significantly 
lower in the knock-down cells. However, treatment of cells with an interaction 
inhibitor, for instance, would be a more suitable negative control. An inhibitor could 
be anything that blocks the interaction or competes with the binding sites such as 
overexpressed soluble C-terminal FGFR2 fragments that could bind to the ARD of 
TRPA1 or vice versa. Nevertheless, the fact that the PLA signal was detected in 
HCC-515 cells indicates close proximity between FGFR2 and TRPA1 (endogenous 
levels) and supports the Co-IP results.  
3.3.3.3. FGFR2-mediated regulation of TRPA1 
Notably, hardly any calcium response could be detected in HCC-515 cells, which 
express higher levels of TRPA1 compared to HCC-44 cells, by calcium imaging 
experiments using AITC as an agonist indicating a non-functional TRPA1 channel. 
In contrast, HCC-44 cells, expressing very low levels of TRPA1, had a high calcium 
response upon AITC treatment which was specific to TRPA1 because the response 
was reduced in the presence of a TRPA1 specific inhibitor (Figure 3.18). Additional 
experiments such as calcium imaging on FGFR2-transfected HCC-44 cells which 
exhibited lower calcium response to AITC, are included in our publication (Berrout 
et al., 2017). These data suggest FGFR2-mediated inhibition of TRPA1, possibly 
via conformational changes in the ARD that translate into pore opening regulation.  
The observation that TRPA1 activation can be influenced by physical association 
with other proteins is not new. Previously, it has been shown that TRPA1 complex 
formation with TRPV1 causes inhibition of TRPA1 both in overexpression systems 
as well as in sensory neurons (Weng et al., 2015). In this study, Hao-Jui Weng, and 
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colleagues described that the C-terminal domain of Tmem100 (a membrane 
protein) containing the KRR sequence binds to TRPA1 and increases its activation 
in the presence of TRPV1 by weakening the TRPA1-TRPV1 interaction. The 
authors also propose that individual interaction sites on each component of the 
complex are responsible for the interaction and thus, channel modulation however, 
no specific domains of the channels were investigated.  
 
3.3.4. FGFR2-TRPA1 complex exists in 1:1 and 2:1 stoichiometry and can 
possibly form higher order complexes based on Expansion Microscopy data. 
 
3.3.4.1. Molecular counting in Super-resolution microscopy 
ExM 10x was performed as an attempt to determine the complex stoichiometry in 
FGFR2 and TRPA1 complexes. The use of single-molecule super-resolution 
microscopy methods for molecular counting has been described before however, 
there are certain challenges related to over-counting, due to fluorophore blinking or 
under-counting, due to limited detection efficiency. Despite those challenges, 
scientists developed strategies to quantify molecules, including RAF kinase 
multimers, the bacterial Flagellar Motor Protein FLIM and PIP3 content in 
endosomes, by super-resolution techniques such as STORM and PALM (Deschout 
et al., 2014; Nan et al., 2013; Puchner et al., 2013).  
In contrast, ExM 10x provides a much simpler platform to perform molecular 
counting since no photoswitching-derived challenges are faced. For example, 
Sheard, et al., were able to count single RyR molecules (Ryanodine receptors) 
within clusters in nanodomains of rat cardiac myocytes as well as match them to 
phosphorylated RyR by two-colour imaging. Centroids of individual RyRs were 
calculated and matched to any phospho-RYR signal within a radius of 30nm 
(localisation error) (Sheard et al., 2019). Similar approach was followed in the 
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present ExM 10x experiment in which 30nm error for each molecule was taken into 
consideration when estimating the maximum distance between FGFR2 and TRPA1 
required to form a complex (Figure 3.23).  
3.3.4.2. ExM limitations in this study 
The present preliminary ExM experiments have certain limitations. To begin with, 
the calculated expansion factor depends on a crude measurement of the gel pre- 
and post-expansion in the macroscopic scale. The macroscopic swelling of the gel 
does not always represent the true expansion of intracellular structures in the 
microscopic scale. Another limitation to consider is whether the expansion is 
occurring homogenously and isotropically throughout the gel resulting in a uniform 
expansion factor.  
A relatively new approach designed to overcome these issues proposes the use of 
nanorulers as a calibration tool to quantify the microscopic expansion factor. 
Nanorulers are utilising the DNA origami technology to create a DNA platform of a 
determined size in which two marks, separated by a set distance (e.g. 80nm), are 
linked to fluorophores. Conventional confocal microscopy will not be able to 
separate the two points of the nanoruler. Following ExM, the two points will be 
separated, and the microscopic expansion factor will be determined as the ratio of 
distance between the two fluorophores post-expansion divided by distance pre-
expansion (determined nanoruler size). Interestingly, it has been shown that the 
microscopic expansion factor can deviate from the macroscopic one. This deviation 
is probably derived from the fact that the nanorulers are initially attached to the 
coverslip and the friction generated between the coverslip and the swellable gel is 
preventing full expansion, which ultimately highlights that the gel is expanding un-
isotropically  (Scheible and Tinnefeld, 2018). 
An alternative approach is to utilise cellular ultrastructures of known size as a 
calibration tool such as α-actinin lattices, peroxisomes and centrioles (Gambarotto 
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et al., 2018; Sheard et al., 2019; Truckenbrodt et al., 2018). Sheard and colleagues 
performed ExM 10x and proved consistent and isotropic expansion by comparing 
the 2-strand morphology of α-actinin lattices (z-discs) and z-disc width (sarcomeric 
length) in cardiomyocytes, respectively (Sheard et al., 2019). The same optimised 
and validated protocol was implemented in the present ExM 10x experiment and 
thus, isotropic expansion was expected in our samples.  
An additional issue emerging from this ExM experiment is the lack of a membrane 
marker that would ensure imaging of the membrane surface. However, this would 
necessitate the use of a third fluorophore which would increase the complication of 
the experiment. Imaging in TIRF (Total Internal Reflection Fluorescence) in which 
only fluorophores within approximately 100nm above the coverslip surface are 
imaged, would also facilitate cell membrane imaging (Fish, 2009). However, a TIRF 
imaging set up was not available and therefore, an alternative approach had to be 
implemented. Since FGFR2 and TRPA1 are membrane proteins and cells are 
mostly flat on the coverslip, images were obtained at the lower focal plane (flat, 
near-surface) in which FGFR2 and TRPA1 fluorophores were present.  
Furthermore, the ExM experiments were performed on overexpressed proteins 
which can generate artefacts due to protein abundance. HCC-515 cells would be 
the optimal system for ExM since FGFR2 and TRPA1 are endogenously expressed 
and complex formation between the two proteins has been shown (Figure 3.17).  
Mander’s co-localisation analysis of 10x ExM images showed that 11.2% of FGFR2 
co-localises with TRPA1 and 23.7% of TRPA1 co-localises with FGFR2 (Figure 
3.23). However, there was no other condition to compare these percentages to. 
Cells over-expressing FGFR2 and TRPA1-Δ10 would be an ideal negative control, 
since TRPA1-Δ10 does not interact with FGFR2 as effectively (Figure 3.12).  
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3.3.4.3. Stoichiometry of the FGFR2 and TRPA1 complex 
Preliminary ExM 10x experiments performed on FGFR2 and TRPA1 expressing 
HEK293T cells revealed physical association between the two proteins and suggest 
a putative complex stoichiometry of 1:1 and 2:1 (Figure 3.24). The use of regular 
antibodies for detecting the two proteins generated a localisation error of 20-30nm 
per molecule. Smaller localisation error can be achieved by an alternative detection 
method utilising nanobodies (fragments of monomeric variable domains of 
antibodies). Nanobodies confer a more accurate signal localisation because of their 
smaller size (1.5 x 2.5 nm, 13 kDa) compared to regular antibodies (10-15 nm, 150 
kDa). The smaller size also facilitates access to restricted areas that antibodies 
cannot reach due to steric hindrance and therefore, the detected signal is more 
specific in regard to the true number and location of labelled proteins (Ries et al., 
2012).  
Based on the interaction mechanism, which involves the binding of the TRPA1 ARD 
to the C-terminal domain of FGFR2, a theoretical stoichiometry model could be 
constructed: TRPA1 is a homotetramer meaning that each channel possesses four 
ARDs which can potentially interact with four different FGFR2 molecules (4:1 
stoichiometry). However, as observed by ExM 10x, it is more likely for FGFR2-
TRPA1 complexes to be present in 1:1 and 2:1 stoichiometry.  
There are three possible explanations for this observed phenomenon. A possible 
explanation would be that not all antigen sites are occupied by an antibody due to 
steric hindrance.  Secondly, (for the 2:1 model) two adjacent ARDs could be 
interacting with the same FGFR2 molecule and thus, all ARDs are actually 
occupied. Thirdly, this is a “pre-complex” in which not all ARD sites have been 
occupied by FGFR2 yet. Interestingly, areas with higher signal density were also 
detected raising the possibility of higher order c+omplexes. However, those images 
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were blurry most likely due to signals from different focal planes and therefore, z-  
stacks would be more informative regarding 3D interactions.  
Moreover, it is still not clear whether the two FGFR2 molecules in the 2:1 model are 
individual monomers interacting with one ARD each or act as a dimer that is 
connected to one or two adjacent ARDs. At this stage, it is fairly difficult to express 
with certainty the exact complex composition, since specific details regarding the 
interaction are still elusive. For example, can more than one FGFR2 molecules bind 
to one ARD (multiple interaction sites) ?, Can two ARDs bind to a single FGFR2 
molecule ?, Can an FGFR2 dimer bind to a single ARD ? 
Taken together, even though ExM 10x provided information regarding the possible 
number of molecules comprising the complex, it is not able to characterise the 
network of interactions between those molecules which could potentially determine 
the fate of the downstream FGFR2 signalling. The FGFR2 signalling upon TRPA1 
interaction is studied in the next chapter (Chapter 4).  
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4. Chapter 4 
Investigation of the function of the FGFR2-TRPA1 
complex 
4.1. Introduction 
It has been shown that the basal FGFR2 signalling is regulated by protein-
protein interactions occurring at the proline-rich motif which is located at the 
C-terminal domain of the receptor. Those interactions in combination with 
the expression levels of the components dictate which downstream pathway 
prevails and regulate cellular behaviour (Lin et al., 2012; Timsah et al., 2015, 
2014).  
Dimeric GRB2 binds to the proline-rich motif causing FGFR2 pre-dimer 
formation and phosphorylation of A-loop tyrosine residues, in non-stimulating 
conditions. However, these pre-dimers are inactive since GRB2 covers 
regions on the C-terminal domain which are important for signal 
transduction. Upon stimulation, FGFR2 becomes fully activated and 
phosphorylates GRB2 resulting in dissociation which enables FGFR2 
signalling (Lin et al., 2012) (see Figure 1.12 ).  
PLCγ1 recognises pY769 on a stimulated FGFR2 molecule and becomes 
active upon FGFR2-mediated phosphorylation (Huang et al., 2016). 
However, PLCγ1 also binds to the same region on FGFR2 as GRB2 and 
becomes activated even in non-stimulating conditions. PLCγ1 and GRB2 
compete for the binding site on FGFR2 and therefore, the protein equilibrium 
dictates the fate of FGFR2 signalling (Timsah et al., 2014) (see Figure 1.12).  
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In Chapter 3, it was suggested that TRPA1 directly binds to the FGFR2 C-
terminal domain which implies a potential competition between the other 2 
components (GRB2 and PLCγ1) as well as a regulatory action of TRPA1 
towards the FGFR2 signalling. In this chapter, we investigate the effect of 
TRPA1 binding on FGFR2 dimerisation, phosphorylation and downstream 
signalling activation.   
4.2. Results 
4.2.1.  The FGFR2-TRPA1 interaction affects the FGFR2 basal level signalling 
To investigate the effect of FGFR2-TRPA1 complex on FGFR2 activity and 
signalling, western blots were performed to detect activity levels of FGFR2 
as well as downstream signalling proteins (Figure 4.1). Phosphorylated 
levels of FGFR2, PLCγ1 and ERK were used as an indicator of protein 
activity and therefore, pathway activation in a series of conditions. HEK293T 
cells were transfected with FGFR2-FLAG and/or tGFP-TRPA1 and remained 
serum starved or treated with FGF9. FGF9 was used as a positive control 
because it is an FGFR2 ligand and activator of the FGFR2 signalling 
pathway (Wing et al., 2005). Quantification analysis involved the 
normalisation of the phosphorylated against the total levels of each protein.   
As shown by the western blot, p-FGFR levels were increased after FGFR2 
overexpression (lane 3) and that indicates the basal level of FGFR2 activity 
in non-stimulating conditions. When the cells were also transfected with 
TRPA1, p-FGFR2 basal levels were decreased by approximately 50% (0.51 
± 0.04, p-value = 0.042 by Tukey’s post-hoc) compared to the FGFR2-
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expressing cells suggesting that the binding of TRPA1 causes inhibition 
(direct or indirect) of the FGFR2 kinase.  
Basal p-PLCγ1 and p-ERK levels were increased when cells were 
transfected with FGFR2 by 48 ± 9.2 (p-value = 0.000004 by Tukey’s post 
hoc) and 12 ± 2.2 times (p-value = 0.018 by Tukey’s post hoc) compared to 
the un-transfected sample, respectively. Considering the lower activity of 
FGFR2 in the presence of TRPA1, it would be expected that signalling 
proteins like PLCγ1 (substrate of FGFR2) and ERK (downstream of FGFR2) 
would also have lower phosphorylation levels. Indeed, p-PLCγ1 basal levels 
were decreased in the FGFR2+TRPA1 cells (lane 5) by approximately 60% 
(0.40 ± 0.03, p-value = 0.002 by Tukey’s post-hoc) compared to the FGFR2-
expressing cells (lane 3). However, p-ERK basal levels were not significantly 
different between FGFR2- and FGFR2+TRPA1-expressing cells, suggesting 
that the binding of TRPA1 to FGFR2 does not affect the MAPK pathway.  
Notably, except for p-ERK (increased by 2.2-fold ± 0.1, p-value = 0.001 by 
Tukey’s post hoc), p-FGFR and p-PLCγ1 were not increased under FGF9 
stimulation (lane 4) as it would be expected (further discussed in section 
4.3.1). 
The same experiment was performed with a strep-tagged FGFR2 construct 
to demonstrate reproducibility. Firstly, the interaction between FGFR2-
STREP and tGFP-TRPA1 was confirmed by Co-IP using an anti-TRPA1 
antibody (Figure 4.2a). Indeed, consistent results were obtained by using a 
different construct of FGFR2 containing a different tag. Both p-FGFR and p-
PLCγ1 levels were decreased in the presence of TRPA1 while p-ERK levels 
were not changed. This experiment was performed once.  
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Next, just to verify that the p-FGFR bands in the western blot belong to p-
FGFR2 specifically and not to any other phosphorylated FGF receptor, a Co-
IP was performed using an anti-FGFR2 antibody to precipitate total FGFR2 
and then probed for p-FGFR to specifically detect phosphorylated levels of 
FGFR2. As shown in Figure 4.3, p-FGFR2 was decreased approximately 
55% as similarly observed in the previous western blots with FGFR2-FLAG 
(Figure 4.1).  
To further investigate if the MAPK pathway is also regulated by TRPA1, a 
western blot was performed to detect levels of p-ERK in cells that were 
TRPA1-transfected and kept serum starved or treated with AITC (TRPA1 
agonist) and/or HC030031 (TRPA1 specific inhibitor) (Figure 4.4). The 
results show that there was a nearly 2-fold increase in the p-ERK levels in 
the presence of TRPA1 (lane 2). The p-ERK levels were further increased by 
another 2-fold in TRPA1-expressing cells that were also treated with AITC 
(lane 3). However, AITC was capable of increasing p-ERK by approximately 
3-fold in HEK cells that were not transfected with TRPA1 compared to 
untreated cells (Figure 4.4, lane 1 and 4). To further understand whether the 
detected increase was due to TRPA1-mediated calcium signalling or due to 
an alternative mechanism, TRPA1-transfected cells that were serum starved 
or treated with AITC in the presence of the TRPA1 specific inhibitor 
HC030031 (prior to and during AITC treatment). The addition of HC030031 
(lane 5 and 6) did not alter the p-ERK levels compared to non-HC030031-
treated cells, suggesting that this effect of TRPA1 may not be mediated by 
the channel’s activity. Due to time limitations this experiment was performed 
once.  
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Figure 4. 1: Western blot analysis of FGFR2 signalling using FGFR2-
FLAG. a) Western blot on un-transfected and FGFR2-FLAG and/or tGFP-
TRPA1-transfected HEK-293T cells using the antibodies against the 
indicated proteins (anti-TRPA1 and anti-FGFR2 from Santa Cruz). The cells 
were serum starved for 2 hours prior to any treatment and lysis. β-actin was 
used as a loading control. b)  Quantification of the western blot by 
densitometry using ImageJ. All densitometry values were normalised to β-
actin. The bar graph illustrates the ratio of phosphorylated divided by total 
protein levels as normalised by the un-transfected control. F2 = FGFR2-
FLAG, A1 = tGFP-TRPA1, F9 = FGF9. ns = non-significant. One-way 
ANOVA with Tukey’s post hoc analysis, n = 4, Error bars = S.E.M.  
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Figure 4. 2: Western blot analysis of FGFR2 signalling using FGFR2-
STREP. a) Co-IP experiment using an anti-TRPA1 antibody (Santa Cruz) on 
lysates from un-transfected (UT) and FGFR2-STREP and/or tGFP-TRPA1-
transfected cells. b) Western blot on un-transfected FGFR2-STREP and/or 
tGFP-TRPA1-transfected HEK-293T cells using antibodies against the 
indicated proteins (anti-TRPA1 and anti-FGFR2 from Santa Cruz). The cells 
were serum starved for 2 hours prior to any treatment or lysis. β-actin was 
used as a loading control. c) Quantification of the western blot by 
densitometry using ImageJ. All densitometry values were normalised to β-
actin. The bar graph illustrates the ratio of phosphorylated divided by total 
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protein levels as normalised by the wild type control (n = 1). F2 = FGFR2-
FLAG, A1 = TRPA1-tGFP, F9 = FGF9.  
 
 
Figure 4. 3: Detection of basal p-FGFR2 levels in the presence of 
TRPA1. a) Co-IP experiment using an anti-FGFR2 antibody on un-
transfected and FGFR2-FLAG and/or tGFP-TRPA1-transfected HEK-293T 
cells. Results were analysed by western blot for p-FGFR. b) Quantification of 
co-IP results in a bar graph illustrating the p-FGFR2/total FGFR2 ratio 
normalised against the FGFR2 sample (n = 1).  
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Figure 4. 4: TRPA1 increases p-ERK. a) Western blot on un-transfected 
(UT) or tGFP-TRPA1-transfected HEK-293T cells that were serum starved 
or treated with AITC and/or HC030031 using antibodies against the 
indicated proteins. Treatment with AITC or HC030031 and TRPA1 
transfection are indicated by – and +. β-actin was used as a loading control. 
b) Quantification of the western blot by densitometry using ImageJ. 
Densitometry values were normalised against β-actin and presented as a 
fold-change compared to the control (un-transfected cells) (n = 1).  
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4.2.2. The FGFR2-TRPA1 co-expression affects FGFR2 dimerisation 
The canonical RTK activation mechanism requires dimerisation between two 
receptor monomers prior to kinase activation, and subsequent increase in 
phosphorylated tyrosine residues (p-FGFR2). In the previous section, it was 
demonstrated that the basal p-FGFR2 levels are decreased in the presence 
of TRPA1 and therefore, it was hypothesised that the TRPA1 binding can 
influence FGFR2 dimerisation. To investigate the effect of TRPA1 on FGFR2 
dimerisation, PLA experiments, specifically designed for receptor 
dimerization, were performed.  
HEK-293T cells were double transfected with two differentially-tagged 
FGFR2 constructs: FGFR2-STREP and FGFR2-FLAG. Anti-STREP and 
anti-FLAG antibodies were utilised to detect the two different FGFR2 
molecules and create PLA signal if located in proximity. In this case, 
proximity between the FGFR2 molecules is translated to dimer formation. 
The PLA signal was analysed in the presence and absence of TRPA1.  
Firstly, it was crucial to confirm the efficiency of the triple transfection 
(FGFR2-STREP, FGFR2-FLAG and tGFP-TRPA1). Immunofluorescence 
staining of triple transfected cells (Figure 4.5) revealed that there are cells 
expressing all three proteins (yellow circle), as well as cells that miss the 
expression of TRPA1 (yellow arrows) or one of the FGFR2 receptors (red 
circle). Therefore, only GFP-positive cells (TRPA1 expression) with PLA 
signal (both FGFR2 expression) were analysed.  
The PLA signal (n = 41 cells for FGFR2 only and n = 34 cells for 
FGFR2+TRPA1) corresponding to FGFR2 dimers was approximately 50% 
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lower (p-value ≤ 0.001 by Mann Whitney U test) in the presence of TRPA1 
indicating inhibition of receptor dimerization (Figure 4.6).  
Moreover, to verify the PLA results, FGFR2 dimerisation was studied by 
comparing the dimers/monomers ratio in the presence (reducing) and 
absence (non-reducing) of β-mercaptoethanol (β-ME) by Western blot. The 
ratio of FGFR2 dimers/monomers in FGFR2-expressing cells was 
approximately three times lower (n = 3, p-value ≤ 0.0001 by 2-way ANOVA 
with Tukey’s post-hoc) in the presence of β-ME, a chemical agent reducing 
the disulphide bonds which could possibly stabilise the dimer (lane 1 and 2). 
When the cells were co-transfected with TRPA1, the dimers/monomers ratio 
in absence of β-ME was significantly decreased by approximately 40% (n = 
3, p-value ≤ 0.0001 by 2-way ANOVA with Tukey’s post-hoc) which indicates 
TRPA1 has an inhibitory effect on FGFR2 dimerisation (Figure 4.7a, lane 1 
and 3, and b). Similar to the FGFR2 condition, β-ME decreased the ratio in 
FGFR2+TRPA1-expressing cells by three-fold (lane 3 and 4). Cells 
expressing FGFR2 and treated with FGF9 were used as a positive control 
however, no differences were observed between treated and non-treated 
ratios (Figure 4.7a, lanes 1 and 5, and c).   
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Figure 4. 5: Efficiency of triple transfection for tGFP-TRPA1, FGFR2-
FLAG and FGFR2-STREP by Immunofluorescence. Immunofluorescence 
staining of HEK-293T cells transfected with tGFP-TRPA1 (green), FGFR2-
FLAG (magenta) and FGFR2-STREP (red). Cells expressing all three 
proteins are indicated by a yellow circle. Cells expressing both FGFR2 
constructs but no TRPA1 are indicated by the yellow arrow. Cells expressing 
TRPA1 and FGFR2-STREP, but no FGFR2-FLAG are indicated by a red 
circle. Representative images are presented. Scale bar = 20µm. 
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Figure 4. 6: TRPA1 inhibits FGFR2 dimerisation as shown by PLA. a) 
Representative images of PLA on FGFR2-STREP and FGFR2-FLAG in the 
presence and absence of tGFP-TRPA1. PLA is indicated with Texas Red, 
DAPI = nucleus, GFP = TRPA1. Scale bar = 10µm. b) Quantification of three 
technical replicates from this PLA experiment (n = 1). The scatter blot 
illustrates the number of PLA puncta per cell in the presence and absence of 
TRPA1. Significant difference is indicated by *** (p-value ≤ 0.0001, by non-
parametric Mann Whitney U test). FGFR2 = 41 cells, mean = 17.3 puncta 
per cell. FGFR2+TRPA1 = 34 cells, mean = 7.5 puncta per cell. 
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Figure 4. 7: FGFR2 dimers are decreased in the presence of TRPA1. a) 
Lysates from HEK-293T cells transfected with FGFR2-FLAG and FGFR2-
FLAG+tGFP-TRPA1, were subject to SDS-PAGE and mixed with SDS 
loading buffer in the presence or absence of β-mercaptoethanol (β-ME). 
Results were visualised by a Western blot against total FGFR2. FGFR2 
monomers and dimers are indicated by black arrows. The average 
normalised dimers/monomers ratio for each condition is shown in red. b) and 
c) Quantification of the dimers and monomers by densitometry using 
ImageJ. Dimers densitometry values were divided by the monomers values 
creating the dimers/monomers ratio which was normalised against the 
FGFR2 without β-ME sample. ns = non-significant. Significant differences 
are indicated by asterisks (2-WAY ANOVA with Tukey’s multiple 
comparisons analysis, n = 3). Error bars = S.E.M.  
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4.2.3. Reduced PLCγ1-FGFR2 interaction in the presence of TRPA1 
The experiments, so far, suggest that the FGFR2-TRPA1 interaction inhibits 
basal receptor dimerization (Figure 4.6), activation and FGFR2-mediated 
PLCγ1 phosphorylation (Figure 4.1). Based on the literature, PLCγ1 directly 
interacts with the FGFR2 receptor and acts as a substrate for 
phosphorylation that will eventually activate the phospholipase (Huang et al., 
2016). To study the FGFR2-PLCγ1 binding in the presence and absence of 
TRPA1, co-IP experiments were performed. Anti-FGFR2 antibody was 
utilised to precipitate FGFR2 and the presence of PLCγ1 was detected with 
an anti-PLCγ1 antibody by western blot. PLCγ1 was precipitated with 
FGFR2, confirming interaction between the two proteins. However, there 
was an approximately 30% reduction when cells were co-transfected with 
TRPA1 which indicates TRPA1-mediated inhibition of the FGFR2-PLCγ1 
interaction (figure 4.8).  
Reduced FGFR2-PLCγ1 interaction can be translated into lower levels of p-
PLCγ1 bound to FGFR2. Similar co-IP experiment was performed to detect 
differences in the p-PLCγ1 levels that are bound to FGFR2. As shown in 
Figure 4.9, p-PLCγ1 levels, precipitated by FGFR2, were approximately 50% 
reduced in the presence of TRPA1. Notably, p-PLCγ1 levels were not 
increased following FGF9 stimulation.  
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Figure 4. 8: TRPA1 inhibits basal PLCγ1-FGFR2 binding as shown by 
co-IP. a) Co-IP on un-transfected (UT) and FGFR2-FLAG and/or tGFP-
TRPA1-transfected HEK-293T cells using an anti-FGFR2 antibody (Santa 
Cruz). Results were visualised by Western blot for the indicated proteins. b) 
Quantification of western blot by densitometry using ImageJ. PLCγ1 
densitometry values were normalised against FGFR2 levels. Bar Graph 
illustrates the fold-change in the PLCγ1 precipitation in the presence 
compared to the absence of TRPA1 (n = 3), Error bars = S.E.M.  
- 183 - 
 
Figure 4. 9: Reduced p-PLCγ1 bound to FGFR2 in the presence of 
TRPA1. a)  Co-IP on non-transfected and FGFR2-FLAG and/or TRPA1-
tGFP-transfected HEK-293T cells using an anti-FGFR2 antibody (Santa 
Cruz). Results were visualised by Western blot for the indicated antibodies. 
b) Quantification of western blot by densitometry using ImageJ. p-PLCγ1 
densitometry values were normalised against FGFR2 levels. Bar Graph 
illustrates the fold-change in the p-PLCγ1 precipitation in the presence 
compared to the absence of TRPA1 (n = 1). 
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4.2.4. TRPA1 allows FGFR2 activation under stimulating conditions but 
hinders PLCγ1 binding to the receptor 
To further understand the mechanism by which TRPA1 inhibits PLCγ1 
binding to FGFR2, it was important to monitor the phosphorylation levels of 
Y769 on FGFR2, which is the PLCγ1 binding site (Huang et al., 2016). Co-IP 
experiments were performed on HEK-293T cells transfected with FGFR2-
STREP in the presence and absence of tGFP-TRPA1 (Figure 4.10). An anti-
FGFR2 antibody was used to precipitate FGFR2 and the phosphorylation 
levels of both FGFR2 A-loop (Y653-654) and Y769 were detected by an anti-
p-FGFR and anti-pY769 antibody, respectively. The binding of PLCγ1 and 
TRPA1 was also detected by an anti-PLCγ1 and anti-TRPA1 antibody, 
respectively. As shown in previous experiments, PLCγ1 binding and p-FGFR 
levels were drastically reduced in the presence of TRPA1 (lanes 3 and 5). 
According to the densitometry values, pY769 levels were also reduced in the 
presence of TRPA1, which could suggest a mechanism for the TRPA1-
mediated PLCγ1 binding reduction (Figure 4.10). However, due to the poor 
quality of the antibody as well as the single repeat of the experiment, pY769 
levels cannot be identified with certainty. 
Based on the general RTK signalling, receptor stimulation by a ligand 
causes increased tyrosine phosphorylation and activation of the receptor. To 
test this phenomenon in the presence of TRPA1, cells treated with FGF9 
were also included in the previous co-IP experiment. Firstly, the interaction 
between FGFR2 and TRPA1 under stimulating conditions was confirmed by 
detection of precipitated TRPA1 in both the absence and presence of FGF9 
(Figure 4.10, lanes 5 and 6, TRPA1 panel). p-FGFR2 (A-loop) as well as 
pY769 levels were also studied. Interestingly, p-FGFR (A-loop) levels, in this 
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one experiment, were increased upon stimulation in cells expressing 
FGFR2-STREP+tGFP-TRPA1, which could suggest that FGFR2 can be 
activated by its ligand in the presence of TRPA1 (lane 5). However, more 
repeats are necessary to fully understand the regulation of the receptor in 
the presence of stimulation. Once again, the pY679 levels in the presence of 
FGF9 could not be identified with certainty due to the poor signal to noise 
ratio in the western blot. Interestingly, PLCγ1 binding to FGFR2 did not 
increase in the presence of FGF9 compared to no FGF9 stimulation even 
though A-loop tyrosine residues seemed to be phosphorylated (lanes 5 and 
6).   
Therefore, the IP in Figure 4.10 suggests that the FGFR2-TRPA1 interaction 
still occurs following FGF9 stimulation possibly resulting in receptor 
activation, yet TRPA1 still inhibits PLCγ1 binding. One possible explanation 
could be that TRPA1 physically hinders the binding of PLCγ1 to the receptor. 
To test this hypothesis, co-IP experiments were performed with an anti-
TRPA1 antibody on FGFR2-FLAG+tGFP-TRPA1-expressing cells (Figure 
4.11). If FGFR2, interacting with TRPA1 through the C-terminal domain, can 
still interact with PLCγ1, then TRPA1 would be able to precipitate PLCγ1, 
because they would all form a complex. The ability of TRPA1 to co-
precipitate PLCγ1 indirectly and through FGFR2 was tested by probing for 
PLCγ1 in the western blot. TRPA1 precipitated FGFR2 but not PLCγ1. This 
result could suggest that TRPA1, FGFR2 and PLCγ1 do not form a complex 
all together and that TRPA1 may therefore physically occlude the binding 
site for PLCγ1 (lane 3). As a negative control TRPA1-expressing cells were 
used to show that TRPA1 does not interact with PLCγ1 in the absence of 
FGFR2 (lane 4).  
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Figure 4. 10: FGFR2 phosphorylation in the presence of TRPA1 and 
FGF9. a)  Co-IP on un-transfected and FGFR2-STREP and/or tGFP-TRPA1-
transfected HEK-293T cells using an anti-FGFR2 antibody (Santa Cruz). 
Results were visualised by Western blot for the indicated proteins. b) 
Quantification of western blot by densitometry using ImageJ. All 
densitometry values were normalised against FGFR2 levels. Bar Graph 
illustrates the fold-change in the PLCγ1, p-FGFR and p-Y769 levels in the 
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presence and absence of TRPA1 and FGF9 compared to the control sample 
(FGFR2-expressing cells) (n = 1). 
 
 
 
 
 
Figure 4. 11: TRPA1 does not form a complex with FGFR2-PLCγ1 
through FGFR2. Co-IP on un-transfected (UT) and FGFR2-STREP and/or 
TRPA1-tGFP-transfected HEK-293T cells using an anti-TRPA1 antibody. 
Results were visualised by Western blot for the indicated antibodies. 
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4.3. Discussion 
4.3.1. FGF9 as an agonist of FGFR2 signalling 
FGF9 is a ligand that recognises the IIIc splice variant of FGFR2, FGFR1 
and FGFR3 (Ornitz and Itoh, 2015). Throughout this chapter, FGF9 
treatment has been used as a positive control that will activate FGFR2 and 
downstream signalling pathways. However, FGF9-treated cells over-
expressing FGFR2, consistently lack increased levels of p-FGFR2 and p-
PLCγ1, while exhibiting elevated levels of p-ERK, compared to un-treated 
cells (e.g. Figure 4.1).  
The fact that FGFR2 forms pre-dimers even in the absence of extracellular 
stimulation could possibly explain this phenomenon (Lin et al., 2012). Pre-
dimer formation and basal phosphorylated receptor levels have been 
reported for other RTKs in the past including, EGFR, VEGFR and TrkB 
(Sarabipour et al., 2016; Shen and Maruyama, 2012; Yu et al., 2002). Only 
EGFR dimers have been shown to be un-phosphorylated which highlights 
the unique characteristics of each RTK. Hence, it is speculated that RTKs 
exist in a monomer-dimer equilibrium prior to ligand stimulation, which 
eventually fully activates the receptors. In the present study, over-expression 
may have caused excessive levels of FGFR2 which shifted the equilibrium 
towards predominantly dimers due to protein abundance. Basal p-FGFR2 
levels are probably saturated and no difference can be detected by 
treatment with FGF9 (Figure 4.1a lane 3 and 4).  
An alternative approach to detect differences in the p-FGFR2 levels between 
FGF9-treated and untreated cells would be to generate a stable cell line 
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expressing low levels of FGFR2 which would also eliminate variations 
originating from transient transfections. Chi-Chuan, and colleagues, for 
instance, were able to detect p-FGFR2 differences, albeit small, by utilising 
an FGFR2-stable cell line (Lin et al., 2012).  
This hypothesis described above is somewhat undermined by the fact that 
treatment with FGF9 increased p-ERK levels but not p-PLCγ1 in FGFR2-
transfected cells (Figure 4.1). Hence, it would be tempting to speculate that 
FGF9 may have a pathway-specific effect on FGFR2, whereby it activates 
ERK but not the PLCγ1 pathway. Ming-Min Chang and colleagues have 
shown that the FGF9/FGFR2 does not activate PLCγ1 in mouse Leydig 
cancer cells (Chang et al., 2018). Jih-Ing Chuang and colleagues 
demonstrated similar results for FGF9/FGFR2 in cortical and dopaminergic 
neurons (Chuang et al., 2015). In contrast, other studies show activation of 
both pathways in cells including human uterine endometrial stromal cells  
(Wing et al., 2005), indicating that the downstream signal programming 
highly depends on the cell type. Timsah and colleagues have also detected 
higher levels of p-PLCγ1 following FGF9 treatment in HEK cells stably 
transfected with FGFR2, indicating that it is posing further questions to why 
PLCγ1 pathway was not activated in the present experiments (Timsah et al., 
2014). 
One possible explanation for the difference in pathway activation is that the 
PLCγ1 pathway was already fully activated prior to stimulation, the same 
way the FGFR2 phosphorylation was saturated. This hypothesis contradicts 
previously published studies demonstrating that RTK pre-dimer formation on 
its own does not activate downstream signalling (Lin et al., 2012; Timsah et 
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al., 2014). However, these studies were emphasised on the MAPK pathway 
and showed no further activation prior to ligand stimulation - they did not 
investigate p-PLCγ1 levels before and after stimulation. The results in the 
present study suggest that FGFR2 pre-dimers, even though unable to fully 
activate the MAPK pathway (only basal levels), are still able to induce 
PLCγ1 signalling, even in the absence of FGF9.  
The reason behind differences in activation of ERK and PLCγ1 downstream 
pathways observed in this chapter is still unclear. Chi-Chuan and colleagues 
proposed that dimeric GRB2, that binds to the C-terminal proline-rich motif of 
FGFR2 promoting receptor dimerization, inhibits downstream signalling by 
masking key residues. With that said, it is likely for PLCγ1 to not be affected 
by this regulation, since PLCγ1 is a direct substrate of FGFR2 and there are 
less regulatory points into activating the pathway compared to ERK, which is 
located further downstream in the cascade. Further experiments are needed 
to understand the basal and stimulated FGFR2 signalling.  
 
4.3.2. FGFR2-TRPA1 interaction affects p-FGFR2 and p-PLCγ1 but not p-ERK 
levels 
Western blot experiments revealed that the basal p-FGFR2 levels were 
decreased by approximately 50% in the presence of TRPA1 (Figure 4.1, 4.2, 
4.3, lane 3 and 5). The antibody used recognises phosphorylated Tyrosine 
residues (pY653-654) in the activation loop of FGF Receptors which are 
important for catalytic activity. Phosphorylation of Y653 increases kinase 
activity by 50 to 100-fold, while phosphorylation of Y654 increases it by an 
extra 10-fold (Lew et al., 2009). Therefore, decreased p-FGFR levels are an 
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indication of decreased FGFR kinase activity. Here, the results suggest that 
interaction of TRPA1 with FGFR2 results in reduced phosphorylation and 
consequently, lower kinase activity. The exact mechanism of inhibition is not 
investigated. However, it could be hypothesised that either TRPA1 
dissociates FGFR2 dimers or has an interaction-induced allosteric effect on 
the FGFR2 kinase activity.  
Following p-FGFR2 levels, downstream signalling pathways were also 
investigated. Firstly, p-PLCγ1 levels were decreased by approximately 60% 
(Figure 4.1, lane 3 and 5) indicating lower phospholipase activity and 
pathway activation. Since PLCγ1 is a direct substrate of FGFR2, reduced 
phosphorylated levels are expected as a result of lower FGFR2 kinase 
activity.  
Normally, lower p-FGFR2 levels lead to lower p-ERK however, this is not the 
case in the present experiment. The MAPK pathway was not altered by the 
presence of TRPA1 (Figure 4.1-4.2, lane 3 and 5). However, it is likely that 
the FGFR2-mediated ERK phosphorylation is actually inhibited by TRPA1 
but at the same time, the presence of TRPA1 alone could be causing MAPK 
activation which compensates for the actual reduction caused by the 
FGFR2-TRPA1 interaction.   
Indeed, the western blot in Figure 4.4 shows that TRPA1 alone can increase 
p-ERK levels (lane 1 and 2). Additional treatment with AITC increases p-
ERK even further (lane 2 and 3) which is consistent with previous studies 
(J.-L. Chen et al., 2017; Schaefer et al., 2013; Takahashi et al., 2018). 
However, it is not clear whether the increase is TRPA1-mediated because 
AITC alone can still activate non-TRPA1-expressing HEK cells (lane 1 and 
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4). These data are similar with studies showing that AITC treatment 
increases p-ERK levels in different cell types including the MDA-MB-468 
human breast adenocarcinoma cells and PC-3 prostate cancer cells (Tsai et 
al., 2012; C. Xu et al., 2006). The use of HC030031 as a specific TRPA1 
inhibitor did not have an effect on p-ERK levels indicating that either the 
inhibition was not sufficient or p-ERK increase is calcium-independent (lane 
5 and 6). Based on previously mentioned studies, p-ERK increase is 
calcium-induced. The experiment was performed once, and more repeats 
are needed to ensure significant differences. Alternatively, the same 
experiment can be performed with cells cultured in presence and absence of 
EGTA (calcium chelator) that will abrogate calcium influx from the 
extracellular space and therefore, calcium-mediated effects can be detected. 
Similar information can be obtained from experiments using a pore mutant of 
TRPA1 that will not be capable of current conductance and thus, show 
whether the p-ERK increase is an indirect effect of TRPA1 expression or 
TRPA1 current-dependent.  
Nevertheless, results from this western blot (Figure 4.4) in combination with 
literature suggest that it is plausible for TRPA1 to induce ERK 
phosphorylation indicating that p-ERK levels are both FGFR2- and TRPA1-
dependent, further complicating the interpretation of the results (Figure 4.1, 
lane 3 and 5, p-ERK panel).  
In conclusion, western blots on transfected HEK-293T cells suggest that 
TRPA1 inhibits FGFR2 phosphorylation and subsequent kinase activity that 
results in a decrease in PLCγ1 phosphorylation, while maintaining levels of 
p-ERK unaffected. 
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4.3.3. TRPA1 binding to FGFR2 affects receptor dimerisation 
FGFR2 dimerisation was investigated by PLA in the presence and absence 
of TRPA1. PLA signal was approximately 50% lower in the presence of 
TRPA1 suggesting inhibition of dimerization (Figure 4.7). This result could 
possibly justify the TRPA1-mediated reduction in p-FGFR2 levels detected 
by western blot (Figure 4.1). However, there are certain limitations deriving 
from the protein expression levels that should be considered prior to any 
conclusions.  
The main limitation is the variability of protein expression due to transient 
transfections. It was noticed that not all cells express all three transfected 
proteins, let alone similar levels. Cells stably transfected with proteins of 
interest would be more suitable for this experiment. Apart from the variability 
derived from transient transfections, possible competition for the 
transcriptional machinery could have created variability too, since FGFR2-
FLAG and tGFP-TRPA1 are under the control of CMV promoter. Taken 
together with the findings in Figure 4.7, reduced PLA signal could originate 
from lower expression of one of the receptors (STREP or FLAG tagged) 
when co-expressed with TRPA1, instead of actual inhibition of dimerization 
by TRPA1.  
However, FGFR2 multimer separation in non-reducing conditions (no β-ME) 
in an SDS-PAGE revealed similar results. The FGFR2 dimer/monomer ratio 
was 40% lower in the presence of TRPA1 suggesting that TRPA1 inhibits 
dimerization of the receptor (Figure 4.7).  
Cell lysates are usually loaded and resolved in a native polyacrylamide gel 
without detergents (no SDS) or reducing agents (no β-ME) to compare 
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monomer and dimer levels between treatments (Yu et al., 2002). In our 
case, the samples were resolved in the presence of SDS so that any 
FGFR2-TRPA1 complexes are dissociated and thus, strictly FGFR2 dimers 
and monomers are analysed and fully resolved. Therefore, the comparison 
was made between presence and absence of β-ME. However, not clear and 
distinctive bands for dimers were formed and therefore, additional 
experiments could enhance this interpretation. For example, comparing the 
pull down between FGFR2-FLAG and FGFR2-STREP in the presence and 
absence of TRPA1 would also show whether there is an inhibition in the 
dimerization/interaction between the two receptor versions.  
Another important finding from this experiment could be that disulphide 
bonds are crucial for FGFR2 dimerisation since their disruption reduces 
FGFR2 dimers in all samples (FGFR2, FGFR2+TRPA1, FGFR2+FGF9). The 
importance of disulphide bonds in RTK dimerisation including TrkB and p75 
receptors has been proposed in the past (Nadezhdin et al., 2016; Shen et 
al., 2019). The present results are also consistent with studies on FGFR2 
and FGFR3 Cysteine mutants that cause increased dimerisation through 
formation of intermolecular disulphide bonds (Adar et al., 2002; Liao et al., 
2013; Plotnikov et al., 2000; Sarabipour and Hristova, 2016). 
Even though inhibition of dimerisation is consistent with lower p-FGFR2 and 
p-PLCγ1 levels, it does not explain the unaffected levels of p-ERK. 
Therefore, it is speculated that TRPA1 promotes ERK activation through an 
FGFR2-independent mechanism that masks the actual MAPK signalling 
inhibition derived from their interaction, as discussed in the section 4.3.2. 
This would also imply that TRPA1 does not inhibit FGFR2 allosterically.  
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It can be speculated that TRPA1 passively inhibits FGFR2 dimerisation due 
to competition with GRB2. Dimeric GRB2 binding on the C-terminal proline-
rich motif, causes FGFR2 dimerisation in unstimulated conditions. Therefore, 
TRPA1 being highly expressed, overtakes the binding site for GRB2 
resulting in an indirect prevention of pre-dimer formation.  
4.3.4. TRPA1 physically hinders PLCγ1 binding to FGFR2  
The results obtained so far reveal lower levels of p-PLCγ1 as a result of 
TRPA1 binding to FGFR2. Moreover, co-IP experiments show reduced 
PLCγ1 and p-PLCγ1 binding to FGFR2 in the presence of TRPA1, which 
explains the lower phosphorylation levels (Figure 4.8 and 4.9). However, it is 
not clear how TRPA1 achieves reduced FGFR2-PLCγ1 binding. To address 
that, the PLCγ1-FGFR2 binding was studied upon stimulation with FGF9. 
A co-IP experiment suggested that TRPA1 and FGFR2 can still interact even 
in the presence of stimulation by FGF9 (Figure 4.10). Results from one 
experiment showed that even if FGFR2 can possibly be activated by FGF9 
in the presence of TRPA1 (increased A-loop phosphorylation), PLCγ1 
binding to the receptor is still reduced. Therefore, the FGF9/FGFR2-
mediated PLCγ1 pathway is inhibited in the presence of TRPA1. However, 
this hypothesis is based on one repeat and more repeats are necessary to 
validate this preliminary result.  On the other hand, due to poor signal to 
noise ratio, results for pY769 levels (PLCγ1 binding site) could not be 
interpreted with certainty.   
An additional preliminary co-IP experiment (Figure 4.11) could suggest that 
TRPA1 sterically hinders the binding of PLCγ1 to FGFR2 because an anti-
TRPA1 antibody was not able to indirectly co-precipitate PLCγ1 through the 
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FGFR2-TRPA1 interaction. This result could mean that they cannot form a 
PLCγ1-FGFR2-TRPA1 complex in the presence of TRPA1, most likely 
because both PLCγ1 and TRPA1 share adjacent binding sites on FGFR2 
(Figure 4.11). The two PLCγ1 binding sites on FGFR2 (p-Y769 and Proline-
rich motif) are likely covered by TRPA1. If this hypothesis is valid, it could be 
plausible for PLCγ1, TRPA1 as well as GRB2 to complete for the binding 
site on FGFR2, since they all bind in adjacent areas located in the C-
terminal domain.  Therefore, the equilibrium between these proteins could 
regulate FGFR2 signaling. Competition experiments would shed more light 
into the dynamics of this network of interactions and validate this hypothesis.   
More repeats are necessary to verify significant results and to achieve more 
certainty in conclusions. However, a hypothetical model of FGFR2-TRPA1 
physical and functional interaction can be constructed based on the findings 
so far combined with literature on FGFR2 signalling (Figure 4. 12). In 
summary, TRPA1 directly interacts with the C-terminal domain of FGFR2 
through the ARD (1-10 repeats). The interaction causes inhibition of basal 
FGFR2 phosphorylation levels. The mechanism behind FGFR2 inhibition is 
not clear however, it is most likely due to inhibition of basal dimerization 
induced by GRB2.  
Reduced basal p-FGFR2 levels result in lower downstream signaling 
including the MAPK and the PLCγ1 pathway. Activation of the MAPK 
pathway, however, could be rescued by an FGFR2-independent and 
TRPA1-mediated mechanism. However, further experiments are needed to 
elaborate on the MAPK pathway regulation and validate the hypothesis. 
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TRPA1 inhibits the binding of PLCγ1 to FGFR2, most likely by physically 
hindering the binding site for PLCγ1, causing the inhibition of the pathway.  
In contrast, only preliminary hypothesis can be made regarding stimulating 
conditions due to lack of experimental repeats. Therefore, TRPA1 and 
FGFR2 interaction could occur under FGF9 stimulation and could cause 
FGFR2 activation and phosphorylation (A-loop at least) while maintaining 
PLCγ1 inhibition. A proposed model is shown in Figure 4.12. Nevertheless, 
more experimental repeats are needed to ensure significant effects.  
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Figure 4. 12:  Schematic of the hypothetical FGFR2-TRPA1 model of 
interaction.  
a) Basal/Unstimulated conditions: Dimeric GRB2 binds to the proline-rich 
motif of FGFR2 causing receptor pre-dimers that cannot activate the MAPK 
pathway, as previously shown in the literature. However, pY769 is possibly 
still accessible to PLCγ1 and could result in phosphorylation by FGFR2 and 
activation of the PLCγ1 pathway.  
b) Basal FGFR2 in Presence of TRPA1: the TRPA1 ARD binds to the C-
terminal domain of FGFR2 possibly preventing GRB2 from binding and 
causing receptor dimerization. Thus, tyrosines on FGFR2 monomers are no 
longer phosphorylated and no downstream pathway is activated. TRPA1 
likely masks the proline-rich motif (second PLCγ1 binding site), preventing 
PLCγ1 from being phosphorylated and activated by the receptor. There is a 
possibility that TRPA1 itself can induce MAPK activation in an FGFR2-
independent manner.  
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c) FGFR2 stimulation in TRPA1 presence:  FGF9 stimulates FGFR2 
dimerisation and complete activation of the kinase domain that can 
potentially induce downstream pathways including the MAPK and PLCγ1 
pathway. However, based on co-IP experiments, FGFR2-bound TRPA1 
could still block the binding site for PLCγ1 (pY769) as well as the proline-rich 
motif (second binding site), completely inhibiting PLCγ1 activation. Activation 
of the MAPK pathway in stimulating conditions was not investigated.  
4.3.5. The effect of TRPA1 on FGFR2 activation: comparison with published 
model 
Notably, there are differences between the model described in this thesis 
and the model we published 2 years ago (Berrout et al., 2017). Even though 
both models involve the interaction of FGFR2 and TRPA1, the findings from 
our publication supported the activation of basal FGFR2 and downstream 
signalling by TRPA1 rather than inhibition, as described here. Particularly, 
TRPA1 was suggested to act as a molecular scaffold that brings two FGFR2 
monomers in proximity causing receptor dimerization and activation. 
Differences in methodology as well as use of different cells could possibly be 
the reason for this discrepancy.  
As mentioned before, FGFR2 was expressed in high levels, as a result of 
the transient transfection, which saturated the activation state of the 
receptor. No further activation could be detected as seen using FGF9 and 
therefore, potential activation by TRPA1 would not be detected either. The 
binding of TRPA1 to FGFR2 could then induce the internalisation of the 
receptor as a response to activation, resulting in less p-FGFR2 in the 
western blot. Next, FGF9 effect on FGFR2 signalling was potentiated when 
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cells overexpressed TRPA1 suggesting that lower levels of FGFR2 are 
crucial for studying activation. Therefore, the FGFR2 levels can potentially 
affect the fate of FGFR2 signalling.  
Another important observation was the fact that total FGFR2 levels were 
increased when HEK-293T cells were co-transfected with TRPA1 (western 
blot results not shown), suggesting that TRPA1 somehow induces FGFR2 
expression. TRPA1 increases ERK and p38 pathway activation. These 
pathways can positively regulate FGFR2 expression through 
phosphorylation of pRb and subsequent release of E2F1 to the nucleus 
resulting in FGFR2 gene activation (D’Amici et al., 2013; Kondo et al., 2013). 
Another possible TRPA1-mediated mechanism of FGFR2 overexpression 
could be via the increased p-ERK and subsequent CREB activation that 
binds to the CRE (CREB Response Element) position on the CMV promoter 
located in the plasmid used for transient transfection (Chen and Stinski, 
2002).  
Therefore, to obtain equal amounts of total FGFR2 between single and 
double transfected cells, half the amount of FGFR2 plasmid was used for co-
transfection with TRPA1. Phosphorylated FGFR2 levels were always 
normalised against the total FGFR2 levels to obtain an accurate result in the 
experiments presented herein. Therefore, it is possible that the detected 
increase in p-FGFR2 levels and FGFR2 activation, described in our 
publication, was a consequence of the TRPA1-induced FGFR2 gene 
overexpression.  
Another possible explanation for our contradicting results is the use of 
different sub-cultures of HEK-293T cells (“older” cells). HEK-293T cells are 
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characterised by extreme chromosomal instability and karyotype diversity, 
reviewed by A.A. Stepanenko and V.V.Dmitrenko (Stepanenko and 
Dmitrenko, 2015). HEK-293 cells cultured in different banks or labs exhibit a 
variety of copy number alterations and numerical chromosome instability. 
For instance, HEK-293 cells from ATCC are hypotriploid with 30% of the 
cells having 64 chromosomes while HEK-293 cells from the European 
Collection of Cell Cultures (ECACC) have 62-70 chromosomes. Therefore, 
cells derived from different sources or undergone long-term culturing can 
exhibit chromosomal diversification which occurs due to expression of the 
E6/E7 oncoproteins of Papilloma virus 16, dysregulation of genes involved in 
genomic and chromosome stability, occasional lack of telomerase and rare 
multipolar mitosis.  
Furthermore, transfection of HEK-293 cells with oncogenes or even empty 
vectors has been reported to affect chromosomal stability. Therefore, it is 
difficult to discriminate whether results are a consequence of the product of 
the transfected gene or a result of the chromosomal changes caused by the 
gene transfer (Stepanenko and Dmitrenko, 2015). 
In our case, the use of a cell line with unstable genome over the period of 
3.5 years would have caused enough genetic variations that were eventually 
able to alter the biological process. Taken together, it is likely that both 
activation and inhibition of FGFR2 signalling can occur depending on a third-
party factor that has not been identified yet. Nevertheless, further 
experiments with various expression levels between components 
(competition experiments) as well as use of different cell types are 
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necessary to understand the true biological phenomenon and add 
information into our previous publication.  
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5. Chapter 5 
Summary and Conclusion 
This study provided the first indication of direct interaction between FGFR2 
and TRPA1. Experimental evidence indicates that this interaction is 
mediated by the C-terminal domain of FGFR2 and the ARD of TRPA1 (AR1-
10).  
Preliminary super-resolution microscopy experiments suggested that the 
majority of the complexes exist in 1:1 and 2:1 stoichiometry 
(FGFR2:TRPA1). However, formation of higher order complexes cannot be 
excluded.  
The role of the TRPA1 ARD in protein-protein interaction and channel 
regulation remains elusive. Here, we propose a novel role for the ARD which 
involves direct interaction with an RTK. According to our publication, FGFR2 
inhibits TRPA1 activation highlighting the regulatory role of the ARD in 
channel activation (Berrout et al., 2017).  
Protein expression of FGFR2 and TRPA1 was shown in a LUAD cell line. 
The endogenous FGFR2-TRPA1 complex formation was detectable in HCC-
515 cells which implies a possible role in tumorigenic signal regulation.   
To further understand the effect of TRPA1 on cancer signalling, the FGFR2 
activity and downstream signalling pathways were subject to extensive 
investigation using over-expressed proteins. The major findings revealed 
that the site of interaction is very critical for the FGFR2 signal regulation in 
both the absence and presence of FGFR2 stimulation.  
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According to the literature as well as our findings, it is conceivable that 
TRPA1 could compete for the C-terminal domain of FGFR2 with GRB2 in 
basal conditions. This prevents GRB2 from binding resulting in inhibition of 
basal FGFR2 dimerisation as well as phosphorylation and downstream 
signal transduction.  
Co-IP and western blot experiments (e.g. Figure 4.1, 4.8 and 4.10) also 
suggest that high levels of TRPA1 prevent PLCγ1 binding to the same C-
terminal domain of FGFR2 upon stimulation, resulting in PLCγ1 pathway 
inhibition.  
Taken together, our data could suggest a protective role of TRPA1 against 
FGFR2-mediated cancer metastasis. Activation of the PLCγ1 pathway by 
RTKs has been shown to increase cell motility and invasion and is linked to 
worse disease-free survival (Lattanzio et al., 2013; Timsah et al., 2014).  
Therefore, inhibition of the FGFR2-mediated PLCγ1 pathway activation by 
TRPA1 could abrogate invasion-related cellular responses. Functional 
assays including migration and invasion assays would strengthen this 
hypothesis.  
In contrast, studies have also proposed that TRPA1 favours cancer 
progression. For instance, Takahashi and colleagues recently proposed that 
TRPA1 promotes cancer cell survival by activating anti-apoptotic 
mechanisms that overcome the oxidative stress conditions. These 
mechanisms involve calcium dependent activation of the RAS-
ERK/AKT/mTOR pathways (Takahashi et al., 2018). Furthermore, our 
publication demonstrates FGFR2-mediated inhibition of TRPA1 activation as 
a result of direct interaction with the ARD (Berrout et al., 2017). 
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Consequently, our study indicates that the use of TRPA1 or FGFR2 levels 
alone as a prognostic marker is not adequate and proposes the 
combinatorial use of FGFR2, TRPA1, GRB2 and PLCγ1 expression level as 
prognostic markers for cancer progression. High levels of FGFR2 and 
TRPA1, in combination with low levels of PLCγ1 and GRB2, are likely to be 
protective due to the reciprocal negative regulation between FGFR2 and 
TRPA1 (Timsah et al., 2015).  
Exploiting the interaction between FGFR2 and TRPA1 as a drug that mimics 
the binding could potentially combat FGFR2-related malignancies including 
head and neck, lung, gastric, bladder and breast cancer (Commissioner, 
2019; Fletcher et al., 2013; Kim et al., 2019; McDermott et al., 2018; Timsah 
et al., 2015). The design of a non-conventional FGFR2 inhibitor that can bind 
to the C-terminal domain of FGFR2 and mimic the TRPA1 inhibitory effect 
provides a specific and targeted therapeutic against FGFR2. Ankyrin Repeat 
Proteins (DARPins), developed as a binding platform that is superior to 
conventional antibody recognition, are already investigated as potential 
inhibitors in therapeutics (e.g. DARPin H10-2-G3 against HER2 and breast 
cancer) (Epa et al., 2013; Houlihan et al., 2015).  
However, additional studies are necessary to fully understand and verify the 
results presented in this thesis. Firstly, competition experiments between 
TRPA1 and PLCγ1 as well as GRB2 will confirm our interpretation and 
model of interaction between FGFR2 and TRPA1. Functional assays such 
as proliferation and invasion assays will also be informative regarding 
cellular responses induced by the FGFR2-TRPA1 complex. It will also be 
beneficial to investigate alternative signalling pathways that are activated by 
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FGFR2 such as the PI3K/AKT pathway, which is mainly involved in cell 
survival. Identification of the exact binding sites on both proteins will also 
have a therapeutic interest.  
So far, the direct interaction between an RTK and a TRP channel has not 
been reported and future investigations on this phenomenon will determine 
whether it is a unique characteristic of FGFR2, or a mechanism widely used 
by RTKs and TRP channels. Apart from TRPA1, TRPC and TRPV channels 
carry 4-6 ankyrin repeats in their N-terminal domain and therefore, 
interaction between other TRP subfamilies with FGFR2 or other RTKs would 
be possible (Gaudet, 2008).  
In conclusion, our study was a first attempt to characterise a novel 
interaction between FGFR2 and TRPA1 and determine the mechanisms of 
reciprocal regulation and role in cancer signalling. Our previous publication 
suggests an activating role of TRPA1 towards the FGFR2 signalling which 
contradicts the findings of the present thesis.  Further research is needed to 
identify whether TRPA1 has a negative and/or a positive effect on FGFR2 
activation and downstream signalling, as well as whether the outcome 
depends on the cell type, third-party molecules or even expression levels of 
the components. Nevertheless, it is evident that TRPA1 plays a key 
regulatory role on FGFR2 signalling, a phenomenon that is worth 
investigating. 
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Appendix 1: Representative FGFR2-TRPA1 complexes as captured by ExM 
10X. Scale bars represent 500nm/10 (expansion factor) = 50nm.  
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